var title_f7_24_7552="Management foreign body ingestion";
var content_f7_24_7552=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F57363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F57363&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 521px\">",
"   <div class=\"ttl\">",
"    Algorithm for management of suspected foreign body ingestion in children",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 501px; height: 573px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Dr. Mark Gilger.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7552=[""].join("\n");
var outline_f7_24_7552=null;
var title_f7_24_7553="Contents: Pediatric allergy";
var content_f7_24_7553=[" <script type=\"text/javascript\">",
"  $$.inlineInitCustomer(",
"	false);",
"	var quirksmode = document.compatMode == \"CSS1Compat\";",
"	if (quirksmode) {",
"		$(\"html\").addClass(\"ie-standards\");",
"	}",
" </script>",
" <div id=\"message-wrap\">",
"  <div id=\"message-bg\">",
"  </div>",
"  <iframe id=\"message-bk\">",
"  </iframe>",
"  <dl id=\"message-container\">",
"   <dt id=\"message-title\">",
"   </dt>",
"   <dd id=\"message-body\">",
"   </dd>",
"   <dd id=\"message-controls\">",
"   </dd>",
"  </dl>",
" </div>",
" <div id=\"topPanel\">",
"  <div id=\"header\">",
"   <div id=\"header_container\">",
"    <h2 id=\"logo\">",
"     <a href=\"./toc\">",
"      Wolters Kluwer Health UpToDate",
"     </a>",
"    </h2>",
"    <div id=\"header_right\">",
"     <div id=\"searchpanel\">",
"      <a href=\"/login\" id=\"loginbutton\">",
"       Log in",
"      </a>",
"      <div id=\"cmsSearchBox\">",
"       <div class=\"header-search\">",
"        <form action=\"./search\" id=\"cmssearch\" method=\"get\" name=\"SearchForm\">",
"         <div class=\"header-search-left\">",
"          <input autocomplete=\"off\" class=\"searchfield\" id=\"cmsTxtBox\" name=\"search\" placeholder=\"Search UpToDate\" type=\"text\"/>",
"         </div>",
"         <div class=\"header-search-right\">",
"          <input alt=\"Search\" id=\"cmsSearchSubmit\" src=\"/sites/all/themes/uptodate/images/search_button.png\" type=\"image\"/>",
"         </div>",
"         <div class=\"clear\">",
"         </div>",
"        </form>",
"       </div>",
"      </div>",
"      <div id=\"cms_lang_dropdown\">",
"       <form accept-charset=\"UTF-8\" action=\"/\" id=\"lang-dropdown-form\" method=\"post\">",
"        <div class=\"form-item form-type-select form-item-lang-dropdown-select\">",
"         <select class=\"lang-dropdown-select-element form-select\" id=\"edit-lang-dropdown-select\" name=\"lang_dropdown_select\" style=\"width:100px\">",
"          <option selected=\"selected\" value=\"en\">",
"           English",
"          </option>",
"          <option value=\"ja\">",
"           ���������������������������",
"          </option>",
"         </select>",
"        </div>",
"        <input name=\"lang_dropdown_type\" type=\"hidden\" value=\"language\">",
"         <input name=\"en\" type=\"hidden\" value=\"/\">",
"          <input name=\"ja\" type=\"hidden\" value=\"/ja\">",
"           <noscript>",
"            <div>",
"             <input class=\"form-submit\" id=\"edit-submit\" name=\"op\" type=\"submit\" value=\"Go\"/>",
"            </div>",
"           </noscript>",
"           <input name=\"form_build_id\" type=\"hidden\" value=\"form-on4lUWpxHun_wp6revUkjCG6rK2IBuCGME9Cw0HXeok\">",
"            <input name=\"form_id\" type=\"hidden\" value=\"lang_dropdown_form\">",
"            </input>",
"           </input>",
"          </input>",
"         </input>",
"        </input>",
"       </form>",
"      </div>",
"      <div class=\"clear\">",
"      </div>",
"     </div>",
"     <ul id=\"utility\">",
"      <li class=\"first\">",
"       <a href=\"/home/about-us\">",
"        About Us",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/news-events\">",
"        News &amp; Events",
"       </a>",
"      </li>",
"      <li>",
"       <a href=\"/home/contact-us\">",
"        Contact Us",
"       </a>",
"      </li>",
"      <li class=\"last\">",
"       <a href=\"/help\">",
"        Help",
"       </a>",
"      </li>",
"     </ul>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"nav\">",
"    <ul>",
"     <li id=\"productTab\">",
"      <a href=\"/home/product\">",
"       Product",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"editoralTab\">",
"      <a href=\"/home/editorial\">",
"       Editorial",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"whyUptodateTab\">",
"      <a href=\"/home/why-uptodate\">",
"       Why UpToDate",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"supscriptionOptionsTab\">",
"      <a href=\"/home/subscription-options\">",
"       Subscription Options",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"/store\">",
"       Subscribe",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"     <li id=\"wkhcsTab\">",
"      <a href=\"/home/wolters-kluwer-health-clinical-solutions\">",
"       Wolters Kluwer Health Clinical Solutions",
"       <span>",
"       </span>",
"      </a>",
"     </li>",
"    </ul>",
"    <div class=\"clear\">",
"    </div>",
"   </div>",
"   <div id=\"greyBar\">",
"    <div id=\"greyBarTitle\">",
"     <span class=\"emphasis\">",
"      <a href=\"UTD.htm?3/3/3134\">",
"       Contents",
"      </a>",
"     </span>",
"     <img src=\"./../images/space_arrows.myextg\">",
"      <a href=\"UTD.htm?17/55/18302\">",
"       Pediatrics",
"      </a>",
"      <img src=\"./../images/space_arrows.myextg\">",
"       Pediatric allergy",
"      </img>",
"     </img>",
"    </div>",
"    <div id=\"greyBarButtons\">",
"     <div id=\"printGB\">",
"      <a class=\"icontxt\" href=\"?view=print\">",
"       <img align=\"middle\" alt=\"Print this page\" border=\"0\" height=\"20\" src=\"./../images/icn_print.myextg\" width=\"24\"/>",
"      </a>",
"      <a class=\"icontxt\" href=\"?view=print\" title=\"Print this page\">",
"       Print",
"      </a>",
"     </div>",
"    </div>",
"   </div>",
"   <!-- menuMessage.jsp -->",
"   <!-- /menuMessage.jsp -->",
"  </div>",
"  <!-- header -->",
" </div>",
" <!-- topPanel -->",
" <div id=\"leftPanel\">",
"  <ul>",
"   <li>",
"    <a href=\"UTD.htm?3/45/3806\">",
"     Specialties",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?18/22/18798\">",
"     Patient Information",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?3/13/3294\">",
"     What's New",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/37/606\">",
"     Calculators",
"    </a>",
"   </li>",
"   <li>",
"    <a href=\"UTD.htm?0/40/654\">",
"     Authors and Editors",
"    </a>",
"   </li>",
"  </ul>",
" </div>",
" <!-- leftPanel -->",
" <div id=\"rightPanel\">",
"  <noscript>",
"   <div id=\"javascriptDisabled\">",
"    It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"   </div>",
"  </noscript>",
"  <div id=\"printHeader\">",
"   <div id=\"printHeaderLogo\">",
"    <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"    </img>",
"   </div>",
"   <div id=\"printHeaderText\">",
"    Official reprint from UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"    <a href=\"file://www.uptodate.com\">",
"     www.uptodate.com",
"    </a>",
"    <br>",
"     &copy;2013 UpToDate",
"     <sup>",
"      &reg;",
"     </sup>",
"    </br>",
"   </div>",
"   <div id=\"printHeaderLinks\">",
"    <a href=\"#\" id=\"printHeaderPrint\" rel=\"\" title=\"Click here to print\">",
"     Print",
"    </a>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"     Back",
"    </a>",
"   </div>",
"  </div>",
"  <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" id=\"tocTable\" width=\"100%\">",
"   <trs>",
"    <tds>",
"     <h1>",
"      Contents:",
"			Pediatric allergy",
"     </h1>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds valign=\"top\">",
"     <div class=\"toctable\" border=\"0\" cellpadding=\"0\" cellspacing=\"0\" width=\"100%\">",
"      <trs>",
"       <tds>",
"        <strong>",
"         Allergy pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/43/19129\">",
"           Increasing prevalence of asthma and allergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/41/20119\">",
"           Primary prevention of allergic disease: Maternal avoidance diets in pregnancy and lactation",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/6/31848\">",
"           The biology of IgE",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?16/57/17304\">",
"           The impact of breastfeeding on the development of allergic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/22/30056\">",
"           The relationship between IgE and allergic disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Anaphylaxis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/15/17656\">",
"           Anaphylaxis induced by subcutaneous allergen immunotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/11/9401\">",
"           Anaphylaxis: Confirming the diagnosis and determining the trigger(s)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/29/35290\">",
"           Anaphylaxis: Rapid recognition and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/62/38888\">",
"           Differential diagnosis of anaphylaxis in children and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/9/26777\">",
"           Exercise-induced anaphylaxis: Clinical manifestations, epidemiology, pathogenesis, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/45/42709\">",
"           Exercise-induced anaphylaxis: Management and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/13/1241\">",
"           Fatal anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/17/34071\">",
"           Idiopathic anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/54/40809\">",
"           Laboratory tests to support the clinical diagnosis of anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/44/5833\">",
"           Long-term management of patients with anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/21/18778\">",
"           Pathophysiology of anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?23/17/23832\">",
"           Prescribing epinephrine for anaphylaxis self-treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/53/33625\">",
"           Unique aspects of anaphylaxis in infants",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma epidemiology",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/13/7383\">",
"           Natural history of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/12/20682\">",
"           Risk factors for asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/6/34920\">",
"           Wheezing phenotypes and prediction of asthma in young children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma evaluation",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/45/30424\">",
"           Approach to wheezing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/25/26010\">",
"           Chronic asthma in children younger than 12 years: Evaluation and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/17/25878\">",
"           Flow-volume loops",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/27/29112\">",
"           Overview of pulmonary function testing in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/41/1689\">",
"           Wheezing illnesses other than asthma in children",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma management",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/23/11642\">",
"           Acute asthma exacerbations in children: Inpatient management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/16/33034\">",
"           Acute asthma exacerbations in children: Outpatient management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/44/22218\">",
"           Acute severe asthma exacerbations in children: Intensive care unit management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/1/30746\">",
"           Agents affecting the 5-lipoxygenase pathway in the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/36/33354\">",
"           Alternative and experimental agents for the treatment of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/37/8794\">",
"           An overview of asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/24/20870\">",
"           Anticholinergic agents in the management of acute exacerbations of asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37354\">",
"           Chronic asthma in children younger than 12 years: Controller medications",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/47/39670\">",
"           Chronic asthma in children younger than 12 years: Quick-relief agents",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/18/31014\">",
"           Delivery of inhaled medication in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/60/7114\">",
"           Major side effects of inhaled glucocorticoids",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?0/53/854\">",
"           Peak expiratory flow rate monitoring in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?35/57/36760\">",
"           The use of inhaler devices in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/57/11161\">",
"           Theophylline use in asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/46/18154\">",
"           Treatment of intermittent and mild persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/7/26745\">",
"           Treatment of moderate persistent asthma in adolescents and adults",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/9/44184\">",
"           Trigger control to enhance asthma management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?29/42/30376\">",
"           Use of medication nebulizers in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/15/31991\">",
"           What do patients need to know about their asthma?",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma pathogenesis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/61/15319\">",
"           Chronic asthma in children younger than 12 years: Definition, epidemiology, and pathophysiology",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Asthma triggers",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/30/1513\">",
"           Exercise-induced bronchoconstriction",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/42/34472\">",
"           Nocturnal asthma",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/44/22216\">",
"           Treatment of recurrent virus-induced wheezing in young children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/15/2298\">",
"           Virus-induced wheezing and asthma: An overview",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Bites and stings",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/16/24839\">",
"           Approach to the patient with a suspected spider bite: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/22/6502\">",
"           Bees, yellow jackets, hornets, and wasps: Avoidance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/3/9271\">",
"           Bees, yellow jackets, hornets, and wasps: Biology and identification",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Cutaneous disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/31/26104\">",
"           Contact dermatitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/40/42631\">",
"           Epidemiology, clinical manifestations, and diagnosis of atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/40/3721\">",
"           Overview of dermatitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?25/59/26551\">",
"           Role of allergy in atopic dermatitis (eczema)",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Diagnostic methods for allergic disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/22/44391\">",
"           Overview of in vitro allergy tests",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/55/32633\">",
"           Overview of skin testing for allergic disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Drug allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/5/43097\">",
"           Allergic reactions to vaccines",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/46/23274\">",
"           Allergy to penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/0/39944\">",
"           Aspirin exacerbated respiratory disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/2/26663\">",
"           Beta-lactam antibiotics: Mechanisms of action and resistance and adverse effects",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/36/27209\">",
"           Clinical manifestations and diagnosis of acute interstitial nephritis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/17/41241\">",
"           Drug eruptions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?2/25/2456\">",
"           Drug fever",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/36/31305\">",
"           Immediate hypersensitivity reactions to radiocontrast media: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/57/43930\">",
"           Infusion reactions to systemic chemotherapy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/5/1110\">",
"           Penicillins",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/40/8842\">",
"           Serum sickness and serum sickness-like reactions",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/59/1978\">",
"           Vancomycin hypersensitivity",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eosinophil-related disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/10/24745\">",
"           Approach to the patient with eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/2/27688\">",
"           Causes of pulmonary eosinophilia",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/43/40632\">",
"           Eosinophilic meningitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/45/32474\">",
"           Pathogenesis, clinical manifestations, and diagnosis of eosinophilic esophagitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Eye disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?34/2/34856\">",
"           Allergic conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/1/37910\">",
"           Atopic keratoconjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/17/20760\">",
"           Conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?4/60/5062\">",
"           Giant papillary conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/19/6452\">",
"           Toxic conjunctivitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/30/37352\">",
"           Vernal keratoconjunctivitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Food allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/52/11082\">",
"           Clinical manifestations and diagnosis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?14/29/14808\">",
"           Clinical manifestations of food allergy: An overview",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/12/5321\">",
"           Diagnostic evaluation of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/9/33944\">",
"           Egg allergy: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/58/13223\">",
"           Egg allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?1/63/2042\">",
"           Food allergens: Overview of clinical features and cross-reactivity",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/39/3705\">",
"           Food allergy in schools and camps",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?41/48/42759\">",
"           Food allergy: Impact on health-related quality of life",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/52/34631\">",
"           Food protein-induced proctitis/colitis and enteropathy of infancy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/0/38920\">",
"           Food-induced anaphylaxis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/21/10585\">",
"           Future diagnostic tools for food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/1/44057\">",
"           Future therapies for food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/17/26904\">",
"           History and physical examination in the patient with possible food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/30/20967\">",
"           Influenza vaccination in individuals with egg allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?24/37/25175\">",
"           Introducing formula and solid foods to infants at risk for allergic disease",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/35/37430\">",
"           Management and prognosis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/48/18185\">",
"           Management of food allergy: Avoidance",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/60/29640\">",
"           Milk allergy: Clinical features and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/9/40087\">",
"           Milk allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?22/56/23433\">",
"           Molecular features of food allergens",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7993\">",
"           Nutritional issues in food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?19/59/20409\">",
"           Oral food challenges for diagnosis and management of food allergies",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/42/43689\">",
"           Pathogenesis of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/41/5785\">",
"           Pathogenesis of oral allergy syndrome (pollen-food allergy syndrome)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/35/38457\">",
"           Peanut, tree nut, and seed allergy: Clinical features",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/27/9654\">",
"           Peanut, tree nut, and seed allergy: Diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/9/32919\">",
"           Peanut, tree nut, and seed allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/55/38776\">",
"           Respiratory manifestations of food allergy",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/61/16346\">",
"           Seafood allergies: Fish and shellfish",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?12/28/12746\">",
"           The natural history of childhood food allergy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Hypersensitivity pneumonitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?26/22/26985\">",
"           Approach to the infant and child with interstitial lung disease",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Immune complex disease",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/49/40729\">",
"           Clinical manifestations and diagnosis of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?3/62/4070\">",
"           Hypersensitivity vasculitis in children",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/62/28646\">",
"           Management of Henoch-Sch������nlein purpura (IgA vasculitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?5/54/5993\">",
"           Renal manifestations of Henoch-Sch������nlein purpura",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Insect allergy",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/36/7752\">",
"           Entomology and control of imported fire ants",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/35/28216\">",
"           Insect bites",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?42/1/43031\">",
"           Prevention of arthropod and insect bites: Repellents and other measures",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?7/51/7994\">",
"           Stings of imported fire ants: Clinical manifestations, diagnosis, and treatment",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Mast cell disorders",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/1/6170\">",
"           Clinical manifestations, pathogenesis, and classification of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/13/18650\">",
"           Evaluation and diagnosis of mastocytosis (cutaneous and systemic)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?43/22/44393\">",
"           Mast cells: Development, identification, and physiologic roles",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/50/41767\">",
"           Treatment and prognosis of cutaneous mastocytosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/56/39817\">",
"           Treatment and prognosis of systemic mastocytosis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Other",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?10/54/11110\">",
"           Assessment of mold in the indoor environment",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/48/31496\">",
"           Chinese herbal medicine for the treatment of allergic diseases",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?40/58/41895\">",
"           Control of secondhand smoke exposure",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?9/35/9785\">",
"           Latex allergy: Epidemiology, clinical manifestations, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?39/8/40070\">",
"           Latex allergy: Management",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?17/29/17882\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Clinical manifestations; pathogenesis; and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/0/33801\">",
"           Stevens-Johnson syndrome and toxic epidermal necrolysis: Management, prognosis, and long-term sequelae",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?38/8/39049\">",
"           Subcutaneous immunotherapy for allergic disease: Indications and efficacy",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Rhinitis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/53/22362\">",
"           Allergic rhinitis: Clinical manifestations, epidemiology, and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/17/30999\">",
"           An overview of rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/5/18519\">",
"           Atrophic rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/61/12250\">",
"           Chronic nonallergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?6/39/6775\">",
"           Pathogenesis of allergic rhinitis (rhinosinusitis)",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?36/60/37834\">",
"           Pharmacotherapy of allergic rhinitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?20/18/20776\">",
"           Relationships between rhinosinusitis and asthma",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Sinusitis and nasal polyposis",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?8/36/8775\">",
"           Fungal rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?30/4/30794\">",
"           Management of chronic rhinosinusitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?11/25/11674\">",
"           Orbital cellulitis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?27/6/27751\">",
"           Preseptal cellulitis",
"          </a>",
"         </li>",
"        </ul>",
"        <strong>",
"         Urticaria and angioedema",
"        </strong>",
"        <ul>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?37/31/38391\">",
"           An overview of angioedema: Pathogenesis and causes",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?15/22/15721\">",
"           Cold urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?18/52/19272\">",
"           Hereditary angioedema: Epidemiology, clinical manifestations, exacerbating factors, and prognosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?33/4/33864\">",
"           Hereditary angioedema: Pathogenesis and diagnosis",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?28/61/29658\">",
"           Hereditary angioedema: Prevention of attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?32/55/33657\">",
"           Hereditary angioedema: Treatment of acute attacks",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?21/24/21898\">",
"           New onset urticaria",
"          </a>",
"         </li>",
"         <li>",
"          <a class=\"tocItem\" href=\"UTD.htm?31/60/32714\">",
"           Urticarial vasculitis",
"          </a>",
"         </li>",
"        </ul>",
"       </tds>",
"      </trs>",
"     </div>",
"    </tds>",
"   </trs>",
"   <trs>",
"    <tds>",
"     <img height=\"10\" src=\"./../images/spacer.myextg\" width=\"1\"/>",
"    </tds>",
"   </trs>",
"  </div>",
"  <div id=\"footer\">",
"   <div id=\"footerNav\">",
"    <ul>",
"     <li>",
"      <a href=\"file://www.wolterskluwerhealth.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Wolters Kluwer Health",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.factsandcomparisons.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Facts &amp; Comparisons&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medispan.com\" rel=\"nofollow\" target=\"_blank\">",
"       Medi-Span&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationordersets.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Order Sets",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.provationmedical.com\" rel=\"nofollow\" target=\"_blank\">",
"       ProVation&reg; Medical",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://pharmacyonesource.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Pharmacy OneSource&reg;",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.medicom.com.cn/\" rel=\"nofollow\" target=\"_blank\">",
"       Medicom",
"      </a>",
"     </li>",
"     <li>",
"      <a href=\"file://www.lexi.com/\" rel=\"nofollow\" target=\"_blank\">",
"       Lexicomp",
"      </a>",
"     </li>",
"     <li class=\"last\">",
"      <a href=\"/home/privacy-policy\">",
"       Privacy Policy",
"      </a>",
"     </li>",
"    </ul>",
"   </div>",
"   <div id=\"footerLogo\">",
"    <a href=\"./toc\">",
"     Wolters Kluwer Health | UpToDate",
"    </a>",
"   </div>",
"   <div id=\"supportFooter\">",
"    <span class=\"sfInfo\">",
"     &copy; 2013 UpToDate, Inc. All rights reserved.",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Release: 21.3 - C21.34",
"    </span>",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    <span class=\"sfInfo\">",
"     <a href=\"/home/terms-use\">",
"      Terms of Use",
"     </a>",
"    </span>",
"    <br/>",
"    <span class=\"sfInfo\">",
"     Licensed to:",
"     <span class=\"emphasis\">",
"      UpToDate Marketing Professional",
"     </span>",
"    </span>",
"    <span class=\"sfInfo\">",
"     <span class=\"pipeSpace\">",
"      |",
"     </span>",
"     Support Tag: [0505-95.154.198.148-F1636296AE-14]",
"     <br/>",
"    </span>",
"   </div>",
"  </div>",
" </div>",
" <!-- rightPanel -->",
"</body>"].join("\n");
var script_f7_24_7553=[""].join("\n");
var outline_f7_24_7553=null;
var title_f7_24_7554="Patient information: Pneumocystis pneumonia (PCP) (The Basics)";
var content_f7_24_7554=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/17209\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/3/10294\">",
"         Pneumonia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?12/29/12754\">",
"         Patient information: Community-acquired pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?43/39/44658\">",
"         Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Pneumocystis pneumonia (PCP) (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/pneumocystis-pneumonia-pcp-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H31386544\">",
"      <span class=\"h1\">",
"       What is Pneumocystis pneumonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pneumocystis pneumonia (also called PCP) is a lung infection that causes coughing, fever, and trouble breathing (",
"      <a class=\"graphic graphic_figure graphicRef55943 \" href=\"UTD.htm?10/3/10294\">",
"       figure 1",
"      </a>",
"      ). It is caused by a fungus.",
"     </p>",
"     <p>",
"      PCP is most common in people who have conditions that weaken the body&rsquo;s infection-fighting system. Doctors call the infection-fighting system the &ldquo;immune system.&rdquo; If the immune system is weak, it cannot fight off the fungus that causes PCP. People with healthy immune systems rarely get PCP.",
"     </p>",
"     <p>",
"      Conditions that increase the risk of PCP include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        HIV, a virus that affects the immune system",
"       </li>",
"       <li>",
"        An organ transplant or stem cell transplant",
"       </li>",
"       <li>",
"        Cancer, especially blood cancers such as leukemia",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      People who take medicine that partly &ldquo;turns off&rdquo; the immune system, such as steroids, also have a higher risk of PCP.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31386559\">",
"      <span class=\"h1\">",
"       What are the symptoms of Pneumocystis pneumonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;The symptoms of PCP can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Cough &ndash; Most people have a dry cough that does not bring up mucus",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling tired",
"       </li>",
"       <li>",
"        Chills",
"       </li>",
"       <li>",
"        Chest pain, especially when taking a deep breath",
"       </li>",
"       <li>",
"        Losing weight without trying",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31386574\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have HIV or another condition that weakens your immune system, and some or all of the symptoms above, see a doctor or nurse as soon as possible. PCP can be very serious. It is important to get treatment right away.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31386589\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Your doctor or nurse will ask about your symptoms and do an exam. He or she will probably do a chest X-ray to look for infection in your lungs.",
"     </p>",
"     <p>",
"      If the chest X-ray does not show infection, your doctor might do an imaging test called a &ldquo;CT scan&rdquo; if he or she still thinks you could have PCP. A CT scan creates a better image of the inside of your body than an X-ray does.",
"     </p>",
"     <p>",
"      You might also have other tests. These can include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Tests on fluid from your lungs",
"       </li>",
"       <li>",
"        Blood tests",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31386604\">",
"      <span class=\"h1\">",
"       How is Pneumocystis pneumonia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;PCP is treated with medicines to kill the fungus that causes it. These include",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?23/2/23589?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      (brand names: Bactrim&trade;, Septra&reg;),",
"      <a class=\"drug drug_patient\" href=\"UTD.htm?16/24/16772?source=see_link\">",
"       atovaquone",
"      </a>",
"      (brand name: Mepron&reg;), and other medicines.",
"     </p>",
"     <p>",
"      Depending on your situation, your doctor might also give you steroid medicine to help your lungs get better. Steroids help by reducing inflammation in your lungs. This medicine is not the same as the steroids athletes take to build up muscle.",
"     </p>",
"     <p>",
"      Some people can take medicine at home, but many people need treatment in the hospital. People who are treated in the hospital might get medicine into their vein through a tube called an &ldquo;IV.&rdquo; Some people also get extra oxygen to help them breathe more easily.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31386619\">",
"      <span class=\"h1\">",
"       How soon will I feel better?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Most people start to feel better 4 to 7 days after they start taking medicine. If you do not start feeling better, the doctor can give you a different medicine or give you medicine through an IV.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31386636\">",
"      <span class=\"h1\">",
"       Can Pneumocystis pneumonia be prevented?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Sometimes. Doctors can give antibiotics to people with certain medical conditions, such as HIV, and to some people taking steroid pills or getting IV steroid medicines for a long time. The antibiotics help prevent PCP.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H31386651\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?12/29/12754?source=see_link\">",
"       Patient information: Community-acquired pneumonia in adults (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/39/44658?source=see_link\">",
"       Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 14, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?7/24/7554?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 17209 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0603-189.41.181.191-AA596B28AF-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7554=[""].join("\n");
var outline_f7_24_7554=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386544\">",
"      What is Pneumocystis pneumonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386559\">",
"      What are the symptoms of Pneumocystis pneumonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386574\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386589\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386604\">",
"      How is Pneumocystis pneumonia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386619\">",
"      How soon will I feel better?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386636\">",
"      Can Pneumocystis pneumonia be prevented?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H31386651\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/17209\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/3/10294\">",
"      Pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?12/29/12754?source=related_link\">",
"      Patient information: Community-acquired pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/39/44658?source=related_link\">",
"      Patient information: Preventing opportunistic infections in HIV (Beyond the Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_24_7555="Pulsed Doppler HCM";
var content_f7_24_7555=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F67484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F67484&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Dynamic subaortic outflow tract obstruction",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 275px; height: 360px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFoARMDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5nnke5u3WFJXfOQiDkY9AOgH/ANeqInl3gtLJxg/ePb/9Zr2v4Fa7o/g+LWPE+raxbWl8s0NhZQhBcSlWcPM5iBB2lECBxwC578Hgvi9Y6VY/ELV/+EdvrO90i6l+120ltKsiosnz7DgnBUkrg88UAcm0nDEOec4wMf54/wAKbvznjHHqeKjHFB5Of5UASCRywO4huec8mnCZhsYMwIyDhuo+lQ8YpeMZPWgCQSspcAk577skVYjkYSEqQG255zjp3/n+vSqfAb1H16irtnE0rF0YKgHzFu/PT3Pf8M9eKALtlbXc0ckscRESrvcnsCcEnPTt19cnimETOm6ViiAiJmfrzzx2xx17Z57V1mh2csfh6+h8pJkeLk/dwMkj/Pb3yQOXh0u+njKW6vvjUN5bD9R7/wCeetAFUiXzQJt0R6gdSevHr149vrUjLc+XujLmOQ4Uk+gzjj37f1qnLJKT++3uc4XdnII4q6L22W2ghMUqvG25iDyD0PP6/p70ARstyoYQgsU4OznGRz7jP+eapRsTHhQSR0A/nRJO3mOY3YBvwq3bOlxLbQwRCN8bXbGdwPXP+f8AGgCsWYzbFf5UbIywxwfUf0qzFZ3czyhVLbMg5OCe/H+f60iWMs/lThUEMkuzGRwc+3UfSuj0lI4NVuIJoxLg8H5vxGPw6j8OM0APslns/C+o+ZG4QyRlUORnqB+OO/vjpzVLRfCXifxBZzXug6Jql/aQu0Ukltbs6qwAJTgHnBH5ivdfihYRJ8KrOZIEEnlxtuUAEAqDk9s59P5ZrG+C/jzw74c8C2llrWqafbahb+Izqbx3VlPKxg8hUZojEuBKTuALHAGeMYoA8ClldB5TGRdmQVPGDk5BqIudqgndj3rR8Rz2dz4h1S40wTtp8lzLJbm4OZBGWJXee7YIyfWsugBzPnqM855NKJW+XcSQvQZpnajjAPfNAEhYgEbicE8bv85pobHr6jnofWgrgDuT0x3pvagCSMk5BI6jkmtSHTZLmxu70SbxbkDB4JBOM4/L6fSrXhfw8NXd5Ji8cCnjH8Xrz/n9MVsWulqlrqVpA2weTnMhwcg5x/n/AOtQBx6R+Zjc+1twDHIAwePX2qOUSIcMxyCeMng1bTS5TcRR9A4JDNwpx79qqTwNCzowwyNtIIxQBZPnSQxxrkrKSdqjJJHr61ADiMgSZ3+4+vr60+PUJ4TF5LKhiztKjGeMc/hVUnJzgD2oAkwd3zEjPJz6UI+XUMWx04P9frSLIGdd+FHqBT4xCWh8x8Kf9Z8vTkj8eMUAWILdbksis/mY+Uduv/1/w962tV8J6xolmlzdW5jjfaVII6HpkfgR7fjmsrR5vLvo0V1wzhQT2z35Ht/hXvfxLtFm8OWE8iSeWqxhtoAB3DPP0P8APjjNAHg8KARgeTcNjuIziite7tL+G4eMzuhU/dUKAKKAKHiiKOO8ijihQfKPutnccAdv6f41mRwrJZNKFIkRwG9GBBI/kf8AIOVv2M0+DuJ3YBY5OM8dfxqpyBjPB7A/zoANpKAhD9aQDjp0ox2Bz3pDjJ9O3NAABnpS7TtJAJAP3h0pAM9KXGRxyf5UAWLG2a6uVhjQ73YAcEgfX9K9SvPC8NlokUEatK4GTwMk5/P7wx/9ejwJokTadbpFg3UhBlXg7gOR6d/89K7bxH5ckUUarvMYKsQRjOOOnuP8nmgDzHwaZFvLu2d5Ps4jOxeOSDkcD3B6fh3rpNEgVb6NowzFgB0x0+7056E//qzWB4b17SdMvL+O6kmW4ZzGn7nduycEHHI55456Y5zXoGjx+XF5iKruc7dxxwfXHPr/AE4zQBx3xN8IR+U2saYqiAgCWGM8jHG4D6cn0+nNeWSq25txJK4BP/6/avp+a1SfRNywjDMRndnqeSD06Z//AGa8O8eaBHpd+j2eXgkySSOhz05/z+GKAOOJ3MCxPuaEdkYFGKkdCDipCo+RRgkjg9up/wA81F2oAkEkmWPmHJyTz1z1q3YtuvI2bzXycnLYPr+P9ao9Pp7d6ntMtcRjjuV6YBx70AfUviqa3u/hfp4cNuFvGN27gHGeT9efwz7V8/eKLaDyLR7eSFsKEYDBJPXd/X9enFew61dh/hcu47z9njUkD7vy/meMn/6/FfPt2x3q/Xjgnv0P8iKALFpAj2V0JODHlkbHDEdVP4c1mtuIGc+xNTAr5TbT8xHSopFK4yyngYwc8UANo7A479aBjHP5UqAZJboOuKAJ33HeXHznr14GP/1Va0fTJb66VMMIerNjjGegP1xVS1ha6uEihjy7EAAGu2sJl0hEt40j2Egt2Zm6beff/OeaAOt8JxR/bYoooysYXYB04zz/AOPcf/Xqrr+ni3XUFt8BRETljg8EkdPfP8+vFdX4Gs2uHkmmBTYNwOAR/j17f1rK16B7i5v41QKrwsdwOePXA7/565oA5Tw5MZrS3AijIXldzkFRz3xxzmrXjHwpFfWkd7py4u0Hzoo/1npn361Q0iLMqoSNiAgH5g3T0H9Pw713un+a5iZEU4IV+/HHP+fw70AeASx+VLIkispU42sMEVFXsPxZ8IBbqS+tIAJwAZFQABlxndx0/D+VeROuGYHC47UAMJzS9euc9OlJRnigCxYqGu4QwwCw5zX0/rBhv/CdrbXRWaEwRqzAjoV46eoyc+2R3r5cgYLIp25O4EZPvX0XaXDS+F7FC+1THHkg53ccfmP89qAPKNUBtr6SCaNJGjwocuuWUAbT09MUVsa5p9u+qztK8ockHCnI6DHb0ooA4LUI3Sabeq7ix53E9fr/AF/HtVPZjczY646dPXj/ABrZ1q3KSbk3MSW+XDDuOeenXvnGBntWWyh2kx1JyCe+D05/r+vFAFfkfNuJ7nH1oJOS2eTzwen1qytuzMqoUCjguf6//W+nWkWI+dhgImHByrcHP55/z1oAqEltoAyegxWvpenO9wqkYcsFAJHXHUfT/OeoNNs2WZWnXOBuC4x35wTx+XrxXS+HoXGtQq0bKGPLlc4Hp659PbpxmgD0Dwb5Wh2rSSbW42AEDI4x09unXvjpzVLV/ECrcSNLu3EExRjkdMdPfp+nbNS+Ird7aXCiPyApJU4+ZsdeOAAeOe3tXJXsMjywyvKnmk7ht6H254x2+nHTBoA6fwei6nFq4lWAB4/vKdxLE/3sZJJ47dPbJ63QdN+2o4lZnZF3KoOc5OfbOevvjIx0rB+HtjNDHcybg0cwBAYEhsZPzZH6HHTnHGfSPDlhM4WWNMtkDJBIJOe3H1+vvwQCmbNRohCsWkDfKwGcDqR7f3v16cV5r4hsopUMMsabtoJUjbkDJ5zn1z+vTp7tcWcS2skYU+aEwSRnJ29fy5+vPXivL9dtxZTsq7BMMgY+XPHQ9e368+1AHhfiDQm0y8ygC25OUO7kd8H/AOv61gOpVQGBBGR+Pp/n1r3XWtMt7yxZZ4CylWChTgI23r3xjOe+Pft5Fq+jyaVI0dwBySQ4OA3Tof8AP1NAGQw+Vsx7SDngHipLYeW53pnsQR0P/wCv/OcUskaln2AuSTg7SMcjqM1PZEeZ5a/xkHaeB1Hft/kdeaAPatSDj4dgBTvaBOM98jn1PIx/9evE7iHCupQqRng5yvPT/P8APivd7xBN4IiDEnbbr0PTnj3/AM46814tMkHmzKqlcgYJB67jyfw7dc8DnmgDNz5ixKoA2rwcHPX/AD0/nVfcSRtHPt61oCFhGquWJAHy4PTJ4H8/5c1XaEblbaxQ9Bjn/P8An1oArgYP3gMEd6fbQvPOsMS7pHIVcdiTUqQMxCAE4bnaCcfl1/z713HhHSl0kDU71JPPwdibSCvqcDn6YoAy73QpNC07zZh/pTkAqf8Aln/h9eevvkVNHSe4vLYTfMm5f3hPTAx19un6e9dR4gvxfyCOboVymQoCc/l7fQnHGapaRpjNfCfCqBLuHlYXnP8ALOR06cdOaAPWNJ1BNF8NhXVTLJleOTt6f/W/T3rkdSk1i/ubqTRFhuLjdtcyvuUo3Ug8dwB+fetuezt2mgWcbYFG91DY7+n1yPpweMGp9KiQm/W3YvG0JBLZLY3cccfj6jjjrQBy/h2wuntlmu4VNySxcjkMc9gOvTt6V3unWaNbDCEl8YBPIyc5/wA+nHejw1pDXUA8lS4yqkMmSOfwz3/+sevfaZ4c+ygfKSGQNjJI9CPr3/wxyAct4n051sxPI4mDKoySDlf888V4P488NCKVr+wiKBlLSxDnafUY7Ec+npxX0ZfAFzaTjMabQG67hzxnHJ/L+lcXrummHzEmVHEg2cgkMuOen+e/tQB82bTjp7UHtxium8UaH/Zk7SW4P2VmOVwSUOOh7f5z04rnWUBFbBBPI+n9aAFg4c/ORnrgZyO/+TX0JpKSzeHbMQlirxghsn2z0HX/AD14Pz1ECZCMEntxzmvpPwQ5m8P2IIO1YwAFB3Y7fn1/Q84oA5m9tLhrqQnHJ/56N/QUV0mqQxRX0qFDxjqkhPQdcd6KAPDNXgWGbe4lQBtwyD1B44ycYz+GR1zxREZZNuQyKeC5xjA4B9PT8cehrf1aAR3TOxUbTzjCnjIzxwByB7dsgmqAtVSUllzt/wBZt+6p+7g+nUcDPp3zQBS8p/sxRiduAAu4HB244H6fXjrzWvYaRc39+bm/imnDfMzMGZmJHU9+en1HHIzWt4U05Z7oBhGtqDzhSc87eh688f8AjvTBr3HUvCtrremRNokYE0aAMgXPJ44B69Dx36HGOQDwe7t1Vg8SkD5jzkDn07HOOMfhjnPT+Dba3ERmmcJNkhdwxuzz9ecZ4+owMirl14bvVuiyQucYBY9Oe2fTg/X2xWfPaTQGSKQBmDA7VbA557cnjt368dKALPiK9W5mEO4eWjdscAHP06c89v8AZ4rGXT/NuodkirHgMrjoBk5yDxnHbrz/AHcVZlCOGMrKCiiSQBvTnr24+oxz04q7ptqhllfzUZTxkrwSFz17cY/meDQB6H4BaHzDDcFfLKDgAk56HIP4dfx7V69Y2ttAqlYlUAYwRnPHfPv/APX5ryXwPFm8diwIijO4MGUEDAIIPT8c9ge1dhf+M7C0jMQk8wgdxt746n3/AF464NAGlclV1CRnBG4fKSc4z9eevp9fvVwPimyk+1Gdise4khhjPXjp78/qOcir1142E93G0BCJkAs2MHnHA6nv07/7VLrN4t3arI6jJ6FTgevb6f4c5oA4cJJICDyVPGHPyfkOO/T8O4qDWfD0F7YNHMiLckZjfnK4+7yPTn8/rWmsqZzHHtAYHcQQO5wCOPy/DnNQW9032iRlCOvTA/pjn/PHegDxO+00WF69vcMyNHlyuAAFzweDj+f49aht4ojPGPNDHOBl8HHOAT0Hfpn0969O8aWNlfiNIPLW8QZBAUDABJXjjqe3TtxmuDWwlF0hZRgfK5yeOAMeoGfTjnHQ0AexwJv8FrFHsVfsoBUHkDAGR+HH14968eudPTzJvkYgnacKSRkY6fp+GOOp9j0v5PCiW7BNot9oQHLLwFHB4P8AkdMGvMtSgkWULEitng/JnHYfTkHjv0PY0Ac8iLE5HRSTwR1yMccc5xjjGenB5qt9mU3PcqCSR97qB+ef8477c8TOoVyA0nQqeeeB2579evTjAqXStHe7uovMP7gAsSeSM9OOmeD9fbFAGv4D8H/2terd3J2xKdysoOG+mOPy69u9dH4ws/I1FI1BbrhcH5RnIyBz0yeOMdO4rrfBtxaedbwKyrCVUggZAJ6YJ6jj059sVs+OPC8st215Y5likiy6heR3yAOox/j7UAeLLa7pFE+1uSV+VfXjGOg7/TpxmtrQ0iFwgCo0obdhMDPOecDPQ5+n+zUsljlz5q424yrEZ5BIwccfUdufap47aTTyrKBg9CSOSBnjHJ4I/DnpxQB2PiWDThp0VxYhGcoA6Becjr7AY/TrxXMaDdLDdzJLG2JYXX5ecfnz0/wPGKguLvzoXBbBJLbegKgdz0HUfQe3FRaOC97Iu0KcOVOPYZHzfh/XjFAHQeGNSnspkEbncc+Zu59ujde3XHv2r1+ynzYI8kv7thufJ6ev+fzrwvTo/NuH8xk+9nkgHsOc/wBfTntW/wCKNRiECW9pcOwUBGIORnPT07fX17UAdXr2p20FwH89JGOdxUEgj8uecdf51g+IJE1KwDRxsD/eXOSf/wBff8evFcELqXcAm9g4wucktzn5vX8f54rb0DU3SNo5EjfdkYPKjnIOP8efxoA47xJYgtIj5JbBzjjrkc/Xnp7+orhNW0prCckOfL+8rep9Pwzn2yD3r1zXbN/NabahGTkcYI65B6+/Hrkc5rnLi2juoJIZvLKyAjlsEEdccf7Q+nUdSKAPO7e1xJH0DFlwf7pHr6Y7+me/Ue++DInj0ywLBshVRiMkLxjP9P064NeVXekSafcxQKpdRuwc5PB/Tk9unbNexeDFiSxs3cuA67WwuQcADv7/AJdPegCXXLcNqk58tz93nDn+EejUVuSQPcOZEjfaemyHI4467qKAPm+6aOR3ITexG5UbaDj8OOhP9OM1NYWrT3aCPcvPzYbHGcY/LPTI/DNX7nT2/tDaIeZGJwMHrzkY7cdvw4zUaQSQyiVFkiIYNu5wuPmx+JGOOO/SgDr7Py7TKK2coBj3zjJ9OOOf/QcGuz8K+IptLkEUqlkdsjgdDwRzx6DHtg9q800zVUZkhwNxbOMHJHLdT7568f8AAcV0sLlUWQS5C/MeB0HQc8d/8e1AHqEl3Z6rM0oZIXZAHiABDerZ6g9P/wBeK4PV9KElxMySqEVuct1z7Drn/wCvweK2dE0SeW3jurOUEy5Byccdsd+5/rziryeC7q9kRpEMWeE+bC9f8Oefx+agDzW/sHQHJXZnYuGORgZ6jpzzxn168VJpNo8UitCoAXLAsCCTxxn9fxz3Ir1G08DIlsftUxVFZgwOTjnBOcenp9RzXLaxpU2mXzCyfzI1O4kjH8uemPzyO4oA07W6utLspESy2h4z1XG36Dpx/X0PHn+s6k8cjyO+3aR1Tpn37Y+7+nvXodpqer3mnOtxAgjRF3HbyAQe3T0GR/LNcVqNp504mlCFCBvGACMDPX68fhj7vNAGLpl9K1xEgj2xzOWyecn6enRffp15r0fT55ZNGwzsxH3cHOePb8vwx1rhWtdsZePKkj5MDJ9sfjnr24PY1t6HekLGyOWz1U5O0+/of8+9AEd+k0cskcgMkiHliDhiec5HXPt1x6g1lSI+F8txHjjJUnJ9cDnn16cZHeut1iDz1XaysD90sM5IH6/19sVkG3Jg2MSxc9gD3+v69/agDESJ3ul8zd5aK23DKcEd8gfjx9RxmsXVrCSS7+1RzEDfjnI6Y/zkcd/u5rqNRuba0jkMyuxwSQpBYZ59v0+vtXLX15LLHGgZhFv38A9c55/HH8+nFAHoekEf2A29d5W3y3ykc9M46fr/AOO1wd1+8bblkTHyjCg88EjPt/8AX4xXZeE2FzZzRcvKLchlC4zjnjt1P9enFc+unMSzQw5difmIHHfHpjnHHfrxQBzsVqJ52iRxlz95h36HH5d/x7V2Wi2a2Ns9ukqSsAH5BJY9/b0/r2rLbRLsyv5akFCOFAOMDI/P3/HtVyyuntHk84G4ULjr8wx056ev9e1AFubEVyry7iU74zn+v+eea9N8BeIEcPa6h+9idQPmGccZz/X/AOvxXndpLC7bkZHXBwDzjHA68nr/AI9qtWheQN9mYRvwACQPl6ZH4c+vrzQB6jb+CtL1J2u7e5ZopDuVNxPv39ev4Z9q5vx1oDWYtxEjtGvKtk4/L9f19q6Dwbd3MCw+W26LBAUsfl7cfh/nNdffQR6hZSrNDzGDgsT09v8AP68UAfONzZsznP8Aq1yDt42j6+2M/r7VY0m0RSA+1DgqUPyY+vPbrjtn0r0bVvCFxMgNnCGDYYL0IHfn8O3rxUGl/Dq7mkV79hGOrbPl+vA/D6UAcfpui21yqql6sCSAnryOenPTHv0z9KmvfDiCJUVy0JAYyAFeecDJ/L+faunbwOdKuYDHJuCtnOdvqcfn+VW/E9jL/Z8RJUDGS3Izj3oA8qjtktniijAkEzkLw3y47E/pz9OuK1LaKFPKknQkklSEIDY6/TrgYPPbrT107cxiSQrtGchfz/z+HvXRW+jr9nSQszxgfwkEnPH+f8eaAMN4PtkW5RvmGRlhnJx6fpx6cc5qjZ6KZZWlVAxwcbs9evb8f6d67Q2gs4FbzSNvBVzxyMZPf3/+vXOa94ksrCGSC2UuhBAfrg9CcDnjH+HegCh4gsbf7EElcMFOVbqeMY/r0/DjNa3g8iEWCzHK58sAD8Mc+3H/ANbmvPbnX1mfzGlVlIyqgc57/wAucfhxmtDwZrrf2nahnzaxv5jAADvknB54PA/woA90ubG0SdlW1YAYx8qnt7nNFB8TaOx3LMjg87iY+T3680UAeQ6vY36qLhEt90SgbTKvzAjPUdCeT74yOhFY0t1etbLazWqRwMu/5pASwA3dB35Jz079Mil1CUyzSRKWjxkE5yB0x+n68+1ReSZFlJG9zkBevAIOCfTHp356cUAZtx4euLnfd6LEFi2DzVY/NGcZJ9hyD+OenA0dE0jV7SW0lMqeTIpkPGOFODy3AI/Tv1FNtFmsnbJKcjJUkd8njoMccn69DitWbV724tDBLJvTgrhApPrhjx6f1zkUAekeHdd0+xhWO+nSNuSQr5B5x0/Ifp1xXVL4ns5QBBOkyvk5z93n26c8c/jzXzl5cyM3lPIDhQMdMYOeDzn1H9cVfs7ee2h82LdGEz/ERu49uOvr/OgD6Piu0FqGR428wgKu84PJwfz9OuPWp3tNOuNqbI2cEHaT+vHPr/TvXzxDrN6iMpMilV3JuySPl6e/4fh81aS+Jb5W3IH3j5iUYj6jjn16fhzmgD3Sa3tIbaTEUfkCPjpj2z29en8s15nrOlwXhinsYlVM4KAgMrDjjH+yev4dKrweObv7DJA0fztEwwSM9R0xx+XvjjNc+dbmVeYdjl85VgBjdzjHPoP/ALGgDpbfwxLt8qWMxh0JBlO1euD+n88dOaxbu0TTLkCaSNkOPuIWyc4Iz36D+R7Ump+KdUubVbNiTEANpLfMMnof5c9uvGKwpZ7i5YJPJJsUgBG+vB57/wCT2oA17rWrIKPldyc7tw9evXk9AO2fwrJOpf2iFihk+zOeYywBBz1yPfjn+WKqT2k0kW4lSznIJGc+nXn65/HtVYW8sLxkbvu5AIyAPoe/c/rzQBbHh+efe97q0G8jBVpMh1IznOPXn9e2KguNCjg01ZEu7cyRLuEfd8fNwO/POfYH2pgjdy5Idg3Tc59Ppzx/nNRzwO53bGd1AYfL246+vBPPrz7UAb/w8mQX1yecCJscYxxnv+ftnPQ4q1dalHpyqLWLzFBJZXYAgDBBB/X2znoag8G6a32m5KR4byS3I+b14PuB/X2pstqGkLSLtyMZHG4e/wCBH8+lAFeXVPtbSyW4a0nBIk3HcqgdOnTr+Gfeqa6JJNEZpdaiWQsxZAjD/Pp7Z57Ven010hHlgnOCxB49x7dvp9Kqrp8iyo0KAKp27tpPPfn06f5xQA6Tw3ZLbeauqqs/9zYQQe/HX0H86t6dHYwyRfaZ5HkUBS8RGSc/ljt+nWo2091RiwbzCACoULz078/n+NTWmmP5xzujUgAYA67fyzn/ADnFAHf6X4ztbWziRYsyIeA7YyM8/jkf5NdpoHjO01lvJZTCW+Zfm3ZHp+f+c14bJYMgIky4A+XIOTwef8/zqxbxTWtmHRpElXJbGeAQPw6f5zmgD37ULyGGSJi4G0/uwDkHjjn6+n4U1NXhKKgYKCfmUEZ9v6/0rwOS81RzOy3UpRMsqk/QcHqOPT145zU+narqVvdmTzWzuOG4I7dMfXj9O9AHu1zqemxpgvEUGR8z4bjn8KzL+TT9RsJUS7gMbIdpJAPt+leMXN1PPLm4eYKGOSScD8v6fyzVFnuICSszMpyCnIPJ6D9Pb8KAOwuL7RNLLRrmadDjhcIOcEe3HH6Vzl/4seCVDYgorHox3bRkj8BjjH4VkS2c0isfmctztKjPX9P8jpzUZ0or+8RJNxG5g3Jb2+nt6UAQXut6lqN7i6u2OWwAOQVPYjvnp74xxjNVxDp7GPzIZNwI5RiwOc8Y9O/vj2q4mkygb5FlWXIAUDIGemfU5/wqeLTJJJVeONjjIQFSRyM9P85oAxPsGlRxkXGnuTu+STzM5GM/r1Pr16ZrFMDwzXB04CCIy5285VcZxz9c/r0rv/7JONnlEk5DEjoD7/T8zz7VE3hmUlkYSIqj5di9eff2wP8A61AHIzL5shc4JPfzUX9CM0V1raEYTsMT5AHTav6EZooA9kn+EcbMFa9dCOQVzzyD6d+OnXGevFMX4Sk7At6WwwYpn75zn8s/49eK1PBeueKPGmo3us2+oaXZaFaarJYjTpbV3leONgGZpd42yHJIAUjOM89fUBCTux0YZGM4x/nHP9c0AeLr8KowjETYAI3gp93v07cnOffPfAhHwnQKp+2OOh37dgGARjPOMZ/DOOc8e3TWgVCdiA9SccAfyB/z61AYgEKsBGMjODgn16en6dqAPGT8LkVXiguTGF6EAZHbP5cfjj3qT/hWKkoouTISeuM4HTv+X6e9evTQxbjtIyDgMB15x+PPH6dOaZOrqrbEBHByVznnH4en/wBbmgDyh/hZbs4C3Lj5sn5dwbt+OenHp7ZqJfhfbosgW8Lbj8yAA7vU/j/T1r2KGNZG4APH93rz79e//wBbrVd4g0iJs5HTK8cn0oA8m/4VZbHazXUhAA2kADPtx+fHpnpmnj4W2ccYKXxLqAykAen+W/8ArV6k6SKgVH34+bcepznv349h/SqMjgkD5hNjg5zxjPp16/z9qAPPpPhjayI2LhyzKdzZBHQfgMf/AK+Khn+HVoCC075U4Clc5wMZyf8APPPavRgjs2d5+8RjGcYGfw/XH04qPymdThSvqp46emf8/WgDzd/AFi80vnzSHr8qgYXpxzyfx/HtT/8AhXFhIjAzOoycDg5yff8Az+NehGEpIQwCy5OVOP5c/r+OeKn8to49oG0553dMen+f50Aeaj4d2qTrteZVCkMGckkk/T/PXrV5Ph1pTu6SSSs7sGyTg9fyPI7/AF613X2be5VV+XB5yT/P/P41MsCpGGJ+YDIHHP8Akevf3oA5az8D6dYnzbcyuzLsLN069iPfn9evFA8B6V9xTJlz13kdzjnHv+HX2rrG+SJg524xhdw9PT8B07+9CuGALsCpGT19M9u/+RzmgDmk+H2lLEEYMVCjb82Tx7dsfp71PD8PdH2kNDJwARhsfr/nFdTEq8lQAgGOP1P/AOr14q2rDzBtG3A67evtQBxc3gTRANiQuMgfKW/n/L/GpIvBOkuY18gYTklm/D+XH+c11UqiSVkBAdTgA8Ac81JHhdsZVgq/xD6/5H+c0AcxH4H0UMxNptBwM7z83bH9KbJ4T0c8PZqATyzn3/8A1D8PXmuvlYMgDDBzjBGe+P8AP+TVR4zLGwAKg8YC/wCf8/nQBzMvgrRlBb7IjFxjAPX/APX7enFMh8IaGbPclpCxIDZGOR17dMn+XHeumWAlBgsQpyCP5H1/r7VEjMMBmOduAOO2eaAM1PC+i7ox9hRjgcnoff0/L/GnN4d0YMjLp8W/aBkL1GP8/wD6q14Hx5YIwQDzn1+lPyfNjyPvLg7ecUAYyeHtHxn7DbBSD/AuTx/n/wDVVkeGtKnVB9li3BeoUdAMf5/LpV9huXGzczZwdwGf8/54q2w8lYwDwEOc9+aAOfm8N2AlKNawOrZ/h3dhycj2HWli0CwhC7LGE4JwNgPXHXP0/T2rTH3/ADCXLMT1HQfj/X8e1Txx/dJYMQehHt7/AOfxoAz7jR7ONUZLOASchnVBzk5/nz+vtUK2Fss5iMMCn+MlApx2GP1/WuhkB8r5WyxGc45/z/nrVQwqyPJgYxuBHb3/AM/zoAw5bSEyNhLZO219uR9eKKviOTH7vlTyCM9/oKKAMaT4e+FR4kbXF0pU1N5hctIksqo8w6OYgwRmz325z3yc11iOxIDAg9dozxxj/wCt+HrzSur53MwJLYGV59Px57fh703yzhRsEi44JGQM/j6/4ds0ASfaVKlwxbIGMHr+P4dvw71WdjJGGTEjL8yjPrznj6dvw4px2GRTFv8AmPDDpz/Pp/nvNbqFkYxklm5yec55z+n9fagBnGRt+bt+PX/P+FVyWm6j94Dj5ep79/b/ADiryJ8pC5xnJLc479f8/wBKq3MYRGeRi67ue2P8j/H2oAiC4y4DBlPz8gY556+3r+PGKZcgoMyDcpb1H+fT+vanNInluCSTyhDYwcD39sdfxyOKdhZIdxyNrHC5GOOPw/H/AAoAhlRiuORLgDPb39+uOv8AOoZIHaQmUbuNx4PXP+PP/wBerygCQnnJ6nHI579/8+uDTSDnBYlcjv74/wDr/wD1+aAM/ILRBgXbdxj+Hk469OeeP51CVKSbIxtDHAIHp0/r/wDX5q9dxgybgpByuWzyAM4x+WePw5zVVAM7xHtIxnafQe31/njvQA/92gTjAzjAG3bjpn6fjQ0I+Rkcgj5TnoMDjn6U1flCD5RwMBc4OOgGOMfT8O9SLI5nHnBju6lVOBjjBP4/T8KAGJELdcKG25zjP4evvj9PekRUXcvGACFJwAOMc/y/zmnyAKijavGMAAfTt/n8Kj2qZXkbuuAWHTt+H+R0oAY8TTITK2TjAIOBk4GOOe2P/r81OsIEfync3Jwcnk8dB+X8sc0i4aJSgLOTwc5HPHT65/l05qzGpKhY+EHXPJ56DH1H4+1ACQf6pm25RumG7k4/p1H4VNhg5ck7sHjOR1/z/TjNQx4LtuDEEgYA6E9Pr0/H2q7tD3P3iG74+nHH+fwoAZJtExbIGOgDcknp04/z6VHGGLbWUqxOQFJP+eP84qVgTcSHAK4B+UAk/jT4wWcEllODntjjPf8Az36cUAR43OfmJwMsAR/np/nFRuVQZ34z3H6j8sf/AKqsyybZDnBwvJ44+vp/ntUBWNWB2DOM8kY/X1FADuDgMQMjnHf1/Pj+vaqzRN5ihxvQAt8vbn19+K0IU/fuGwcZBOenTqP8fx7U1FcghSDJnLDnjmgDNePMhYbmGCGXb1/H605WYhAwcKORx3z/AI81pSQxopZQ7PjBx9ffn/PrUc6/KiKGABG3HTr/AJ//AF0AUkaY7GBG3Jx3HXr7c8/5xVi4bLAzcADIQY5P+TUe4I6kFcDIbOc5zn/Pv71NfKpZHyA2CQeRzQBDGCQgxtZBuIIxgj8e2ffGe9WbdX8xSEOE49M8Y7/5/GqJEiTxKoIVQGYgccD/AOv/AId604MhwW6K2OmO3rQBLMD5aKF5/lxSJHE6ZOW3DkAkZ7du3+fWrDqc5BPAPA6VCXLD5BgkbQeuM9KAKyKsCiNOFXoPm6fgcUUya2eaQyb1bdjny/b60UARurbS235ewA5Pboe2PXj8K4rUfiLZWnirU9CstE1fULrTTH9q+yRxlIy65XlnBxjHb68Yr0LJCud3MeDu4PHX/P5+1eQeAJVk+OHxOJTBZ7FskgEYgzigDsvCvjTS/E09zDavcW9/ahDd2N1E0c0G7P3gex455HHJ6V10CgEHJKt0Vs88c5z7+v4814h4p1Kex+Neky6erC4GkzC5Y5Ikh3gR7h7MWwT/APXr0ltfuLe0eTapMYBxg9enc/z/AJ80AbGvanb6Hpd3qWoy+XY2kZllfGdqgdfXj/PNcHB8UPD99ZLcWNl4hnhcBlmi0yYo4YZBHHIzz+tS+P8AUotX+E3ihlP3rCUOCOh24OM/5/GsP4dX/wAQpPBvh4Lpvhj+zxZw7Ha8l8zy9oGSgXAbHbOKAPUEfdbI0cbKrqpSMjaQCARx2P8AL3q0FPlOEyvBOA3T8fz/AM9IkER2mRcl+Plzx6n0/L8KkhwFZD97r0J/Lv8A5+tAA0YyGzwTjbjofTHT1H6e9M2srv0K5HRRx/kcfp71M3KphemMrjIyR37f59KgYoZQNo5BGeg/zn/OKAIBFJ17K3OONxHP4/16cUzywq73ztPUdSR/Tr+P4VYlZ42AJKnPH5cf5P48VDIxkG0KM5Kng57f5/n2oAqtCCioFYMp+91/Xv8A5xTwQjxnB2u3IGRx24/XP49KLqcRI7FuxA74Pbk8/wCeaoOZbpJispjeNGkTHTcOgx9P854oA1WiHGwge2R/P9f16U9I1ETjILAE/wD6v8fx6Vxcmu3UGrWdrJIHSQZ5OTk/h/nr7V2Sy7Bjnk+uT+Pt7/j7UANEKxZZTh2IxwcD354HHr6+lSSAkHKDbxnPTk+/Hp/XtUu3DLkhQDkgAYPP6f5PtUxkHlKJByDgAsOv+TQBQ2GJJZDtVjt3BT+fPX8/xq2IyzboWCDbuOCTz/L8PzpGaNmlBCjAAAz1wKsWsm0JucggAAHnj60AIUJ3dd+Bz/nnrTWiMp4VdqkEk+p9vr/nNWpgBjrlvX0poY7gADgnOAevH+f/ANdAEGxg+NxbqM4/z39KSWEYjKnvnnj/AD/SptqMAuCSw6jt7f5/nSIUaEDazEdc9etAEaEEswGC3QgdP/1fpUynYwdgPm6YGMjrUAkCPKxwrFQcDPcf56fh3qS3IdsMp3bc9OaALBXlSCyk8EDjIqG4UFFU4bAz/wDqqdQygFgc+uP8/wCfaqtygDxEq4XGOP8AH/P5UAQ7N2AwJOOMD/P+eKnuo40tyWDEhTyOcYp0bqp2soVNuf8A61JeqJEwAAoU8HvmgDN8wKwG4YTIzkenH1/D8O9SWsmZgV5xnAJzj8uvH+cVWYBpBtBKgHvk/wCf88VLG6icc4UtkMw5H+f8+lAG4hSOIKoGB2FRIAGOVJ5zk55P4/5/Sowd7AHJAzgk+9KzN5q7SBuHQ5/SgCOTO89f0H8+aKnLyrxyMe4ooApXHmRJLtXcx6DPQ49e3PP69eK8vu/h083jLVdb0zxVq+l3GplJLhLRkVX8tAqZyD05/Pv0r1uTIEj7evY59v8APH86yZYpTKgjQ5yVYjOF7/1/w70AcPofhDTvD+oXdzbPd3N1eACW6vZTLLIV6cnhVAJ4HTPvxua9aCTSioUAEgK20DGDjp9OP096uToVnjSUowVmPTlgCM8dP8+lWJY2cgbQxBHAAzjOP5/4dKAPPrC3i1KfXvDc9z5EOoWxi8wAZG75SRnr6fp716LoGlDQ/D2n6PHJ532K3jhEpxlgoxkj3x/T3rivENlHpuqJqykxosihgOm08dPr/h05rdsfE1vc6kLaBw6ZVNw9cdOaAOoklJCH7+7ABA+9n3756UxgGJ2o27byDnJyP/rfpUKTF2I3cEcZ5GD0/lT5C2VBBZmznAzx159elACyFzahFceaF4bORyM/Tp/nHFIEQIWD7uoA4445/Dv/APWpyNk4Zgq5zkjr3x+X+PtTsbWKKfmZuc/XOff/ACfagCGRVZsZY4yT7Y6/5P40XbESJ1CkE88g+v64/rVkIeO7KQGz0HWq13gQEK2VAHTgA5oAydZBMRZ23OV5UDJ69fXrj+tMsVI86OZgctnBA6n9Ov8AnNPvS8VuolbHIxg9e31pllKsqsZM5U88g4wP8/8A66AOX8R6TKJFltmCyoxZTzgE9R+f+PWuo8OXc15o1tJN/rDw+B3Ht6ZHX8etUr1XbKFfkPVRk8YP+f8A69M8KsEu7y2DtsU7lXd90FR2/wA/nQB1juiPjAGegA7j19Oc/wA+tVFnYuGjGFUcsR34x/ntTpXAcY3M2SflHXgc/wAun86bBbZhcEDBORgkDjr05/zxQBZyEcpnLY64zjn9Ov8A+urNtGAoAVtxB6nPfj9OKhaIRwPuZCQOoHHWrVuMKjOAABz9fXP5UAKzsiYHRT1xjPPT8uKTzjsTaThjnggEc4/z+VNZAzhQQec9sfX86FHlvyc89fbpigBjBjIJeeHwB0z/AI08KBEArF8fdx79qkl+6cj92Wzg9+341Xu5jHBEzHAZgoIHP5UAQiMbt2PmIB56dPX/AD7VLC3+kNznOM89P881ZjGGOcgYPGM8H0p0a7FGXPXcTj/PrQBJg7QBkAD8/pUd0uIY2YjKkEnParJ5bjOAOMVS1NAYNoY7tw5wT3oAa7YXHABUgg/5/wA/SmPJ5ZT5f4Tx6+v9KmkhMgQn/lmOgPf8ajuWVY13NuCr2GOtAFPzBgiMZYKQ2Qf8nt1pkrTKYQdrLvAORknjv26j+vXih/kVDHtVT/d44/z6/wCFVZbpYJ41dhh3AzyOSPfj/PrQBqhm2joWXJ25yf8AOc/zqWLcylkBCn2wR6D+dVmuYI5QqlCwByAenGep/wA/jUqXCs3l9dvJAHv/APXoAJFZnY7iOenpRT2aFmJKnOccLxRQBKLhXhdo3VlEmxCvPIOMH8cjj+dZF1dmOaMxEJJuzj5vmBB7dunX2471qAERqwbKhcYJPOf5/h/Oua8TMsNik7dQ6pyp3DP0PP4fh0OQCeZ4pZ7Jo9rITh3Hc7Tj2xj/ADjNaYCxrE3y7SDtK9+Mf5x/Ks+0RI4bXzXwwwRnBJ+nb/OemRWxJjcEIXaeTyAPp/n+VAHM+J9NbUNKuVTkuOOM8468e3r+PHNeX2AuNMumdwSqSFs9egx349v0PavbyreQcBcEkdM/y/z68Vh3+gWxE5khSXcu3kZ6/X3/APr8YoAm0q6XUdPinz+9YckDjPfGeT+P49q2YWBYK4JGDuBGc8//AKuvpXBeEbtNPtpbJn2tDMQN57Hpweee+fx7V2i3GyA7Y8ybd2Dg5P8An1/nQBb2eWxJb5iPlY9Dz6/r/wDX4pI1AztkbGec/XP/ANf8c+1VbG5FzAJAhUZIZSeR357+/wD9firW8ylm4zjl1J9P/wBR9j75oAUsGffwUUhfpj+WOtVZ45fJKxADqGx3H9Mf171KZOGBGOT1Gfy/+t74qKYFY+FLK3Qj+n+fpQBz+szeR9nRjs38AcYBHt7dPxq3Yhy0qO6KcAljjk9Mf0xWX4oQyapp4kHlqWIMY45BHatS3CveyKFIWML8ynHQ44/z7e9ABIGkUt5YwTjgH6f/AFv85rmTFJpfiZ7uRilpKdpIGRnIA/lj/wCvXYpGTclAwOMkBF4+p/z7e9ct40Zl0x1AZiCMMR059f6fhnvQB0MWqJPq8NsrDaFEhwBj2/PGPw9a1FV8KysHUtkcn8B6/wD6uK5DwLEHliuGkLbo16sM9wR/n6ds116ThpCFyrbgSeoAz/n60AW1G4HHKjBA98GoL2XFsCCPLIC4Pb0Of8/lSyuyRBssXPzOf8/5NchNrKxXsluW5yWAZ8EAf5/H6UAXNe15NKhZC+ZhjBx14z9On+cVnQeLZprlSHHlMD1z/d7f5/Sorqyuda1EbkGAQTz27ew/z2qLVvC0ltYXE1tkSRjgLn9P5fT2oA9BhmEtlFLGDtlG4jqeQPX+tYfitJp47byvmdOQF5796f4N1FrnRYI3OJIwFIxyfr6fj/LFX3dLi+dMBiEK59uw/wA/j2oA0NOk822hc8llw5xwT/XPWrARnl5wV649PSqWmtmzKnG5cqPfv/8ArrQQDIK8Z5wcjPFACbQRznPUE9v89abOhKEYy2OuOM1IzAEhl7entmq11KI8DK5xjAFACFmWMMflO3oD0/z1qvJMfkyVWQZynHPv/n1qO6uCsRUcMjYPP8vT9fxqWRV8hGOEIyNytzQBnzkRzhFbkBn25xt/z0/GvNPHuqzwXypGcAKHyB0IbHH8v/r11niy8bSbi2lEmzJYPu4BJwB/n/HI891m0n1XVLacLujLFGcKcEbiMf5+nXmgCsNe1SWS2XdLvDFgemRn/PT8Oc10vhnxdOddjivDguuw8gZ546f59O9dF4b8Hw26RSyoTnDHf1HGP846/Wsbxx4RMM8F9YlYlgYnKH+f+f5GgD0CSeMtywHA4xjtRXmVrr94sIEjtuBbOQPU0UAexKjyZO7KgAMAAQ/HNcx4u0/7RaxW8SklpA5ULndj8e/H5dsV0Uk8JDDzEy/ygMeufr16Hr9PSqzvby7QjxDJ3KSAQc9D1wTx3x056CgCC2tmdYvN++Bgk9sEcD69ePr7VoujbhliD6nHTP8Ak/r7VWnuIUXcsikZ6bgTz83X6A/z61G99AGLs6YdcjDYJ7/1/r14oAsSIuX3FjtYEDt1z26ev8+Ke+JCMLzgZyOn9KomeLYUaRBt4I3AkY5Ofz/Dr7VI13AmTFcRADOTkdR1GfxH0/GgDz+/0G7i8SXb224RS4fG7G4g8jByf/1854rvbPeyZk+UKQGAI9P8jn8ecVG91CDiVsyLuA5C5Ixxjt1/D3pI7uBZmXzoshjnMgPQhf5np+HvQBdjjMeNoXkfMF6+mT3PP+c0pjAdVjO0HkgZ5z6/j/8AW5zVVby3M+fMUbu5bPOccD6j8+OtTpqcEJI8wduDzweB09/z6UAJcNkly468Ac59P69Pw5zTCrFVGcgAgA8Ajt9P847003FsfLZZk3Hn72Mj6/yx+Hemy3cXTzo1bqDvz/n+WOnGaAOY161lvNYt5ELKkYHyqe/bpwOM/wBOK2bVNksjEjc2M5JGRjj9P84pDd2yyZeaNWAwMN0/Lj/PHFPiu7JQCZg4z1Oe3oR/n8KAJLZVQMxwGxjauOnbv0xx/wDW5qvqlnFfW8kci8sCMsM547fhx+nTmnvdWmAN6f7JyPp+X1/lUgvYCAYXiPb5hye3+f8ACgCnpWlfYmVI3YKqDdk54wPz4wPw/GtUozyH+IMTgFc8j/P44quLyJwxQ5VjkFST147+/r+PGKkS6hDryQGwCCuev1+n+PagC9FAVBU8kgg+/wCJrnI/Cvm6u1xPt8tw2Rnjls9P8+vHSugg1G3ZMu4PGB8uODyP5fjVi2vopIsrl8dCARnPP+TQAq6bDBN5seVJAHrjFWDAkkUgZEw56Yznmo5r2EYI3Mf9kHmo2vkjLkq/BIxs79f5f40AYp8PvZaq1zA37mQfOAeB7+34/wD1qvaDayo9zJcjaSxwPQD/AD/nirn2352Z45DsUnhSPfpRJc7YjtglyAW+73oAltrdUMmzI39Oen+f/wBdTqVUAgk7eCecGsqC/dcJ9mn4zuAOSccdP8+9Sw3zNgfZrgY+XJHQ/wCf85oA0c/cYr9faoJ4BIwI42sOgHIpPtpOP9HlAzjkc0yS8l2sBatuzgAkc0AMktRuz1wcj29Mf/W/nTnBVVeHbhj35xx6f5/nSC4m5Bs3A/2T/n9KrXN1cbV3WrDBz94ndx7UAZOsabFqVrGkuJJEbgbRx9OwwOKh0vQreJURQAoIZcqBg+vXjjA/TpzSyyXnzKttxkE4OB/h/wDW9qfHdX6SkGzUBRgMSBgdP5/5xQB1SLlBgkFcDPA3dM1XurWO6QxSLlJDz9c5zWZHNqEkjKkUOT0Leh6dPp369+1WJZtU2lkt4MHlgXI9/T/PX2oA5280FXupWS52qWOAQv8AhRW41xeg/NBbZPPLt359KKAHtp1o3Jgye5Oe/wBfb149eMVAdJszA6iFEBGSdwPPcc++OvPrzivP7jxrdxIghCK0YUkHIyfxPHXvx68YrsPDd/Je6ZFM7DzfXA5AOOh6dT159ecUAaF1pln5WViDFDhjnk/j16/5zUK6dbJEqIgG84O7cSfb88nn+dRaZes8l0hBbbKQMnAA6D36f53VeRijRkNgY2hDnqTz056f5zmgBG022KKFh+fGB3IHbvj8unbmoZNOtST5cAyvf3/n6/Tt3q+9wpZshUJALf5/Lp+HOahWQq7MnynHLHge/v8A5470AUJ7a0gjcSoqoegwF/DHTj9PfNSpDZOhmVUO75QSent/T8cdOa57x1fSjSUCf8tPlGzAzx+XX8u3Ga87PiK9tmgjN1Ivkj5lyQW9z6duB9PunNAHtCwwAkuq9MhcZzj/AGf0/T3pFt4slRDuOQAAAce349OvOMdqydC1mLUIo2CqxMfTkHoAcA+/Y/Q8YNact0iRtjaG7fxdcdj3/n7YoAmMNvgr5QAHfGN3rz3z+uKgl+z+WNyqUx045x3/AB6++K4fxP4pngupYbfKOI8ggAZyR+fH5+xrN07xFcXU8Cl8RMwyGOeT1/z39ulAHoxigePzPKQAKcNjcc9OT0Oev60tvFGsUYMaOFOANvA9yP1z+PSqjNvtskMrlTheuO/X/P4UWKyzWYeRiO7ZGcd/8/n7UAXmgiKgBU2kDk44PQ/4/r0prW8e5SojBPXA6Dp/nt+FMgdDlGaQMuG+Y4zzn6f5z0qWRwFCrxj5uOAe/P5/5FAD1ijYYlQH1OcYH4/Tv+PGKRAHU/u2YkgHdyTxz14/zz2qOU7LUiP+DBAwQOOe/wBe/wCPaneY0UCyRqduQBzjkdOvH+ee1AF23G5dzBdw4Ix6fr+f41ct0VCJYwoVeCAfXn+f+c1ys1+0YuIwGXptIzkn0/L/AOvzXR2DkWqeccA7eTxg9Ocf5/GgC/JuVF2qpb37f1FMUZLDGcD0AouJ440BOR3z2/x6f5zT425HAQNzjjmgCaVgsXpxndjpTFdXTgYyuC2cUly2YCrqfTp/n9PwqCyQpahGO4gZwDQAyO8gW6aJzsdQOG4wD/n+lLBPEJzBuBIB4Az3/wAiuI8aLd2mqrcx7tsmAQPYenb+nToc1Y026KeKoi8hInt9yAjI9P8AP5e9AHcs+ADk9cY2/wBKdNlFBJ3AdcnmqnnqUySwOemRUskvmRSHAMeMn5uvHSgB0syIhd3yAAcZBz7/AP6qhlIkVT2TscnHvWZ+8kdnRiUdM4bnj096zXvGWZk8w4xyPY88/l/WgC/cSIkrpzvzjJPX156e/wD9ai3mRwTvOQu1QTgkZ/X1/wDrYrE1FpZtUhlVvlP91jn+8Bnp/n0q6rhJsPnBGcgjGRn9ef8AHtQB0Fo6t/FhiMt7fT/6/wCPan+cAjsW4yBn3/w6e/41nwyARAY4i54PPoP59/xpXnRUXdg5IKnnr06f5/OgB8t2UkK+apx3Kv8A04oqqGhYZdAzdzvcfoBRQB5DpunSX+r+Xc25RJCNyshXbgD8sZ79M9wRj0nSruL7Y1nGyItspG1XXrkDHtjgYPPPPUU6PRTAkQ+8y43NgDce/wBOvf8AqMY+l6PLB4necEhYwA2MAE4Ofp175/kaAOj0+Dy7m7OFAaQ4HY84+vXj9OvNXWi3HagTO8Bs5457f5/WljDQvIscm4lvwHGOO/8AnHXmpZgOm84C5JAPpj/Pr9aAIt+11J5AAbJGf8/5xzmo5Yw7lpRtHB2g/wCf89O9KzlZJG2gbSTtzgc/p/njvSiQkN5hAyDnnkEkf5/l3oAytStEnRNwzGpztODgY9v8+nFcbr/hdZ7meW2XaWj3cE4GBx+mf5dK9FCl3TDDKk5GOBz+X+eOKxNe1vTdBlik1efa1w3lwQqjNJMwOcKoGSev4e1AHn+ky3OlatY+YMRsCj+nAx0PHTA5+h4wa7q5vIJLCeKIjBTPAB4PHf8AL36HHFee32sWGsa5JLppkljtGUTQSI0bxSNnAkRuRntnjHXjFNj1B0i82N8NGqDa54OGI78dv5Z7UAZ8IlvNSndyTgFZpG4CjnJJ9OPxxzjFdX4M0+GVYbmC5huodu5JEYFTnkkHoc4znvj1qtotukGka3e3FuJh5LyGJ8YkAQnDfUDB/XmtH4SXP9q/D3SrsW1vZLNCSsNuMRoozhQBx0/x60Adckq+YiIVdu3OSM89ffr+tX4bYwhF2c4yRjgd+n6/r7Vh2enmKf7QGzIBjceeD2rejLqoDDLfxeg7/wCfz9qAI0cGIqxAKnaF3DjHOfb1/WmEKrNGR8p+6VbGeM/j/k+1PWMJuA3NJ1Jz/n/PPtSAmNQSrbx2U8D6f4/jQAk7DY+U24X5gDjbgdefTNZt3LJFbAK207uoAGPzz/nrWhLhYnHytwDnp6k/z61nXkyRiNpX2plSDwAR+P8AkUAZ3mNNMwfABIygHI5x9fb/AOvXaWJMqFYx8iDHJ6/5/wA81xGmbZNQhRMuZWwWJxwM9uv5/TrzXd2sMfmAKfnVeG/D2/z+NABIHWIcBtvzAD6/4/5zU0MpcNuVcAZPHejZut5CwOSegyeMc0iKohYR5z6de3+f/wBdAE93KFs3bIGF4yeh/wA+lULe/wB6Ax4+6MNjgD14qw8YeBxJhiVI+v8An2qjaogVsDjHbueM4x/n8KAMbxkTLpbMpUNFyN3PXj6dOPbp0rKvVAbT7slTLEEHToDwf04/TpzXRa3ZLLZuqpk7s8/X8v8APpWXrFhGmnPLGh3BFIQex9/8/hQBuwyuINzsF3KG27c7vw/z+lRNfMMp0kHcngZ6/wCf8Kdo0iX1vmJlOUAb2+v0OarajDLhlij4CZH+JoAfFdlgiEgkq25lbrx+uayYFjubdlcjcp25wfTOT6j/APX7VfgjKQLIVc/KQBnk9+vesyUfZ7bYoIkkJYA+nXB/z159qAKcFzIl+6jLBI9/Xpxnr+Of19q27SYyWy70K568gD6/h61haOqza7fygBWVRkDr/wDW/wAn2rpNPQbI+SI92MYAx145/wAigC7ZxsqPt8wsVYOG7c/0/TvTZkJVmbB3DqevXn8P89av2W0KfmJKgKc98ccY6VBdt9onAyhfGdwPtj/P5UAZTyMGIETkfRv8aKe8DljtjLD1ERP65ooA2ZBIGjUxsq4yMrgrjvnt/TPvUCYLSbIyrYx8x+7x+n/16uTyNcMu8FdnQjpn1+v5+2aqFd9y5UnkYbGeORyP/rdvbNAD2EhwcDA54PPTqR/47+nvSbSw4UsAcDjcR+H6YpzwJvV8Sbw20AdG57/56cdOan2jzGGBngdOOvv/AJ/nQBQEREojLOCBnA6MP65/p2p6ADaJUUEj15brz/n/ABq0UYEBjlSFCkL3z19f89sVXK4kQKGOBjZkcDHXFAFa4fy7Ul2LksOhHT/9XNcF8T10Zr3w5NqtxqWmyiZ2stZtc7bGXbj951G1hnrx68V6HJGvkBZFyST3yBxnr2/L/Cm/Z7doHiaON06MrDKtxnkf59fagDx/QLu61PxB4g0/7db65aRwQN/a8dp5TlznEcjdJCBzntn0Nc1PBI9+Vy6KXZSDjHP1/D+vavoLyYbWLbBGkSR5ARFCj1z6AZ/L6cDh5NDtWvDLDNFKrTl/kZTjBGMkZ75+nfNAC38tnovgXUri+ljig+yyq7Nn7zAgDjnOSB9evNV/ghYXFn8JNAiulMUwhZtjLhirNkcduMf15rthbxLbmGSPdt/hYAjOfQ/1/nUzFUZT944zkc/h/n+dAFLK/aHyWz0zjgnPHv8A59avKij5jjjk/LnHPb/P61mwyeZcuq5ABIOex6Y9en+c1oJNgvkZycE7gR0/z+PvQAKxjkBJGeMEcYGf8/8A66kAAjYk8ddvYYzTEdSZGHmE4PPfOOo/nx396VIx5ZA3KWHPGfr+P/1+9AETszR7ShXjOVGMD19sZ/Wud1FGbT1wSjZGGxjHv+HT2zXUzgrE3RX2lTjt78fXt/jXPXjfuuGAZVJXbwMZ9Rn/AD0yKAKtgpOq24jX/Vjc235R056fl7Zx7129tLHIGcKxO3BO7PXp/hXDeHZFN2VCno2efQ46f549q7awk82NMLuAIXJHJ5wR/n/69AGiqhhg/KcDAz1/z0qqCxlJUYG7B+nqKsY2BQVGSc9OOtNj2mTHzcjODkk80AS4UxqTzgfe9f8APtWdaSqnG5GjPJVeuMdeOavSShoTkEAjBBIz71k2Mi3TybcGNRjA5zxnP+f/AK1AFm5iWa2LIc9CpPpj8v8APpVTV9n2GXgKxQ8Ae2M5P+fwqckpIfLPUfdx1HXr/n16cUXBVkKBVJK/cJ/z60Acx8P2ZRfLkYLkAEfn/k/4V1TRp9oRchgQWHXp6f5/GuUS5Gka0bdUC5YYywA5/wD1966OSYQ75Vmy+w5J6HPFACSOVlcTMCNxGBk45/z/APrrB1OBoUTY2ArEkMoPBOf8/n1rRW4TylDbmx8wPII/r/n1xWRqF5mcox3Boyxz049Pw5+vvQBD4Vt3m1S4nUFm2gfdAwATjPp/k9a6eAqgAbOOPvHoeR/n0rnfDs0iTTkbEeRQx9xjrn/PPTnNalnMtzEHXkgkcE9R9P8APp3oA1YR85RWBBAYKDwOP8agltS9x50cJ894wu/H8Iz/APq/HFPtAjvhzlyxztJHPt/n6cZrUlB8oMVPmDkMoyR69f8AP4UAZCpLGoXyXOO+wH+tFWRbgjMsAZ+5IBJ/M0UATzu3yoh3q4+UsR6cdPXrx6cd653SLm6lu5HbhN/A9Rnj36A9OPwyK6QSBtpBRVk4znOCef6fj7Y5wdMdP7Uul4VJSCpHfjd/Ie3r7UAdAUbPytwDyWJ6/wD6v84p+0MckHPbOOn4/wCfXjFODhd3HK8DJ4xjOP8AP19qj88ruwOSp+8wHTr/ADoAmKYAbjd0YDoPX/J/wpHhVsgsNpznA7d/1/zmmmdQzKTuwMEE84B/z/XNSPKFjLZAU55Dd+nJ6Z5/zxQBWeNkwFJLA4wcnGe/P9P51UihHmOTjnoQOpDZH6/5zWiJFB5J3Hp1z/jj/PWolkjCBwVAByc8cZ/z+PvQBwPxVntv+EYtbK7ivXkv7uG3t7azcRSXMgbeIy+QEU4OWz0PfpXO+HBqOnfEmx02XQdJ0K3vrCSZoLaUPKxjICliBgYDHkZznvXp3iPQNJ8Saf8AY9TiDwB0njZXKSRuOQyMvIPoVPc471iWfw+0DTbuyv7eK5Oo2bEx3slw0k+GGNhYnLLjovQHkd6APM7ya4tfG6/D1tXuDo9xdLcm7MjmeElfMFl5nYnqDnIU4r1vymKpgEbAAvBJAA/yD/k1m/8ACA6K3ha50GYzT2l1MZ5rh3zcGUtuEm8DhgcYwOAMDiujggWCGO3DO4jQRtJIcs+BjJPr/npQBiWETLcXAmO1yVIGPvfh+nX/ABrWIUO2G3cdRjk4/wAj/wCvzVRYWeZw2ApIZeB9Og4/z6VoKQFD4ByDyCQPT+f+cUAEMfDHHzMO3Vvb+nGPz5oQHLD+EZ5+voP89PXJp4BLZwGLLwAvXPGff8cUkS7wruBuPAAHGCccfl/nuARXuWjJU5wvDBuv5cfl6cd6wCoOmM24MyqSrL9fbn3/AJcV0M0Sz2xy5CkEYPPX+fT+dYVyF+xEAEmVTwvfcCenHbn/ADigCHRrSKS4eSI/uwo5A4zjPbj/AD6V1NioWKUkH5McHJxx15/z+Fc74UtBFa5DvtK9znHfH5f4+1dRbMFUg8gDvjPTI/z/AEoAm3Focf8AfXf9f8aajMAGYg9sYqy6grL82Pl6A88expoREw8hBOM8jvQBVvELWMhLDdtOT1BPf/JrH02JljCqxdXP3Md889f8/jxXSGNBakKCcfX9f/r1QsreIeY8LM7HjP8Ad59+P8880AQtbncHDDOOeOnOev15/wA4qJoyjqRxGEAJHGTknJ+lagjWRflC9Mc9ev5/59ag8hVlULtRmHc9cHOOP8+lAHIeLo3hMF1Km10dMPx055PoOf8APa6Lsuio20mSPDYAGeP8j8as+KbZm0O6ydpSMtnJBwvoR/T/ABrmPB2ox3thBINvn26+W4x94D07/wBPTigDXiBaNdsZUocEdxxjB5/D/OazdQiMU6M6EAocMcADtx/L/wCvzXQWyrJCz+WQ+eIsDI7f5x/LmkuBDfx28sXMi5XsQP4cH9ePw6c0AYnh9JH02SbYSZGZUGc5HTPv9Pywc1u2dobaDBjBy+SAcn6cf54+tWrOxWG3t4o/kR++epIx+PT/ADxU8ALN5eQ7F84HOPwPfigC3bRZjBKruzuQjt756dP84q00ZVVORuHvj/P+e1MsyHjkYscMc4J4Bxu/rSTf6xR8uzlcZx79KAKklzErsJs+YDg/d/rzRUVwwWZxlhg9Pl/qKKAHjcBuB3kHOCevHPXn0/LnnFcY91N/wkcce8CJpxkBPvHAP48884P4jFdRuGyQquCGOOG5x35Pv3/HnFcVqLyxarZxRAM6SqxJGc5IXOT9e/P/AALFAHfKxRyiqNxAw2B/T3yf168VHBKqSSDfkk7j2/Xrx1/lmo1d2Clio7E5zz0/zj/0LNKmGbfJEMghMLnIz9Of88d6AHG5AYiWRQhGMH+H0FLL/wAe6JyCCMsADz+fHHH41BcW6yAHaVkBAXacj/D8vw709XYR7Rgvkc4GP1/z6cUAWfmSPKfKAc4Ixx9M8+n6e9NEhDAFxwDgZz7/AP1v096rM/luxGfXkADGOvv+P8qR48ynaSTjgk9sc+3+cdOaALErrvBPz/LwA2VPAOPf0464xxjNSiUMMBsgtnk7v0HXr+P4VUEqyO7AAnG3H/6+v+c9sokaNmNiAc4APJPPv2oAncsI3Ctle2B1Pbn0PXjr14FVmj8pOeWI5AJBz7Z5/wA56VPKMbiWG0HHrz9fz/zxVGRiwwC5XHHO3jOcf5+vtQAxpT9oCHac8nB49MZ6A49fr0qzAZQ7BwFVe4yOM9D+H+cVg2M0p1GZGVsxkckgAjqOf8+vtW4cjdglWAwR+v8An86AHpKNzjhSRz16f59fx4pzyBTlOUGAOAQfz9f/ANfaqKKEnbzGztHH16j9fX+VT+YwQuGUoOOWGeDnp+f079qAHyzM0QaTCkkk7Tjdx78+n9e1c7rMswtoInYMkgOSoJ5/H14PP44Nb06lo5OmFHyDJ7fXnv3/AMKxNUgJ01f4iucZyAT078fn+PNAGt4e3ppUCkEsQRv3f5+v/wBfitO0iKyFydgY4bAxu/D9axdImkjsUXAAUDIJ6Hp356f5zWhYSC4Vss3yuGBzjocYOP8AP40AbsRIhk+Y8DrnnrUe9wiqe+CCOP8AOKqlx5cgRj15AGD74/8ArfzqFJHDEsrEZyAD2PbNAGnIx+zFSpA54HGP8P8A69YPhy4drmZHG1D0fG3/AD6e3T3rRmkcwnLEE5AGACDg/wCf8mub026lW4KOp4TfwcHHsf8APp05oA60SYLEDGOoLY5Hp/L9KgjmIuUAYO2DnBzg9uf8+1VWkLxNk5JXj64646f5x05qGzeQanHvBVDHgZG4gn/P+cUAXpCk9vcQuhIZCDwcdDz7/hXnfgix+xX2p20qEeVL+7IGMr9Ov+cjjNeigl1KSfKTkk+vtmuNldLfxvHbIjeXNCWdvUk5oAktL2P7ZNCQPJ6DJHJz6/5/KltHNrbLcBdqqSQWOAecc5//AFfhUn9kLHerMh3AMRzjjPP+f8ilvog+ky2UQAYMMEnGec4oA6qN3aGAoNryDcc/56fX8e1Q2LxyyMd2+Qn942O/Tv2/z1qFFZbaFCWCoBjrnj/9ff8AHtUVsnk3lwyB/m6EAgccY5/z+NAHQWw2QEuec7cjp1/Oob+SRDGYozgnnp+n+e9TQSK6SK4wB1z/AJ/z9aqX7q0QYORggFhztz9P8+negChJdOrlXCqw4IDYx7YopWXn51y3c5PP5cflRQAsjeWdsi7VLHJxhevT+Q/H3zVCTT4DeNKVBkDA4H8OD0/PjH4e9Xp0WeRo5EDDjPAHOOtMSTY5LDaCoUY7Ecfh/ke9AEheNdgB3hiQBu4P149cj/6/NQvldiKScMDjJOT29/8APGOaeR84VTkZwSrfe47/AJf096juIhcEhg2Dk4GSfp+n4+2KAFLiVsqwCkjJOcH09v8A9XFTNjdjCqwHH9MfUf8A1uKa6qw3IdyY4J/P6VKpGwqpHPc8cZz/AJx/KgCFUQgE4ZDwRwMcd/w/zilCxpMxjyYwQQBk89/bp/nFNDfOCQQo+6CeOv8Anr/Ko7aRwm19qE9Tk/NyT/n/AAoAnZRvYyKod+ccng9fr26/4VCSSvPylDknG76jB/D+tTsqiKL92MAgHIP4Zz2+v49qYsUmGVUxhuQRxj8eP8884oAjMYljDKuXYgFzwMHk/Xp/XrUTxEOiKuec5zhQOT/Pn9evFSnP3Yzk59Pb0/z+dPjBZwrYKgA5Xr09u/8AnrQBntFtn3gfOvHXp7Z7Dv8Ar7VZUsYtxjIIJDA9f89/19qmjj8tJJAcjPGQcj1H/wCqkfGzbnDYwAB/n/PvQBHKuXZhny8YOeCmB19v8mkcgKGfbhOp34x7f56Z75oZyWPTjp7kdvb8KruN4VmyBkE/NjIzQBIoKlgVIJ5IA4H4dsdP88QtAHtnRlKKDk44w319O36e9WFKukiRIflwQx6H1wO3Wi0HyMpYk46YxnjH+f8AJoARLeIwAKuDnKjOM8/48f8A1+asWCKGO0hxk8Ec5z/jx/8AXpkUbEuzsCAOmeBxj/P5e9XLVTsznnIGc5oAsxRKGcwAkHgj2/znpUYto48BVbOcgAngen0/z61KYipcx7iefoQRzVVbh4wVlRs5xt/w9qALYhMkZ2jGDkYGe3/66oJYqk4dlHmEYXoOPX8v84rQilLeYvTIyGzUF0WZcFuAuc9T1z+X+elADIIdi7GK7XGMgcY6D+n/AOqmpEmS5JIBwckn8Rn6VGjSGSNSfLPTBHocj/J/HimgscYJKFsDgjGevX6/49qALAk3GNdwbP3sYPT271zOo2iReKdPulIYOdjDHIz3A/z6+1dHbQDcd3y4IHTlf8+/41i63bOtzaXGdrwsQHUcfT/P86ANae23RuwLbwcAk/j1/X9faodPsmnvJZJgA5A4zjkd8f59auWspmsQzR7s4wDnr7Ht/nvVhnMFwCMZIzxztx6igBwt2YRtypQnKLxgHt/nNVNQkNuxWNXYM2GaMdOep/l+nvWkqyKhwTy+4gjsf5VVufMjdydoToD0J4x/n8qAHxGWRMjAA5UdCeP8cipLm3E7qwUnAz1wR7/zp9ou63KggPjGf0/p/nrSzArndkAcknnPrQBm/ZY25wze+7GfyopJ5lWZgZSvfFFADJCit8wLdDtwMj5SO3p/njmm7g211RgVHXGBgjGPb0/TpzVac5hYswLEkjBHPr+uP6cZqk18y3EcXy4kIBI6nkfpn9OvHNAGpMchct82cMUPUY6Z7+n4Y96YWkJb5N5L5475x/P9cUwsvyqTuCnJxkjr79s+v8sU1iGJkIwrMoCvyM9Oh/z644oAlD/KTkHqrN1HXP69fwqLcFgYDdt4wM4zz0x3z1/Wki+TJJUEEElhnPHH+f60s+NhDyY34IYDjp7f579eKAHF2I4dQMZyW+7n8OPX/OKVcbQTy+PlY9uf8moi7iNkXLHBzg9sf5/n7VHCx2/OTySORg9AcZ+v+NAF2KVCrh1Khc5AJGPU/h/WrJbdK25vLABxg9+O/wClUlk2MsaIRgHLY9Oenb9f8Fds+aUGHBwM/Lnnj/P4e9AE8hHmckZYfd68Z5/Ht/8AXqJJSu4DDcbhxz19vy/+vTVY+buIIGem7jrj88f4e9RzOjuxB3A84znH4/T/AA680APMm540BDqTkdT0P+P+c0bSZS4YH5ctwPX/AD/+uqEM4lZjGQ6kZz1wPf14/wA5oWV2jZZSu3kFgRnHr/n+dAF5kZBGzDK8H6HPB/8A1f40O23YF2DYVGWB46nt/n071Eku8MRIp3LgjP4f5xScrvIC4IxgZJ/D8QP6d6ADDJE6r8u0jI2+x6jpgVBbNIioVQAKMEEDAOP8/wD6qeZG2PgYcDv7/Tjr/wDW4zVaacxwGTaMZ2kdOc+3v/nFAGokpGd/yKRnAHtjP9P096srP5aD5lYnuBnt/kVnWzK6KxIK+/Tr7df89qcSqAgjGTxu/hFAGs0zMHQKJAwOG9eOv0PT8KhEhW2GRukwPl6kk+3p/hSW8fnBZF+9jGcdRioTnfnA4wBgZz/SgC/bjDH95/D6+39etMuWKzFU3HjkZ9v8n/61JZyKU4PAGMA89PWqSTeZOY3cFVByAfbOP8/X2oAtSONzhAXIBZieq+v+P41BKyiRUYMAxOF9Tnp+H+e1TXEwG0kD5sjAH3eOP89qpiXZqMW1RsxxngD/ADz/APXoAVPPhmOCAHc9Scjnpz2/z1rM8TXBt9HZ5dwCzqflwcc4xn3/AM81rk5kcxsDuOAQMkc/5/8A11j+MU26FqO8shCEkHvz0/z/ADoA2NNnP2RY4T91cjk9M/56fzqSK6LzvnarrjDMTg9+f8/1rz/SNdTFoDOxeRVEgGfpj3/D+dbmqXImlZll5RwCFB6f1/z70AdqNyRbnfjKkkAccdfb8KjkHmRgZ4XggEen+R/9auV1nWI7DxBoENxrDWbXAkxZqgZbzEecFh93b146/TNbFlcC4laaNgY5MfKMcY/z/kUAblk4GVwRnqDxn0/wqWS5j5Ugt8uTgf5/yKzrEqJtpUg4xg9Bnn/P/wCqp1McKrliOOS2eePegCSSBnctkc8/exRWWWm/huWx24P+FFAGRqEsMSJhuHJwcg47/wCJ/DPTIrlr6/eHWLPGBFKylMNjvzn6A5445z93gbmrOJYceaUAO4HeAeRkDOOOB+PXtiuN1TUEfXrSJZImEbKASepxnj16gZ6Y56cUAehx7V27z1GTndyO5/Ijr+PGKnjWIlvNwBkcegHXGeB2/r2rJm1K2ghDTS4VRt2gEFT6HPTr37c9CBWXD4ntJr6WGGUybQwwxC8ggYOf8jv1FAHTko7EkbtwO3IH0PJ564//AF05Yd8BIYhQSDxnP+T/APX5qgZgwDLtb+Lk9P6/59cVNZzMsAaQDbnPy8jJOecf17+9AF1h5I2s3zkccEbce49+f/r1UhQyzJMhx2z+Pt7/AOc1W1ieRjCASi+YGfJPT/Pp36c1NakR7jxtwDxyTzntz/njnNAF0/u1+6BHgYwoByPp+J49frTowA5YErjp064x29uP/rc1WeV43zuVguGwMYX6Y7/T8O9TRskSF2PBbJZeM8Y6j/OOnFACSN+4cDg9x74/w4/T3qrNIskeQpOAR1z2xnt9P85qSSXJ+TG9uflXIAxg5HT/AD6VTvpY1tnlTdmMk88n0xz/AJ7dKAOXsw9z5K/aHjcyuGRBkMPcd/Tt6e9bski2v2meWcFM/dZhjpjI/wA/41x2k6jDPrMXlHDEbSMZ6nHT/H6dOazfHviQCyu7aKVQ6dF3ZJO7GPrx/TigD061uUlbfDKGWSPcpz97/HP4dKnZ5epG1h6AnOen1zj/ADivK/hn4pOp3Lwed80qjaAS35Hv09s16agIZVXJB5OBk8jP49P84oAuRMuG+fO7ncT17/T1P/1s1y/jDUWsktWgVQsjBAMn+97e3P69OK2xL+5BAPXjBzkYz1/L+dc14jjF01ukmCrSgswIOMj2/n+PTigDrdLu1ayiACLlPm479/0/ziliuEldllkOcDPB5Hpg/h/WsuJ44beKJNp2gjg56D9P8npVWz1CMapMGUhlBAYHHp/n2oA7WIq0QYgEjquOuf1/zz2qsv75lDOB852gDj/OarWU/DgseT1Pf8+f880k80kTqH+7vz24Gc/57/jQBpwqhk2EnPO1uR9f15/+vWAtykGqTxtjLuduDnkc/wA+f/r5Faok8tkcNja2W69zn/OP51w17qX2fxbFb3DHZM5YHB6H1/z9Oc0Ad1KY/JjeQE4wVK9j/wDWz+ves6K7j3RIgUGQj5So4x2z7Z/Xv2c9zHHaqd2do5x2x2/XjH4d65O91D7OtvghiZSmMDnoPyz26enGaAJfitB4gn0vTl8PR3Ytjch7+GzlSK4lgCnKx7u/bgg+nrXG6JeaVbya7pWnXPiC1mu7JpU0vWdzMNvyl45HJznoVB7dutd/4t0SHxDY2KS3VzbXtnILm1uIG2NDJjaTjlSO2D9OnNYum+E4odVl1bUdRutU1WWE2qzXBAEak8qqgYGT19enSgDzjwfcXV7dyR7maZEbkgndjHHHU8e3T1rsYtYd9YAOXWSMqy8nngj09M/h7HPLaZL/AGP46mFmrCJwykEZHHv3PXr/AErXNl9uu3voEBt0KsxC56n/AOt07/hQB1/ju6iHiz4e3SCLm8eNW6/fiOOenb/IrtLu/tIb2G3LKHkG0Kox1Oc8e3P69K5U+HrDUtc0jVr03D3GmQlraLzR5KuVOWx3bB6/j7VBdXkVx4otMAFxF82CCVbB/wAfy56cUAehWzI8nyOd5Xlvp/8AW9anTJXZIMnAwM/n1/D39e1Ymnh4LhSz8AEccjgf5+lWVU+SJGboWGRnJ5GP8/QelAF+N2CAbEBHBBZqKzZAWkYtIQc/3X/pRQBx3ie9EVsrQuSqliCJO/r07nn8M9sV5tHfmXVLY7CsiuqkZPPPXgc92z2+96ivX73SLea3e2ljJjYEY3HjnpnH69e/Xisi18FacZPmEpZiHyx5JDZ/z+Y5yKAPMvFnieWDTHlLsEjkZWXZjBzjP+zjrntnPQ4rj/CWvzTeOjsIjgmZQX+6E9RnoMfpnHOePbNU+Hek6hGYpmkUGUNtXj1PQdPr/iQI9O+GOj6ddi4tlYbcYxhcEdOecH+XuDQB1Gm3Qu4o5A4IB2/KcduTj9Pbp71pocOp3cK2D3yfT8+P0681WsNOjsrURQgIgIPDYyfU4+v9PetBY9iklB8h+YscjpjPt/ke9AGVqILyoQN218glSQxx04688cdeg55qeBXTaIk3McnnJyPp1POf6c5q04hlkKMAGJz0/DPvx/h70JFHuY4GHGSOSfQk/lQAoZYy7qvmFcYIxk/l+PT8O9EjEJtTvnAY/h256HP6jimlxHl9vD43Hufx79v85pQVnHl78oVwwDdzz256/wD1uKAIyJF2DI255x+me3T/ADis3U7hpIZgVAyrAZHT3556dv6VryAZVjx82MNycdf5/wCcVFLbxjA8rEbEg7uB0z3Pr/nFAHjmiER6wd/CE7iPXr2+mOv06YrgPH8U0t7cSLvaFmG0L3Oec5/D3PQ9q+kjpVnvk8q3gRkAOQFGMc8Z/r+PFVJNF0y6aQy2kROSxZk5OPr/AJ9eMUAfN/w71K603xUkhVgjLsdeTu/Pr269e+MCvqOxnE0EbgDEg9B+P5/56Vhx+FdIS686Kyg3LnGVI5HQYP8AX8e1b8WFKgIsSoSFGB0/P+fPrzigBXcysVRFV1AUN13fj7nn9fasjU4XdCoweCAq8856+/r+vtW26/vhj+fUfzP4/wA+KiC5VSqEjceTnOM/5/n14oAyBHK0cErgs6gg7ecdvw9fbOe9ZdlbXQ1C5WeNtpBw4HIH/wBYY+ma7HYSFjQBTgZz1HPB56f561Eqr5g+X5ThT8o5NAEmiRslusUgww5BPX1xjn/63vU1wFEmFwY88kt/X9P0680W0scZVC3A7ZwPy7f096szSx7R8v3TwpY4I9en6fhQBDvZMjaNxOOMndge3Xn0+nWvL9TtNRufHKTSQOIllAyQdoA5B4/Hj8uc16spjeRQwVd3t+H+fyoW2VjHJtV2wcHGcg0AYYtZWRk+9EuCrZxznj29en4d6w9U0Se4MCxRB2jkLk5A2rnsO/Gf/wBWa7ZipDKAUDYzk4Hrx+X49qIIx9oRSFA27c8EZPP+f8KAMyeKVrZAgUcZwepxx246f5xSXMMs+1iFGAMnPT1/T/6/GK0LiWOJEdsLJvMXzEHccZ+n6fpUFw0YCpnG1e5PX/P/ANfjFAHz7qT6nB8T9e0+KzvL2VUimihgj8whSp3EsTjngfMRnp2Fbmi65aW3gyaWKKadjdizW1KbZTcseYSrYw2fXHAz6Vrvr8Xhj4m+K7zVtN1E6XPb2qxXsFs0qqVU/JgfNzk9c89e1WvC2l2mrjxXrOuaayaVrd/HcWlldxhZAkcYUPtP3HJGRznpnnFAGl4cn1G4vlstY0S+0ydoS6b3WaN1HBxKhIBBOcHB79a04NAuhqD3bzLjYML0PX9fX2698Vy3gOOW38bK+jpr9r4cWB1vYdYmLqZSf3XkhmZhj5s9OMdTxXqBlCAiV1Zshcg5/wA/5PXNAFK1huEjEMgDjPoMqPT2x+me9aNvDPbtj+A9So/Q/wAvbOO9RtMlnErTHhiMc9P8/p2zVu7uYYIXlmZY0ADHcMgcY/z+XTmgCk9qzMWBkIJ6rCSP50VCt/aSAOlwrK3IOO3bvRQBn3etvHd+StthWXzFZmJyTyeo45A/ryBUS648v2crbv5srFChJ9Mhunrzz9evFbculWbzpcyxnzsYHXpg8Y79f8nmmQafaWuzbGAyElDyckjn9OOf50AYVvqvmSXiPE6xwMAJWA5PHPHA5J6Z9eucWry+eyvY7VY1f90ZN4O0kL05Hsfw7ZFaz2Fs8E8U0SGNjmROMHOMnI46+n4c5qq+mRSP5rwgeUNqkNyR+HP0/TjNAFTQdZOpBwkRjiU7eO/bp+n6dOa1NRuRFaSSrsyjDl14HbJz27fp05qG2tvJQiKMDceqqRj8uM5/zirr2iz2u2Qb1YcqeV4+v+fwoA5y81nyL22t5LYEyAbpAMqckjg9wcYx+HHWrbXzm3iuoI1n8zlo1Oec4/XH6e1WriO3iuYoTGgOAEXAJ4+vp/KpYLzS7eM7JIkAfDHHyj8PX/J7UAVbueX+z3uFO6UqJFOM9RnGcZPr+HbFN0q9a8gieUf6W6nC5JBGMjgY9c/r7VrpLbyTqkJD5GcH7x7g889PX+dVprq3tZliZkjZs7ABweRj+f5/lQBgTT6mlnNjy3kV+GAPAxuwfQ45/X2q1I109m0fzI4TJGCAWxn+v+RxWomoWknmElVZTiQdO/H+fX8qcFChgc73IwAe2f8AP+eKAKFhP51ssrKySDIccKVwPf8Ar61JGkgDKTwfl919eT+FJPewWnlx3DFGlIwFOO9XYwFkVtwbAwSc/qaAIGiI/wBYpI58xeR06/5P41navcS2yRNBbs+4kOvBOP5dfX/CthjGyIFbOSMjsR604bMKOMZHXHHHH+f/AK1AGBLcXBMwU/vAiP8Acxyevv1/zmpLuS4hgV7UeZIScqQTnPcfjk/r1relgCQxl8YIHykcdPzxz/TrzVdFiMSsoBU5C/KT1HP+f60AQW8cs0ELyZwRx68Djr05z06dqzL6S5i1CF4FbysFW2rjB7fXA/LPHU1sTFEjJBwvOQO3b/OPwpQMhhhcNzkgc/T/AD9O9AGXq8sxsf8ARYSXWUKVYYYAHtik2X9w0gPmB2Q7CDkL2x0/D9OnNbCKzErtxzjI7/0/z6VeWJ8oFQ+UOc8g56f5/wAKAMbQUvDbRrfOJbhZCu5kxkHjp+nP0961ViQSPjDEsOBzwf8A9XT2q55QCE8An5gSO/8An9PapZIhuLRx7crnPH5UAcrc218dWeSKQG0YDEZHJO3175x+PtiqH2W7S3twkcmVY7oy2MA8g/kM/r7V2joGJdyueflHYds1WULvBc5wegJ59P0/X8qAMDRtLvYr27advNtyMoS/3G64GR6f5xxVfUNGe41I3JLhETZsAPJ75/MV2BYBpHUFQ2MHPP4elc5q+rf2fPb2pRnaUbg46Dn+f+eaAMyz0S7ghiiu5DJ5MjM5we/b2x71pavYeaLV0dHZW+cOoOeOn54//XVWLXboaDPIU8ht6quehXPJ9v1/HNbEQyA/BTaMZ7cf5/l70Ac2+hXD3lzObsGSbBRem09hnrjI/wAOauw6dI9xHciUpLGvKKWCE9uPxP8ATnNJPf3Uct+nBeNG8tCuSwI68cnH/wBbrzWda6tq01/ZrGiNAytvJU4IyB256f560AaviHTE1K0SNHKiNtybRnp0H5Ht07cZq75FzcW7o7K8TRrGFZAQvY9evH+HSo9FnuJri7W/x+7faoxxjk5/z+HFR3h1SK/dIkV7PtxhlOM9+2f84oAp2+gbIVV9jkZGRCp7+5zRTrOTV3t1ZFZlOeXWMHr780UAdOVd4d6gHJ4H95egH9P096mWEkyF493AOD94HPp79P8AOaKKAIJfmHybgrNxuA59vxP8vanBVGcMCMYyT1/D36/hRRQAqRfumGSQehJz/Lp61G9vMoBUKD2Rvp7+3P8A9aiigDLudP8AO1BJvMEZCFWQ4x05I9OP/r8VD/wi0UvzSzeYok3qN236/wCfz7UUUAWDHBb69Gsm4SvCy8DrgjPv6Dn8ecU/U9KgvpF+1KxdTkHBIznP8x/k0UUAQx6VbrITltjY+oGc/wA/85q7FFtaTafnJHOOSPw/P/69FFAFO906C6kg83ejwsCDuxjnPb+n4VajiyGZdyIDgMB/OiigCONv3DICFUcD5RgEfyp8KbIlQn5hjDMcYP8Ak4/GiigB80chhc7iSRtIz07cfy/SmxBlXBOAME4HT/PSiigCRlLFhxk4IPqO1NRBJIqlQdo4XODj2/nRRQAqoIw7Lh1LfeJPWr8JdofmXkckAHJH+ef/AK1FFAEspCqwyG4PA+n/AOrr/KojKpC7yuQCDgcA9/6f5xRRQAwsH8/kEA9xjBPXn/PvzStGzQPtVcA/MefXP8/85oooAmEQ+zqE/ucAk9RVF7eN1Vii9MB2Uf5/zxRRQAyS1iWyKSKnkYGFKjA/D/CplRVCjJbI/DGMcfy/+tRRQAxbZWuIz93+EKf8856VE9mscRIXLenqc9P8+lFFADrdI47gNIMAn7x6nj/J/wA4rQdwYgicDB+XOM/560UUAZkjFXKybdw4O2QAfliiiigD/9k=);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The pulsed Doppler echocardiogram&nbsp;is used to localize the subaortic jet (sj). The location of the sample volume is shown by the black crosshatch on the line running through the four-chamber views in panels A and B. In panel A, the sample volume is at the papillary muscle level, apical (ax) to the chordae, and intraventricular velocity of the sj is low (panel C). However, when the sample volume is moved basally (bs), below the contact point of the mitral valve with the septum (panel B) the sj suddenly accelerates (panel C). The high-velocity subaortic jet has the characteristic late systolic or \"horse's tail\" configuration, although this is partially obscured by aliasing at peak velocity.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7555=[""].join("\n");
var outline_f7_24_7555=null;
var title_f7_24_7556="Sodium citrate and potassium citrate: Patient drug information";
var content_f7_24_7556=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Sodium citrate and potassium citrate: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22211?source=see_link\">",
"     see \"Sodium citrate and potassium citrate: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4948?source=see_link\">",
"     see \"Sodium citrate and potassium citrate: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F221767\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cytra-3;",
"     </li>",
"     <li>",
"      Tricitrates",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10030502\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691689",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat acid problems in the blood.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691402",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower acid levels in the urine.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10030501\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to citric acid, sodium citrate, potassium citrate, or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3069860",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any of these health problems: Very bad heart disease, very bad kidney disease, or untreated Addison's disease.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10030506\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697282",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have kidney disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10030507\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High potassium level. Signs include feeling weak, lightheaded, dizzy, feel like passing out, or have numbness or tingling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698149",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High salt levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697998",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Loose stools (diarrhea).",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10030509\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699070",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of high potassium.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699019",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very loose stools (diarrhea).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10030504\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695845",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take after meals and at bedtime.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Mix with water and drink.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10030505\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10030510\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10030511\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11329 Version 29.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-AA4CF5E739-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7556=[""].join("\n");
var outline_f7_24_7556=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F221767\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030502\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030501\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030506\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030507\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030509\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030504\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030505\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030510\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10030511\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22211?source=related_link\">",
"      Sodium citrate and potassium citrate: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?4/53/4948?source=related_link\">",
"      Sodium citrate and potassium citrate: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_24_7557="GB virus C (hepatitis G) infection";
var content_f7_24_7557=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   GB virus C (hepatitis G) infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7557/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7557/contributors\">",
"     Sanjiv Chopra, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7557/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7557/contributors\">",
"     Adrian M Di Bisceglie, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7557/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7557/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/24/7557/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 31, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Two viral agents related to hepatitis have been isolated and designated hepatitis G virus (HGV) and GB virus type C (GBV-C). Molecular characterization of these flaviviruses has shown them to be virtually identical isolates of the same virus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In comparison, HGV has only 29 percent amino acid homology with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    HGV was initially cloned from a surgeon (whose initials were GB, hence the term GB virus or GBV). Plasma from this patient transmitted hepatitis to tamarins. Three different GBV agents were isolated and designed GB virus types A, B, and C; the first two were probably tamarin agents [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/3\">",
"     3",
"    </a>",
"    ]. The agent designated GBV-C is virtually identical to HGV and can be spread by transfusion of contaminated blood and sexual contact, similar to hepatitis C virus and hepatitis B virus [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/2,4\">",
"     2,4",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISTRIBUTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;GBV-C has a global distribution, with a high prevalence in the United States donor population. Currently, GBV-C can be diagnosed only by detecting its RNA in the serum by polymerase chain reaction. However, the sensitivity and specificity of this test are not known [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/3\">",
"     3",
"    </a>",
"    ], and one study suggests that it may significantly underestimate the true incidence of infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/5\">",
"     5",
"    </a>",
"    ]. In this report, serial serum samples were obtained from 116 injection drug users over a 6.5 year period; a marker of GBV-C infection (either RNA or antibody) was detected in 110, 70 of whom had anti-GBV-C antibodies but were never positive for GBV-C RNA. All eight patients who cleared GBV-C RNA were antibody positive and there were no new infections in 61 antibody-positive subjects. Thus, anti-GBV-C antibodies appear to be highly associated with viral clearance and protection from reinfection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     CLINICAL SIGNIFICANCE OF GBV-C INFECTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical significance of GBV-C infection with respect to acute or chronic hepatitis is not well understood, but the preponderance of other evidence suggests that GBV-C does not cause hepatitis in humans [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/6,7\">",
"     6,7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    GBV-C RNA has been detected in patients with acute non-A to non-E viral hepatitis, in patients with chronic hepatitis of presumed viral etiology, in patients with cryptogenic cirrhosis, and in some patients with primary hepatocellular carcinoma. However, it is often difficult to tease out the direct role of GBV-C in these settings since coinfection with HCV is so common. Studies in patients with apparently isolated GBV-C infection suggest that the acute liver injury is similar to and may be less severe than that with HCV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/3\">",
"     3",
"    </a>",
"    ]. On the other hand, in patients with post-transfusion hepatitis in whom the presence of GBV-C can be documented, the plasma ALT peak and the peak viral titers may be discordant, suggesting that GBV-C may not be responsible for the elevation in ALT levels.",
"   </p>",
"   <p>",
"    The following observations illustrate the range of findings in some of the largest studies:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      75 percent of individuals positive for GBV-C RNA have normal liver function tests [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/2\">",
"       2",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      One report evaluated 189 patients with chronic HCV infection; 21 (11 percent) were positive for GBV-C RNA [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/8\">",
"       8",
"      </a>",
"      ]. The course of the HCV infection and the response to interferon-alfa were not affected by coinfection with GBV-C. Interferon-alfa led to a decrease in GBV-C RNA titers that was not sustained after the cessation of therapy. Similar findings were noted in another study in which liver biopsies were performed [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/9\">",
"       9",
"      </a>",
"      ]. Detailed histopathologic examination revealed no difference between the patients infected with HCV alone and the 15 percent who were coinfected with GBV-C.",
"     </li>",
"     <li>",
"      A study from Scotland investigated the prevalence of persistent infection with GBV-C or HCV in patients exposed to non-virus inactivated blood products [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/10\">",
"       10",
"      </a>",
"      ]. Among non-remunerated blood donors, the incidence of GBV-C infection (by polymerase chain reaction) was much higher than HCV infection (3.2 versus 0.08 percent). However, among 95 hemophiliacs who had received multiple units of non-virus-inactivated concentrates, the incidence of GBV-C RNA was much lower than that of HCV RNA (14 versus 83 percent). Virus inactivation substantially reduced or eliminated contamination by GBV-C RNA in blood products.",
"     </li>",
"     <li>",
"      GBV-C infection is often present (25 percent in one report) in patients who undergo liver transplantation for HCV or nonviral chronic liver disease [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/11,12\">",
"       11,12",
"      </a>",
"      ]. The patients with GBV-C infection have a clinical course similar to those who are GBV-C negative.",
"     </li>",
"     <li>",
"      The median",
"      <span class=\"nowrap\">",
"       liver/serum",
"      </span>",
"      ratio of GBV-C RNA was less than one in one report, a finding in contrast to the known hepatotropic HCV (which had a high ratio of HCV RNA in the liver compared to the serum) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/13\">",
"       13",
"      </a>",
"      ]. This observation is consistent with serum contamination of liver tissue rather than the liver being the main site of GBV-C replication.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to these findings, an early report from Japan documented GBV-C RNA in three of six patients with acute fulminant hepatitis of uncertain etiology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/14\">",
"     14",
"    </a>",
"    ]. However, a later study, also from Japan, provided an explanation for how this might have occurred [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/15\">",
"     15",
"    </a>",
"    ]. Nine patients with non-A-E fulminant hepatitis and one with late onset hepatic failure were all GBV-C-negative at presentation. Because of legal difficulties with organ donation in Japan, all were treated with plasmapheresis and plasma infusion; four became seropositive for GBV-C after transfusion. Other reports have confirmed that the presence of GBV-C RNA in patients with fulminant hepatitis of unknown etiology was related to the administration of blood products after the onset of disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In summary, the exact role, if any, of the GBV-C virus in producing disease in humans remains unclear [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/6\">",
"     6",
"    </a>",
"    ]. There are no prospective studies that have documented histologically the progression from acute GBV-C infection through various stages of chronic liver disease, such as chronic hepatitis, cirrhosis, and primary hepatocellular carcinoma. In patients with chronic non-A to non-E hepatitis or cryptogenic cirrhosis, there is no proof that, if present, GBV-C is the cause of the disease, rather than being an innocent bystander.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Accumulating evidence suggests a protective effect of GBV-C on patients coinfected with HIV [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/17-21\">",
"     17-21",
"    </a>",
"    ]. The protective effect of GBV-C may be related to maintenance of an intact T-helper 1 cytokine profile, the induction of HIV-inhibitory cytokines, and interference with HIV replication [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. While the observations in these reports support further investigation into the mechanisms of interaction between GBV-C and HIV, the therapeutic implications remain unclear. The following summarizes results of the largest reports.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A study of 158",
"      <span class=\"nowrap\">",
"       HCV/HIV",
"      </span>",
"      coinfected patients found 57 (26 percent) who had GBV-C RNA and 59 percent had evidence for past exposure based upon results of antibody testing [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/21\">",
"       21",
"      </a>",
"      ]. Active GBV-C RNA infection was significantly associated with a reduced risk of cirrhosis and death from cirrhosis.",
"     </li>",
"     <li>",
"      GBV-C viremia was assessed 12 to 18 months after HIV seroconversion in 271 men participating in a longitudinal study [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/24\">",
"       24",
"      </a>",
"      ]. A subgroup of 138 patients was evaluated again five to six years later. Since cohort enrollment occurred prior to 1990, fewer than six percent of subjects were receiving antiviral therapy and none were receiving combination antiviral therapy.",
"      <br/>",
"      <br/>",
"      GBV-C infection was detected in 85 percent of patients. GBV-C status was not significantly associated with survival at 12 to 18 months following HIV seroconversion. In contrast, patients with persistent GBV-C viremia five to six years after HIV seroconversion were less likely to have died compared with those without GBV-C RNA. The poorest outcomes occurred among the nine percent of patients who lost GBV-C RNA between the two time points (relative hazard of death of 5.87 compared to those with persistent GBV-C RNA).",
"     </li>",
"     <li>",
"      An earlier study included 362 HIV-infected patients of whom 144 (40 percent) had GBV-C viremia [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/19\">",
"       19",
"      </a>",
"      ]. Significantly fewer coinfected patients died during a mean follow-up of four years (56 versus 29 percent). GBV-C infection remained an independent predictor of survival even after adjusting for the effects of HIV treatment, baseline CD4 cell count, age, sex, race, and mode of transmission of HIV (relative risk 3.7, 95% CI 2.5 to 5.4).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In contrast to the possibility of a protective effect of GBV-C coinfection in the HIV-infected individual, GBV-C coinfection did not appear to prevent vertical transmission of HIV in a retrospective cohort study from Tanzania [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/25\">",
"     25",
"    </a>",
"    ]. HIV transmission to their infants occurred among 28 percent of HGBV-C RNA positive women, 23 percent of those with antibodies to HGBV-C, and 26 percent of those without evidence of current or past HGBV-C infection.",
"   </p>",
"   <p>",
"    There is little information on the natural history of HIV and GBV-C coinfection in patients who are receiving HAART, but the available data suggest that the protective effect of GBV-C coinfection is diminished. One report suggested that HIV viral load did not differ between HIV mono-infected patients and those coinfected with HCV and GBV-C who were followed for one year after initiating HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/26\">",
"     26",
"    </a>",
"    ]. Another report found that coinfection with GBV-C in",
"    <span class=\"nowrap\">",
"     HIV/HCV",
"    </span>",
"    coinfected patients (who were receiving HAART) had no impact on the rates of sustained virologic response [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/27\">",
"     27",
"    </a>",
"    ]. A third report found no protective effect from GBV-C coinfection on CD4 counts or HIV viral loads in HIV-infected women who were receiving HAART [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/28\">",
"     28",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     IMPLICATIONS OF GBV-C FOR THE BLOOD SUPPLY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A contentious issue is whether donor blood should be screened for GBV-C and other viruses that have been discovered in human blood but are not known to cause disease. Potential arguments in favor of such a policy include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The relatively high prevalence of GBV-C in the donor population",
"     </li>",
"     <li>",
"      The transmissibility of GBV-C by transfusion",
"     </li>",
"     <li>",
"      The possible causal role of GBV-C in producing acute hepatitis",
"     </li>",
"     <li>",
"      The ability of GBV-C viremia to persist for several years",
"     </li>",
"     <li>",
"      The possible role of GBV-C in some patients with chronic hepatitis or chronic liver disease of unexplained etiology",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Arguments against donor screening include:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The potential for high donor loss",
"     </li>",
"     <li>",
"      The apparently very low incidence of posttransfusion hepatitis [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/10\">",
"       10",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      The apparently mild disease when acute hepatitis does occur",
"     </li>",
"     <li>",
"      The lack of proof that chronic liver disease occurs with GBV-C infection",
"     </li>",
"     <li>",
"      The apparently very low disease burden due to GBV-C",
"     </li>",
"     <li>",
"      The difficulty in counseling healthy blood donors",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    At present, routine screening for GBV-C is",
"    <strong>",
"     not",
"    </strong>",
"    performed in blood donors.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Unanswered questions",
"    </span>",
"    &nbsp;&mdash;&nbsp;In addition to the above uncertainties, there are a number of other questions that are still unanswered:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Does the virus replicate in human liver?",
"     </li>",
"     <li>",
"      Can GBV-C be transmitted to chimpanzees?",
"     </li>",
"     <li>",
"      What happens during the course of GBV-C in infection in humans in terms of changes in viral sequences and the immune response?",
"     </li>",
"     <li>",
"      Does coinfection of hepatitis C virus or hepatitis B virus alter the natural history of those disorders? As noted above, one report suggests coinfection has no effect on HCV infection [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7557/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      GBV-C has a global distribution, with a high prevalence in the United States donor population. Currently, GBV-C can be diagnosed only by detecting its RNA in the serum by polymerase chain reaction. However, the sensitivity and specificity of this test are not known. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The significance of GBV-C infection with respect to acute or chronic hepatitis is not well understood, but the preponderance of other evidence suggests that GBV-C does not cause hepatitis in humans. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Clinical significance of GBV-C infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      There appears to be a protective effect of GBV-C on patients coinfected with HIV who are not receiving antiretroviral therapy, possibly related to inhibition of HIV replication. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'HIV infection'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/1\">",
"      Linnen J, Wages J Jr, Zhang-Keck ZY, et al. Molecular cloning and disease association of hepatitis G virus: a transfusion-transmissible agent. Science 1996; 271:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/2\">",
"      Alter HJ. The cloning and clinical implications of HGV and HGBV-C. N Engl J Med 1996; 334:1536.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/3\">",
"      Di Bisceglie AM. Hepatitis G virus infection: a work in progress. Ann Intern Med 1996; 125:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/4\">",
"      Frey SE, Homan SM, Sokol-Anderson M, et al. Evidence for probable sexual transmission of the hepatitis g virus. Clin Infect Dis 2002; 34:1033.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/5\">",
"      Thomas DL, Vlahov D, Alter HJ, et al. Association of antibody to GB virus C (hepatitis G virus) with viral clearance and protection from reinfection. J Infect Dis 1998; 177:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/6\">",
"      Theodore D, Lemon SM. GB virus C, hepatitis G virus, or human orphan flavivirus? Hepatology 1997; 25:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/7\">",
"      Feucht HH, Z&ouml;llner B, Polywka S, et al. Distribution of hepatitis G viremia and antibody response to recombinant proteins with special regard to risk factors in 709 patients. Hepatology 1997; 26:491.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/8\">",
"      Tanaka E, Alter HJ, Nakatsuji Y, et al. Effect of hepatitis G virus infection on chronic hepatitis C. Ann Intern Med 1996; 125:740.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/9\">",
"      Bralet MP, Roudot-Thoraval F, Pawlotsky JM, et al. Histopathologic impact of GB virus C infection on chronic hepatitis C. Gastroenterology 1997; 112:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/10\">",
"      Jarvis LM, Davidson F, Hanley JP, et al. Infection with hepatitis G virus among recipients of plasma products. Lancet 1996; 348:1352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/11\">",
"      Fried MW, Khudyakov YE, Smallwood GA, et al. Hepatitis G virus co-infection in liver transplantation recipients with chronic hepatitis C and nonviral chronic liver disease. Hepatology 1997; 25:1271.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/12\">",
"      Vargas HE, Laskus T, Radkowski M, et al. Hepatitis G virus coinfection in hepatitis C virus-infected liver transplant recipients. Transplantation 1997; 64:786.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/13\">",
"      Pessoa MG, Terrault NA, Detmer J, et al. Quantitation of hepatitis G and C viruses in the liver: evidence that hepatitis G virus is not hepatotropic. Hepatology 1998; 27:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/14\">",
"      Yoshiba M, Okamoto H, Mishiro S. Detection of the GBV-C hepatitis virus genome in serum from patients with fulminant hepatitis of unknown aetiology. Lancet 1995; 346:1131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/15\">",
"      Kanda T, Yokosuka O, Ehata T, et al. Detection of GBV-C RNA in patients with non-A-E fulminant hepatitis by reverse-transcription polymerase chain reaction. Hepatology 1997; 25:1261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/16\">",
"      Mu&ntilde;oz SJ, Alter HJ, Nakatsuji Y, et al. The significance of hepatitis G virus in serum of patients with sporadic fulminant and subfulminant hepatitis of unknown etiology. Blood 1999; 94:1460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/17\">",
"      Yeo AE, Matsumoto A, Hisada M, et al. Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Ann Intern Med 2000; 132:959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/18\">",
"      Lefr&egrave;re JJ, Roudot-Thoraval F, Morand-Joubert L, et al. Carriage of GB virus C/hepatitis G virus RNA is associated with a slower immunologic, virologic, and clinical progression of human immunodeficiency virus disease in coinfected persons. J Infect Dis 1999; 179:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/19\">",
"      Xiang J, W&uuml;nschmann S, Diekema DJ, et al. Effect of coinfection with GB virus C on survival among patients with HIV infection. N Engl J Med 2001; 345:707.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/20\">",
"      Tillmann HL, Heiken H, Knapik-Botor A, et al. Infection with GB virus C and reduced mortality among HIV-infected patients. N Engl J Med 2001; 345:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/21\">",
"      Berzsenyi MD, Bowden DS, Kelly HA, et al. Reduction in hepatitis C-related liver disease associated with GB virus C in human immunodeficiency virus coinfection. Gastroenterology 2007; 133:1821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/22\">",
"      Nunnari G, Nigro L, Palermo F, et al. Slower progression of HIV-1 infection in persons with GB virus C co-infection correlates with an intact T-helper 1 cytokine profile. Ann Intern Med 2003; 139:26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/23\">",
"      Xiang J, George SL, W&uuml;nschmann S, et al. Inhibition of HIV-1 replication by GB virus C infection through increases in RANTES, MIP-1alpha, MIP-1beta, and SDF-1. Lancet 2004; 363:2040.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/24\">",
"      Williams CF, Klinzman D, Yamashita TE, et al. Persistent GB virus C infection and survival in HIV-infected men. N Engl J Med 2004; 350:981.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/25\">",
"      Weintrob AC, Hamilton JD, Hahn C, et al. Active or prior GB virus C infection does not protect against vertical transmission of HIV in coinfected women from Tanzania. Clin Infect Dis 2004; 38:e46.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/26\">",
"      Soriano-Sarabia N, Abad MA, Vallejo A, et al. Influence of hepatitis C and hepatitis G virus co-infection on viral and cellular dynamics in patients infected with human immunodeficiency virus following interruption of highly active anti-retroviral therapy. Clin Microbiol Infect 2006; 12:290.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/27\">",
"      Piroth L, Carrat F, Larrat S, et al. Prevalence and impact of GBV-C, SEN-V and HBV occult infections in HIV-HCV co-infected patients on HCV therapy. J Hepatol 2008; 49:892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7557/abstract/28\">",
"      Campos AF, Tengan FM, Silva SA, Levi JE. Influence of hepatitis G virus (GB virus C) on the prognosis of HIV-infected women. Int J STD AIDS 2011; 22:209.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3660 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-0ACB48A304-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7557=[""].join("\n");
var outline_f7_24_7557=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H7\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISTRIBUTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      CLINICAL SIGNIFICANCE OF GBV-C INFECTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      HIV infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      IMPLICATIONS OF GBV-C FOR THE BLOOD SUPPLY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Unanswered questions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_24_7558="Evaluation of a neck mass";
var content_f7_24_7558=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Evaluation of a neck mass",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7558/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7558/contributors\">",
"     Derrick Lin, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7558/contributors\">",
"     Daniel G Deschler, MD, FACS",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7558/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7558/contributors\">",
"     Bruce E Brockstein, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7558/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7558/contributors\">",
"     Rosemary B Duda, MD, MPH, FACS",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/24/7558/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   May 8, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;A new neck mass is a relatively common head and neck problem in patients presenting to the primary care clinician. There often are no associated symptoms, other than the recognition of a \"new lump\" noted incidentally on palpation while grooming, or noticed by another individual.",
"   </p>",
"   <p>",
"    Evaluation of the neck mass must be approached in a thorough and disciplined manner. The mass may be the only manifestation of a serious and potentially malignant pathology, especially in the adult population.",
"   </p>",
"   <p>",
"    The differential diagnosis in a patient presenting with a neck mass is often extensive and will vary with the age of the patient at presentation. A thorough history and physical examination are essential steps in the evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. This will narrow the diagnostic possibilities and help determine the appropriate next diagnostic steps, as outlined in an algorithm (",
"    <a class=\"graphic graphic_algorithm graphicRef80204 \" href=\"UTD.htm?37/49/38686\">",
"     algorithm 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The diagnostic approach to evaluation of a neck mass will be reviewed here. The differential diagnosis is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=see_link\">",
"     \"Differential diagnosis of a neck mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PATIENT HISTORY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A thorough patient history will often narrow the differential diagnosis of a neck mass.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The age of the patient is a critical factor in the indicated diagnostic workup [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/3-5\">",
"     3-5",
"    </a>",
"    ]. The majority of pediatric neck masses are either of inflammatory or congenital origin. These etiologies also account for the majority of neck masses in the age group from 16 to 40, although the frequency of malignant causes starts to increase [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/4,6\">",
"     4,6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A neck mass in an adult over the age of 40 should be considered neoplastic, and potentially malignant, until proven otherwise [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/4,7\">",
"     4,7",
"    </a>",
"    ]. The probability of a malignant neck mass is further increased in the setting of tobacco or alcohol use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Mass growth pattern",
"    </span>",
"    &nbsp;&mdash;&nbsp;Characteristics of the mass, such as its duration, growth pattern, and absence or presence of pain, are critical in making the diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Masses that are present for months to years with little change are likely benign neoplasms (eg, benign salivary gland tumors, peripheral nerve sheath tumors or paragangliomas) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Rapidly expanding masses raise concern for infectious processes or rapidly growing lymphomas.",
"     </li>",
"     <li>",
"      Masses which fluctuate over time, and increase with viral illnesses or upper respiratory tract infections, are often congenital cysts.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Symptoms",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is often related to rate of growth and expansion, but can be related to direct neural invasion in the setting of certain malignancies. As an example, a 2 cm fixed parotid mass which presents with pain is highly likely to be malignant.",
"   </p>",
"   <p>",
"    Symptoms of voice change, hoarseness, dysphagia, and otalgia may indicate cervical lymph node metastasis from an underlying upper aerodigestive tract malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Other history",
"    </span>",
"    &nbsp;&mdash;&nbsp;A review of systems should include the presence of fever, night sweats, or weight loss. This constellation of symptoms is suspicious for lymphoma, whereas high spiking fever suggests acute infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Important aspects of the social history include tobacco use (frequency, total amount, method of use), alcohol use, illicit drug use (specifically intravenous drug use), and HIV status. An occupational history, occupational exposures, animal exposures, and recent travel history should also be included.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     PHYSICAL EXAMINATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The physical examination should include a careful evaluation of all anatomical areas that may be relevant to the neck mass. Although the focus will initially be on the head and neck, a complete examination can indicate signs of systemic illness, including infections, inflammatory conditions, and malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Anatomy of the neck",
"    </span>",
"    &nbsp;&mdash;&nbsp;Familiarity with neck anatomy is critical for diagnosis and management of disease processes affecting this region. The location of the mass can focus the differential diagnosis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/2,6\">",
"     2,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=see_link\">",
"     \"Differential diagnosis of a neck mass\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The neck is traditionally divided into the central and the lateral necks (",
"    <a class=\"graphic graphic_figure graphicRef74489 \" href=\"UTD.htm?41/25/42388\">",
"     figure 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Additionally, the localization of lymph nodes in the neck is shown in a figure (",
"    <a class=\"graphic graphic_figure graphicRef69528 \" href=\"UTD.htm?18/53/19285\">",
"     figure 2",
"    </a>",
"    ), and patterns of lymphatic drainage are shown in a table (",
"    <a class=\"graphic graphic_table graphicRef77551 \" href=\"UTD.htm?30/62/31723\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The central neck includes midline structures such as the hyoid bone, thyroid and cricoid cartilages, the thyroid isthmus and the trachea.",
"     </li>",
"     <li>",
"      The lateral neck is divided by the sternocleidomastoid muscle (SCM) into an anterior triangle which has its base at the undersurface of the mandible and its peak at the junction of the SCM and sternoclavicular joint. The remaining sides of the anterior triangle are the SCM and the medial abutment to the central neck structures. The anterior triangle can be further subdivided by the digastric muscle into the submental and submandibular triangles.",
"     </li>",
"     <li>",
"      The posterior triangle has its base at the clavicle and its peak at the mastoid tip. The anterior border of the posterior triangle is the SCM and the posterior border is the trapezius muscle. The posterior belly of the omohyoid further subdivides the posterior triangle into the subclavian triangle located below this muscle.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Mass localization",
"    </span>",
"    &nbsp;&mdash;&nbsp;Localization of the mass can suggest specific etiologies, as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Preauricular and angle of the jaw: Likely represents either salivary or lymphoid tissue in the parotid system. Therefore, it is essential to consider facial nerve function in evaluation and tissue sampling.",
"     </li>",
"     <li>",
"      Central neck: Most commonly represents tissue that is thyroid or malignant in origin. This could also represent a dermoid cyst.",
"     </li>",
"     <li>",
"      Anterior aspect of the SCM, usually the high jugulo-digastric region: In adults, enlarged lymph nodes often occur in this location, and suggest potential malignant involvement [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/10,11\">",
"       10,11",
"      </a>",
"      ]. Congenital masses, such as the second branchial cleft cyst, are common in the pediatric population, and are occasionally present in adults.",
"     </li>",
"     <li>",
"      Posterior triangle: Masses in this location should elicit a high index of suspicion for malignancy. In one series of 4768 patients with nasopharyngeal carcinoma, an asymptomatic posterior triangle neck mass was the most common presenting symptom, occurring in 76 percent of patients [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Supraclavicular masses, especially on the left side: Suggest malignancy metastasizing from below the clavicle, such as lung, gynecological, or gastrointestinal sources [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Characteristics of the mass",
"    </span>",
"    &nbsp;&mdash;&nbsp;Palpation of the neck mass is critical, with attention to its location, size, shape, consistency, tenderness, mobility, and color.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Neck masses due to \"reactive\" lymph nodes are usually discrete, mobile, firm or rubbery but not rock hard, and are slightly tender.",
"     </li>",
"     <li>",
"      Rock-hard, fixed masses raise concern for malignancy. Lymph nodes representing metastatic disease may be matted to the underlying structures and are usually nontender.",
"     </li>",
"     <li>",
"      Infected lymph nodes are usually isolated, asymmetric, tender, warm, and erythematous; they may be fluctuant.",
"     </li>",
"     <li>",
"      Soft, ballotable, mobile masses are often cystic congenital masses.",
"     </li>",
"     <li>",
"      A rapidly expanding mass (over days to weeks) raises concern for infection or a rapidly growing lymphoma.",
"     </li>",
"     <li>",
"      A firm, lateral neck mass which moves from side-to-side but not up and down indicates involvement with the carotid sheath, such as a carotid body tumor or vagal schwannoma [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/14\">",
"       14",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A pulsatile quality or bruit suggests a vascular lesion.",
"     </li>",
"     <li>",
"      An immobile midline neck mass which elevates with swallowing indicates a thyroid source, such as a thyroglossal duct cyst or thyroid tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21445615\">",
"    <span class=\"h2\">",
"     Components of the general examination",
"    </span>",
"    &nbsp;&mdash;&nbsp;The oral cavity and oropharynx should be examined with thorough inspection of visible mucosa and bimanual palpation of the floor of the mouth and palpable portions of the tongue and neck. Examination of the ears may indicate a unilateral serous effusion related to nasopharyngeal carcinoma. A nasopharyngeal examination should be performed if there is no obvious etiology on oral and oropharyngeal examination; this usually requires a mirror examination",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    use of a flexible fiberoptic endoscope.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A thorough examination of the skin of the head and neck can indicate a potential primary skin malignancy such as squamous cell carcinoma or melanoma.",
"     </li>",
"     <li>",
"      Assessment of cranial nerve function can suggest a neural tumor or ominous neural involvement by adjacent lymph nodes.",
"     </li>",
"     <li>",
"      A generalized skin rash may suggest a viral illness, whereas a localized skin lesion may indicate a more specific etiology (eg, cat scratch disease or tularemia).",
"     </li>",
"     <li>",
"      The thyroid gland should be carefully palpated, and movement of the neck mass with swallowing noted. The position of the trachea should be evaluated for any deviation from midline.",
"     </li>",
"     <li>",
"      The abdominal examination should pay particular attention to possible enlargement of spleen or liver, and presence of any masses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     LABORATORY STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Laboratory evaluation should be initiated when the patient history or physical examination does not suggest transient reactive lymphadenopathy as the cause of a neck mass. Persistence of a newly discovered neck mass beyond three weeks should instigate a further evaluation. If the mass is felt to be reactive, secondary to a known viral or bacterial source, a further trial of observation or antibiotic treatment can be undertaken, but follow-up is essential to assure resolution; a directed work-up should be initiated if no improvement is noted.",
"   </p>",
"   <p>",
"    The extent of the laboratory evaluation will be determined by the potential differential diagnosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most patients should have:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Complete blood count (CBC) with differential",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The following may be indicated for some patients:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Erythrocyte sedimentation rate (ESR)",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      C-reactive protein (CRP) to evaluate for systemic inflammation or infection",
"     </li>",
"     <li>",
"      Blood culture (for febrile patients)",
"     </li>",
"     <li>",
"      EBV or CMV serology (when adenopathy is diffuse)",
"     </li>",
"     <li>",
"      HIV serology (in patients with increased risk)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Specific serologic tests can be ordered when there is an increased index of suspicion for disease based on exposure, history, and examination:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Serology for T gondii, brucellosis, bartonella (cat scratch fever), tularemia",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/35/15924?source=see_link\">",
"       Tuberculin skin test",
"      </a>",
"     </li>",
"     <li>",
"      Antibodies to the",
"      <span class=\"nowrap\">",
"       Ro/SSA",
"      </span>",
"      and",
"      <span class=\"nowrap\">",
"       La/SSB",
"      </span>",
"      antigens, if Sjogren's disease is suspected as a cause of periparotid or submandibular masses.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Abnormal test results may prompt additional evaluation, such as bone marrow biopsy if the CBC indicates possible hematologic malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     IMAGING STUDIES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Imaging studies offer specific details of anatomic position, mass consistency, adjoining involvement, vascularity and potential primary source of malignancy in the region. Imaging options include ultrasound, computed tomography (CT), magnetic resonance imaging (MRI), and combined positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT",
"    </span>",
"    fusion scans. Contrast CT should be the initial study of choice for most patients [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/15-17\">",
"     15-17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The least invasive of the imaging techniques is ultrasound. Ultrasound evaluation of a neck lesion is more commonly used in Europe than in the United States. Advantages of ultrasound include its non-invasive nature, real-time assessment of the mass and its relation to adjoining structures [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/18-20\">",
"     18-20",
"    </a>",
"    ], and the ability to easily guide fine needle aspirations. Disadvantages include dependence on operator expertise, and limited permanent images for use in consultant evaluation or the operative setting.",
"   </p>",
"   <p>",
"    A greater experience has developed in the United States for axial imaging by CT and MRI scanning. These studies allow for the characterization of the mass and its relation to normal anatomic structures of the head and neck, and may also help in identifying a primary source when metastatic disease is present. Angiographic imaging variants can be obtained with both study techniques and may be helpful in evaluating masses of possible vascular origin. CT is well tolerated by patients, and reformatting algorithms allow evaluations in all relevant planes.",
"   </p>",
"   <p>",
"    MRI is indicated for masses that require further definition of soft tissue (eg, infiltrative soft tissue masses, suspicion of malignant perineural spread, or potential CNS origin). Advantages of MRI include outstanding soft tissue differentiation, lack of ionizing radiation and infrequent contrast allergy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/15,21\">",
"     15,21",
"    </a>",
"    ]. Disadvantages include the cost of the study and the need for patient compliance during the exam in a closed space.",
"   </p>",
"   <p>",
"    More recently, positron emission tomography",
"    <span class=\"nowrap\">",
"     (PET)/CT",
"    </span>",
"    fusion scans have been found useful in the setting of malignancy, aiding in the identification of primary disease or detection of distant metastatic disease [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/22\">",
"     22",
"    </a>",
"    ]. Although helpful in the later evaluation of malignancies,",
"    <span class=\"nowrap\">",
"     PET/CT",
"    </span>",
"    plays little role in the initial evaluation of the neck mass. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=see_link\">",
"     \"Overview of the diagnosis and staging of head and neck cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FINE NEEDLE ASPIRATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Fine needle biopsy (FNA) is the next diagnostic step for most neck masses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/23\">",
"     23",
"    </a>",
"    ]. The procedure entails the use of a 23- or 25-gauge needle to obtain aspirations of the neck mass for pathologic diagnosis. If the mass is not easily palpable or a specific portion of the mass requires sampling, CT or ultrasound guided needle biopsies can assure accurate sampling. The number of nondiagnostic biopsies can be further reduced by the availability of a cytologist to immediately examine the material obtained for sample adequacy, allowing further needle passes if needed.",
"   </p>",
"   <p>",
"    The nature of the aspirate may suggest particular etiologies:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Bloody (vascular lesion)",
"     </li>",
"     <li>",
"      Serous dark brown fluid (papillary thyroid cancer)",
"     </li>",
"     <li>",
"      Thick viscous yellow fluid (mucocele)",
"     </li>",
"     <li>",
"      Turbid yellow fluid (branchial cleft cyst)",
"     </li>",
"     <li>",
"      Purulent (abscess)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Proper collection of material and preparation of slides for analysis is essential. In order for an FNA to be successful, the correct area must be chosen to maximize the diagnostic yield. The higher accuracy rates obtained within specialty clinics, compared to specimens obtained in the outside office setting, might be attributable to better fixation techniques in the specialty centers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/24\">",
"     24",
"    </a>",
"    ]. The sensitivity and specificity were both 95 percent in one series of 130 neck masses evaluated with FNA [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/25\">",
"     25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In addition to cytologic diagnosis of FNA samples, advances in molecular biology now allow polymerase chain reaction (PCR) testing on FNA samples. As an example, PCR may identify the presence of Epstein-Barr virus (EBV), which can suggest the diagnosis of a nasopharyngeal carcinoma.",
"   </p>",
"   <p>",
"    FNA aspirates of a neck mass can also be analyzed for human papilloma virus (HPV) which has been implicated in oropharyngeal squamous cell carcinoma. Patients who are positive for HPV tend to be younger, nonsmokers, and nondrinkers. These patients also have a much better prognosis than those who are HPV negative [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7558/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A major problem with FNA is that it provides only a liquid sample for cytologic analysis, and no material for assessment of tissue architecture; in addition, there is often too little material for immunohistochemical analysis. As a result, FNA should be considered the initial means of tissue sampling for diagnosis, but may not establish the definitive diagnosis.",
"   </p>",
"   <p>",
"    Open biopsies are generally discouraged since they can adversely affect the success of subsequent surgical resection by field contamination. If the information gained by the FNA does not establish the final diagnosis, core needle biopsy is usually the next step. In addition, if the FNA suggests the diagnosis of lymphoma, more tissue is usually required for specific tissue typing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Evaluation of a neck mass must be approached in a thorough and disciplined manner, as it may be the only manifestation of a potentially malignant pathology, especially in the adult population. An outline for this evaluation is shown in an algorithm (",
"      <a class=\"graphic graphic_algorithm graphicRef80204 \" href=\"UTD.htm?37/49/38686\">",
"       algorithm 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The evaluation of a new neck mass begins with a thorough history and physical examination. Key components of the history include age, rate of change of the mass, symptoms of pain, symptoms of systemic illness, and use of tobacco, alcohol, or illicit drugs. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Patient history'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The physical examination should identify the localization of the mass, its texture and mobility, and include careful evaluation of the oral cavity, cranial nerves, thyroid gland, and a comprehensive general exam. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Physical examination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Laboratory studies should be ordered based on findings from the history and physical examination. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Laboratory studies'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imaging studies usually start with a contrast CT scan of the neck, though an ultrasound evaluation is also acceptable if there is technical expertise; MRI or",
"      <span class=\"nowrap\">",
"       PET/CT",
"      </span>",
"      scanning may be indicated in follow-up. Fine needle aspiration can provide initial tissue sampling, but is not always definitive. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Imaging studies'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H14\">",
"       'Fine needle aspiration'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/1\">",
"      Alvi A, Johnson JT. The neck mass. A challenging differential diagnosis. Postgrad Med 1995; 97:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/2\">",
"      Weymuller EA Jr. Evaluation of neck masses. J Fam Pract 1980; 11:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/3\">",
"      Enepekides DJ. Management of congenital anomalies of the neck. Facial Plast Surg Clin North Am 2001; 9:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/4\">",
"      Otto RA, Bowes AK. Neck masses: benign or malignant? Sorting out the causes by age-group. Postgrad Med 1990; 88:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/5\">",
"      Turkington JR, Paterson A, Sweeney LE, Thornbury GD. Neck masses in children. Br J Radiol 2005; 78:75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/6\">",
"      Brown RL, Azizkhan RG. Pediatric head and neck lesions. Pediatr Clin North Am 1998; 45:889.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/7\">",
"      Mendenhall WM, Mancuso AA, Amdur RJ, et al. Squamous cell carcinoma metastatic to the neck from an unknown head and neck primary site. Am J Otolaryngol 2001; 22:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/8\">",
"      Ruhl C. Evaluation of the neck mass. Med Health R I 2004; 87:307.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/9\">",
"      Weber AL, Rahemtullah A, Ferry JA. Hodgkin and non-Hodgkin lymphoma of the head and neck: clinical, pathologic, and imaging evaluation. Neuroimaging Clin N Am 2003; 13:371.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/10\">",
"      Gourin CG, Johnson JT. Incidence of unsuspected metastases in lateral cervical cysts. Laryngoscope 2000; 110:1637.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/11\">",
"      Kupferman ME, Patterson M, Mandel SJ, et al. Patterns of lateral neck metastasis in papillary thyroid carcinoma. Arch Otolaryngol Head Neck Surg 2004; 130:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/12\">",
"      Wei WI, Sham JS. Nasopharyngeal carcinoma. Lancet 2005; 365:2041.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/13\">",
"      Giridharan W, Hughes J, Fenton JE, Jones AS. Lymph node metastases in the lower neck. Clin Otolaryngol Allied Sci 2003; 28:221.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/14\">",
"      Pellitteri PK, Rinaldo A, Myssiorek D, et al. Paragangliomas of the head and neck. Oral Oncol 2004; 40:563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/15\">",
"      Weber AL, Romo L, Hashmi S. Malignant tumors of the oral cavity and oropharynx: clinical, pathologic, and radiologic evaluation. Neuroimaging Clin N Am 2003; 13:443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/16\">",
"      Wetmore RF, Mahboubi S, Soyupak SK. Computed tomography in the evaluation of pediatric neck infections. Otolaryngol Head Neck Surg 1998; 119:624.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/17\">",
"      Sakai O, Curtin HD, Romo LV, Som PM. Lymph node pathology. Benign proliferative, lymphoma, and metastatic disease. Radiol Clin North Am 2000; 38:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/18\">",
"      Chang DB, Yang PC, Luh KT, et al. Ultrasonic evaluation of cervical lymphadenopathy. J Formos Med Assoc 1990; 89:286.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/19\">",
"      Douglas SA, Jennings S, Owen VM, et al. Is ultrasound useful for evaluating paediatric inflammatory neck masses? Clin Otolaryngol 2005; 30:526.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/20\">",
"      Gritzmann N, Hollerweger A, Macheiner P, Rettenbacher T. Sonography of soft tissue masses of the neck. J Clin Ultrasound 2002; 30:356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/21\">",
"      Ishikawa M, Anzai Y. MR imaging of lymph nodes in the head and neck. Neuroimaging Clin N Am 2004; 14:679.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/22\">",
"      McGuirt WF, Greven K, Williams D 3rd, et al. PET scanning in head and neck oncology: a review. Head Neck 1998; 20:208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/23\">",
"      Amedee RG, Dhurandhar NR. Fine-needle aspiration biopsy. Laryngoscope 2001; 111:1551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/24\">",
"      Layfield LJ. Fine-needle aspiration in the diagnosis of head and neck lesions: a review and discussion of problems in differential diagnosis. Diagn Cytopathol 2007; 35:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/25\">",
"      Carroll CM, Nazeer U, Timon CI. The accuracy of fine-needle aspiration biopsy in the diagnosis of head and neck masses. Ir J Med Sci 1998; 167:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/26\">",
"      Fakhry C, Gillison ML. Clinical implications of human papillomavirus in head and neck cancers. J Clin Oncol 2006; 24:2606.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7558/abstract/27\">",
"      Psyrri A, Gouveris P, Vermorken JB. Human papillomavirus-related head and neck tumors: clinical and research implication. Curr Opin Oncol 2009; 21:201.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6848 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1105-88.81.100.162-4217E6CC24-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7558=[""].join("\n");
var outline_f7_24_7558=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PATIENT HISTORY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Mass growth pattern",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Symptoms",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Other history",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      PHYSICAL EXAMINATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Anatomy of the neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Mass localization",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Characteristics of the mass",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21445615\">",
"      Components of the general examination",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      LABORATORY STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      IMAGING STUDIES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FINE NEEDLE ASPIRATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"SURG/6848\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/6848|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?37/49/38686\" title=\"algorithm 1\">",
"      Examination of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/6848|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?41/25/42388\" title=\"figure 1\">",
"      Compartments of neck",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?18/53/19285\" title=\"figure 2\">",
"      Lymph nodes head and neck",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"SURG/6848|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/62/31723\" title=\"table 1\">",
"      Lymphatic drainage of the head and neck",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/21/11608?source=related_link\">",
"      Differential diagnosis of a neck mass",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/43/36537?source=related_link\">",
"      Overview of the diagnosis and staging of head and neck cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_24_7559="MRI of primary CNS lymphoma";
var content_f7_24_7559=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83271&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 542px\">",
"   <div class=\"ttl\">",
"    MRI of primary central nervous system (CNS) lymphoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 522px; height: 583px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The MRI examination in the transverse plane is from a 63-year-old female with primary CNS lymphoma. The T1 weighted sequence (A) reveals a single mass that infiltrates the splenium of&nbsp;corpus callosum [a relatively common location for primary CNS lymphoma]&nbsp;(red arrow), abutting the third ventricle anteriorly. The mass enhances homogeneously following gadolinium administration (B), is relatively dark on T2 weighted images (C), and reveals restricted diffusion on the diffusion weighted sequence (bright, D).&nbsp;The reader should note the relative lack of edema on flair studies. These features are consistent with the diagnosis of primary lymphoma of the brain.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7559=[""].join("\n");
var outline_f7_24_7559=null;
var title_f7_24_7560="Bulimia nervosa in adults: Cognitive-behavioral therapy (CBT)";
var content_f7_24_7560=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Bulimia nervosa in adults: Cognitive-behavioral therapy (CBT)",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7560/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7560/contributors\">",
"     James E. Mitchell, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7560/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7560/contributors\">",
"     Joel Yager, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7560/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7560/contributors\">",
"     David Solomon, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/24/7560/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Mar 3, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1743273\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The psychotherapy that has been studied most frequently for bulimia nervosa since it was first described in 1979 is cognitive-behavioral therapy (CBT) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Based upon randomized trials, CBT is the treatment of choice for bulimia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/2-8\">",
"     2-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This topic reviews CBT for treating bulimia nervosa. The epidemiology, clinical features, diagnosis, assessment, medical complications, and other treatments are discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=see_link\">",
"       \"Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link\">",
"       \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=see_link\">",
"       \"Bulimia nervosa and binge eating disorder in adults: Medical complications and their management\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/62/7145?source=see_link\">",
"       \"Bulimia nervosa in adults: Pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link\">",
"       \"Eating disorders: Treatment\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29270630\">",
"    <span class=\"h1\">",
"     DEFINITION OF BULIMIA NERVOSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The core features of bulimia nervosa are excessive concern about body weight and shape, binge-eating (ie, eating an amount of food that is definitely larger than most people would eat under similar circumstances), and inappropriate compensatory behavior to prevent weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/9\">",
"     9",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    The diagnostic criteria (",
"    <a class=\"graphic graphic_table graphicRef70006 \" href=\"UTD.htm?2/46/2796\">",
"     table 1",
"    </a>",
"    ) for bulimia nervosa are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H22668229#H22668229\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H173355904\">",
"    <span class=\"h2\">",
"     Assessment",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial clinical evaluation of patients with a possible diagnosis of bulimia nervosa includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. If the patient was previously treated with CBT, the clinician should determine which components were beneficial. In addition, the assessment provides an opportunity to begin establishing a positive therapeutic relationship with the patient [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/12\">",
"     12",
"    </a>",
"    ]. The general assessment of patients with bulimia nervosa is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link&amp;anchor=H22668257#H22668257\">",
"     \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\", section on 'Assessment'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29271339\">",
"    <span class=\"h1\">",
"     OVERVIEW OF TREATMENT FOR BULIMIA NERVOSA",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-line treatment for bulimia nervosa consists of nutritional rehabilitation plus psychotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. Nutritional rehabilitation aims to restore a structured and consistent meal pattern that typically takes the form of three meals and two snacks per day [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/14\">",
"     14",
"    </a>",
"    ]. Cognitive-behavioral therapy (CBT) usually includes nutritional rehabilitation, and also addresses dysfunctional thoughts and problematic behaviors that maintain the disorder. Pharmacotherapy is also efficacious and often added to the treatment regimen.",
"   </p>",
"   <p>",
"    Additional information about treating bulimia nervosa is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H2#H2\">",
"     \"Eating disorders: Treatment\", section on 'Treatment'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/62/7145?source=see_link\">",
"     \"Bulimia nervosa in adults: Pharmacotherapy\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1743280\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) is indicated as first-line treatment for outpatients with bulimia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/3-5,14,16\">",
"     3-5,14,16",
"    </a>",
"    ]. Use of CBT requires sufficient motivation, cognitive capacity, emotional stability, and energy to participate in therapy and complete assigned tasks. It is not clear if there are specific subgroups of patients who benefit most from CBT. Patients with comorbid personality disorders, particularly borderline personality disorder, may be less responsive to CBT [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/17-23\">",
"     17-23",
"    </a>",
"    ], but such patients are less responsive to treatment in general [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    CBT plus an antidepressant is indicated for patients who either fail to show an early response to CBT alone (eg, after six sessions), or who are depressed and unable to actively collaborate with the clinician using CBT alone [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For patients with bulimia nervosa who are overweight or obese, CBT can reduce binge eating and purging. However, CBT is generally not indicated for reducing weight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/25\">",
"     25",
"    </a>",
"    ]. Thus, clinicians should set realistic expectations about the goals of therapy, and consider augmenting CBT with other approaches that address healthy lifestyle changes and appetite awareness. Treatment of obesity is discussed separately (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=see_link\">",
"     \"Overview of therapy for obesity in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=see_link\">",
"     \"Behavioral strategies in the treatment of obesity\"",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7441169\">",
"    <span class=\"h2\">",
"     Contraindications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Contraindications to treating bulimia nervosa with CBT include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/12,26\">",
"     12,26",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Medical instability &ndash; Needs to be stabilized prior to commencing CBT",
"     </li>",
"     <li>",
"      Suicidal ideation or behavior &ndash; Needs to be stabilized prior to CBT",
"     </li>",
"     <li>",
"      Severe major depression (eg, psychosocial functioning is impaired such that patients cannot engage in outpatient treatment)",
"     </li>",
"     <li>",
"      Substance use disorder &ndash; Patients who are recurrently intoxicated may be unable to perform the work that is required in CBT",
"     </li>",
"     <li>",
"      Psychosis &ndash; Psychotic patients are not candidates for most psychotherapies including CBT (concurrent bulimia nervosa and psychosis is rare)",
"     </li>",
"     <li>",
"      Major life events or crises &ndash; Distracting events can interfere with CBT &nbsp;",
"     </li>",
"     <li>",
"      Competing commitments &ndash; The inability to attend sessions disrupts therapeutic momentum",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H460862\">",
"    <span class=\"h1\">",
"     EVIDENCE OF EFFICACY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) is the treatment of choice for bulimia nervosa, based upon randomized trials that have consistently demonstrated good outcomes, low relapse rates, and superiority to other psychotherapies and to pharmacotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/5\">",
"     5",
"    </a>",
"    ]. Many reviews concur that CBT is the best established treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/3,4,6-8\">",
"     3,4,6-8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Evidence for the efficacy of CBT includes the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A meta-analysis of five randomized trials (204 patients with bulimia nervosa) found that remission (100 percent abstinence from binge-eating) was significantly greater in patients who received CBT than controls (waiting list or no treatment) (37 versus 3 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      A meta-analysis of seven randomized trials (484 patients with bulimia nervosa) found that remission was significantly greater in patients who received CBT than other types of psychotherapy (interpersonal psychotherapy, behavior therapy, hypnosis plus behavior therapy, or supportive psychotherapy) (36 versus 22 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/2\">",
"       2",
"      </a>",
"      ]",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A subsequent study examined five-year outcomes in 109 patients with bulimia nervosa who received CBT in a randomized trial; different definitions of recovery were evaluated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/27\">",
"     27",
"    </a>",
"    ]. Approximately 75 percent no longer met diagnostic criteria for bulimia nervosa both at the end of treatment and at the five-year assessment. In addition, investigators found that the absence of any binge-eating and purging over the past 12 months rose from 13 percent at one year post-treatment to 36 percent five years post-treatment.",
"   </p>",
"   <p>",
"    CBT is often combined with pharmacotherapy, which usually consists of an antidepressant such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    or a different selective serotonin reuptake inhibitor (SSRI) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. The efficacy of psychotherapy plus pharmacotherapy is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/62/7145?source=see_link&amp;anchor=H88015819#H88015819\">",
"     \"Bulimia nervosa in adults: Pharmacotherapy\", section on 'Pharmacotherapy combined with psychotherapy'",
"    </a>",
"    .) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1743287\">",
"    <span class=\"h1\">",
"     THEORETICAL FOUNDATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cognitive-behavioral model of therapy focuses upon the clinical features that maintain binge-eating (uncontrolled overeating) and purging, rather than the factors that led the patient to develop bulimia nervosa [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/12,26\">",
"     12,26",
"    </a>",
"    ]. The predominant maintaining mechanisms are problems with self-evaluation and self-esteem, such that patients judge themselves primarily in terms of body weight and shape, and the ability to control them. These concerns lead patients to pursue thinness by adopting multiple demanding dietary rules. This strict dietary control creates an urge or pressure to eat, and when patients eventually break one of their diet rules, dietary restraint is temporarily abandoned. The result is an episode of binge-eating, which subsequently results in inappropriate compensatory behaviors such as self-induced vomiting or laxative abuse. This loss of dietary control and the compensatory behaviors exacerbate the core psychopathology of overvaluing shape and weight, and perpetuate the disorder by giving rise to renewed efforts at dietary restraint.",
"   </p>",
"   <p>",
"    Other clinical features that maintain bulimia nervosa include adverse events in daily life, interpersonal conflicts, perfectionism, and intolerance of dysphoric moods [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/28,29\">",
"     28,29",
"    </a>",
"    ]. In addition, patients mistakenly believe that purging minimizes weight gain; however, vomiting removes only part of what was eaten, and laxative abuse has little effect upon absorption of calories [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/12,26\">",
"     12,26",
"    </a>",
"    ]. Checking one&rsquo;s body weight excessively or avoiding checking it altogether also can maintain bulimic behaviors.",
"   </p>",
"   <p>",
"    The goals of CBT for patients with bulimia nervosa are [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/4\">",
"     4",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Improving self-esteem",
"     </li>",
"     <li>",
"      Less emphasis upon thinness as an ideal",
"     </li>",
"     <li>",
"      Eliminating dietary restraint",
"     </li>",
"     <li>",
"      Establishing a pattern of regular food intake",
"     </li>",
"     <li>",
"      Eliminating binge-eating and purging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Although the mechanism by which CBT effectively achieves these goals is unclear, some studies suggest that addressing dysfunctional thoughts is a critical component [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1743301\">",
"    <span class=\"h1\">",
"     TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Cognitive-behavioral therapy (CBT) for bulimia nervosa focuses upon excessive concern about body weight and shape, binge-eating, and inappropriate compensatory behavior [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/26\">",
"     26",
"    </a>",
"    ]. The treatment combines cognitive therapy and behavioral therapy, and resembles other forms of CBT that are used to treat disorders such as panic disorder and unipolar major depression. Cognitive therapy attempts to modify the dysfunctional thoughts, beliefs, and attitudes (eg, &ldquo;I&rsquo;m no good because my legs are fat&rdquo;) that maintain bulimic behaviors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/30\">",
"     30",
"    </a>",
"    ]. Behavioral therapy focuses upon modifying the patient&rsquo;s problematic behavioral responses (eg, binge-eating episodes) to environmental stimuli or dysfunctional thoughts through techniques such as stimulus control and exposure with response prevention [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/27\">",
"     27",
"    </a>",
"    ]. CBT is typically administered according to a manual.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647365\">",
"    <span class=\"h2\">",
"     Format",
"    </span>",
"    &nbsp;&mdash;&nbsp;The standard format for administering cognitive-behavioral-therapy (CBT) to outpatients with bulimia nervosa is individual (one to one) treatment, and most studies have evaluated CBT in this context. CBT has also been adapted for group therapy, but outcomes may be superior with individual treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/3,31\">",
"     3,31",
"    </a>",
"    ]. Other stand-alone or adjunctive formats have been developed, including telemedicine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/32-34\">",
"     32-34",
"    </a>",
"    ], internet programs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/35-38\">",
"     35-38",
"    </a>",
"    ], text messaging [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/39\">",
"     39",
"    </a>",
"    ], and self-help programs using a structured workbook (either hard copy or CD-ROM) with little or no involvement of a therapist [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/19,40-42\">",
"     19,40-42",
"    </a>",
"    ]. The choice depends upon patient preference and the availability of resources.",
"   </p>",
"   <p>",
"    Individual CBT is typically provided as a time-limited treatment package of approximately 20 sessions over 16 weeks, with two sessions per week for the first four weeks and then one session weekly. Increasing the frequency of sessions at the beginning of treatment seems to improve outcomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/43\">",
"     43",
"    </a>",
"    ]. Each session lasts 45 to 50 minutes.",
"   </p>",
"   <p>",
"    Group CBT for bulimia nervosa generally consists of six to eight patients plus a therapist meeting in a closed group (ie, group membership is stable by remaining closed to new members once treatment commences). A similar package of approximately 20 sessions over 16 weeks is used, with each session lasting 75 to 90 minutes. The therapist directs the group and asserts control when necessary to limit the time devoted to patients who are nonadherent or making little progress, and instead refocuses the group&rsquo;s efforts on who or what is successful. Typically, some patients drop out as treatment progresses.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647794\">",
"    <span class=\"h2\">",
"     Therapeutic techniques and content",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although the practice of CBT for bulimia nervosa varies, clinicians generally include the following elements [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/12,26,44\">",
"     12,26,44",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Treatment overview",
"      </strong>",
"      &ndash; Clinicians begin treatment by explaining the:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Principles of CBT",
"     </li>",
"     <li>",
"      Goals of therapy and issues to be addressed",
"     </li>",
"     <li>",
"      Need to promptly complete homework assignments (usually daily) in between sessions",
"     </li>",
"     <li>",
"      Logistics, including schedule for sessions and policies for tardiness, missed appointments, emergencies, and payment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Commitment to change",
"      </strong>",
"      &ndash; Many patients with bulimia nervosa are ambivalent about changing some of their bulimic behaviors. Although patients may want to eliminate certain aspects of the disorder (eg, binge-eating), other features may be valued (eg, excessive exercise or fasting). This ambivalence can be addressed with motivational enhancement, which is discussed separately. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=see_link&amp;anchor=H432862274#H432862274\">",
"       \"Overview of psychotherapies\", section on 'Motivational interviewing'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <strong>",
"       Self-monitoring",
"      </strong>",
"      &ndash; Patients use a diary (",
"      <a class=\"graphic graphic_table graphicRef67548 \" href=\"UTD.htm?32/19/33085\">",
"       table 2",
"      </a>",
"      ) to monitor food intake (recording in real time the food consumed and context for each meal, snack, and binge-eating episode), inappropriate compensatory behaviors, and thoughts and feelings while eating. Diary entries are discussed at the following session.",
"     </li>",
"     <li>",
"      <strong>",
"       Healthy eating pattern",
"      </strong>",
"      &ndash; Patients establish a consistent schedule for eating that typically takes the form of three planned meals and two to three planned snacks per day. Patients should try to avoid eating at other times; it may help to emphasize that the urge to eat is often temporary. Many patients are not aware that their restrictive dieting has supplanted normal eating behavior, and it may be necessary to gradually implement the regular pattern over a few weeks.",
"     </li>",
"     <li>",
"      <strong>",
"       Food avoidance",
"      </strong>",
"      &ndash; Patients identify foods that they fear because of the belief that these foods inevitably trigger binge-eating. This belief is disconfirmed by encouraging patients to introduce a small amount of the food into a planned meal or snack when patients feel in control of their eating and capable of resisting urges to binge eat.",
"     </li>",
"     <li>",
"      <strong>",
"       Weekly weighing",
"      </strong>",
"      &ndash; The patient&rsquo;s weight is measured at each session and plotted on a graph, and patients are encouraged to not weigh themselves at other times. This procedure addresses unusual weighing practices. Frequent weight checking is common and can lead to concern with trivial fluctuations and further restrictive dieting; other patients may avoid weighing themselves, which exacerbates their fears about weight gain and leads to further dieting. In addition, the weekly weighing demonstrates that a healthy eating pattern does not increase weight.",
"     </li>",
"     <li>",
"      <strong>",
"       Education",
"      </strong>",
"      &ndash; Clinicians educate patients about the:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Syndrome of bulimia nervosa, including its clinical features, diagnostic criteria, comorbidity, course of illness, medical complications, treatment options, and prognosis",
"     </li>",
"     <li>",
"      Determinants of body weight, its natural fluctuations, and the relationship between body mass index (",
"      <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=see_link\">",
"       calculator 1",
"      </a>",
"      ) and health",
"     </li>",
"     <li>",
"      Ineffectiveness of purging (self-induced vomiting and abuse of laxatives and diuretics) in controlling weight",
"     </li>",
"     <li>",
"      Adverse physiologic effects of extreme dieting, binge-eating, and purging",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cues and consequences",
"      </strong>",
"      &ndash; With the aid of the diary, cues (antecedents) for binge-eating are identified, including",
"      <span class=\"nowrap\">",
"       physiologic/nutritional",
"      </span>",
"      and psychological pressures to eat, as well as individuals and situations that may be associated with negative feelings such as depression, anger, or anxiety. As an example, binge-eating episodes may occur while watching television or after arguments. Patients are encouraged to avoid the people, places, and situations that trigger binge-eating (stimulus control). The social and situational consequences of binge-eating are also delineated (eg, social withdrawal), as well as the resulting thoughts and feelings (eg, sense of relief). The patient is encouraged to focus upon longer-term consequences (eg, social isolation) rather than shorter-term relief of uncomfortable feelings.",
"     </li>",
"     <li>",
"      <strong>",
"       Chains of behaviors",
"      </strong>",
"      &ndash; Patients learn to identify problematic chains of behaviors throughout the day that can eventually lead to the bulimic behaviors of binge-eating and purging. As an example, skipping breakfast to avoid gaining weight, then eating a small lunch, and becoming very hungry in the late afternoon can result in binge-eating.",
"     </li>",
"     <li>",
"      <strong>",
"       Alternative behaviors",
"      </strong>",
"      &ndash; Patients should develop lists of alternative behaviors for responding to acute cues or craving for bulimic behaviors, as well as high-risk times (eg, weekends and evenings) and situations that are associated with bulimic behaviors. Especially useful are activities that are incompatible with binge-eating, such as calling someone, going on a brisk walk, or taking a shower.",
"     </li>",
"     <li>",
"      <strong>",
"       Stress management skills",
"      </strong>",
"      &ndash; Stress can be managed by improved communications skills and techniques such as self-encouragement, progressive muscle relaxation, and distracting oneself during stressful situations.",
"     </li>",
"     <li>",
"      <strong>",
"       Problem solving skills",
"      </strong>",
"      &ndash; Problem solving involves:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Identifying the problem early",
"     </li>",
"     <li>",
"      Specifying it accurately",
"     </li>",
"     <li>",
"      Generating multiple solutions",
"     </li>",
"     <li>",
"      Considering the consequences of each solution",
"     </li>",
"     <li>",
"      Choosing one solution",
"     </li>",
"     <li>",
"      Acting upon it",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <strong>",
"       Cognitive restructuring",
"      </strong>",
"      &ndash; Patients are directed to examine maladaptive thoughts (cognitive distortions) about themselves (eg, &ldquo;I don&rsquo;t have a boyfriend because I&rsquo;m so fat&rdquo;) and substitute more functional thoughts (eg, &ldquo;I might meet people if I join a club&rdquo;). The clinician questions the validity of maladaptive thoughts and then with the patient, examines the evidence for them and discusses alternative, rational explanations for the patient&rsquo;s situation. As an example, homework can include testing a faulty cognition by discussing it with friends. In addition, dysfunctional thoughts about body shape and weight are restructured by discussing the importance of shape and weight relative to other areas of life, including family, work, friends, and recreational activities.",
"     </li>",
"     <li>",
"      <strong>",
"       Body image",
"      </strong>",
"      &ndash; Patients learn to recognize parts of their body that are attractive and to more realistically appraise parts that are considered &ldquo;ugly&rdquo; or overweight",
"     </li>",
"     <li>",
"      <strong>",
"       Thoughts, feelings, and behaviors",
"      </strong>",
"      &ndash; Patients may have difficulty distinguishing thoughts (cognitions) from feelings, and need to understand how they interact and result in bulimic behavior (eg, &ldquo;I feel fat&rdquo; is really a thought).",
"     </li>",
"     <li>",
"      <strong>",
"       Assertiveness",
"      </strong>",
"      &ndash; Patients are taught to assert themselves in a productive manner; this may involve role playing situations in which patients express and negotiate their needs",
"     </li>",
"     <li>",
"      <strong>",
"       Family meeting",
"      </strong>",
"      &ndash; At least one session of individual CBT includes both the patient and family members (or significant others) who are regularly involved with the patient, to discuss the patient&rsquo;s progress, how the family can help, and identify problems such as negative comments about the patient&rsquo;s shape or weight",
"     </li>",
"     <li>",
"      <strong>",
"       Relapse prevention",
"      </strong>",
"      &ndash; The last part of therapy is devoted to:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Reviewing the patient&rsquo;s progress and identifying persistent problems",
"     </li>",
"     <li>",
"      Reinforcing healthy eating and exercise habits",
"     </li>",
"     <li>",
"      Differentiating &ldquo;slips&rdquo; or lapses from full-blown relapses, and accepting that lapses are common and do not necessarily lead to relapses",
"     </li>",
"     <li>",
"      Discussing the patient&rsquo;s goals following treatment",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An enhanced form of CBT for treating all eating disorders, including bulimia nervosa, has been developed [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/12,26,45\">",
"     12,26,45",
"    </a>",
"    ]. This treatment includes additional methods for addressing dysfunctional concerns about body weight and shape, as well as modules that address perfectionism and interpersonal functioning.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647595\">",
"    <span class=\"h2\">",
"     Nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Treatment should be reconsidered for patients who:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Do not adhere to treatment (eg, skip appointments or fail to complete homework) despite repeated efforts upon the part of the clinician",
"     </li>",
"     <li>",
"      Make an effort but achieve little or no progress after 10 sessions",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In either situation, the patient&rsquo;s overall motivation should be assessed and alternative treatments considered, such as an antidepressant (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ) or interpersonal psychotherapy. Patients who make little progress may need a day hospital or inpatient program.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H647374\">",
"    <span class=\"h2\">",
"     Other resources",
"    </span>",
"    &nbsp;&mdash;&nbsp;CBT is usually delivered according to a treatment manual that standardizes the procedures to be used and content of each session [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7560/abstract/12,46-51\">",
"     12,46-51",
"    </a>",
"    ]. In addition, information about training and conferences is available through the",
"    <a class=\"external\" href=\"file://www.abct.org/\">",
"     Association for Behavioral and Cognitive Therapies",
"    </a>",
"    and the",
"    <a class=\"external\" href=\"file://www.aedweb.org/\">",
"     Academy for Eating Disorders",
"    </a>",
"    .",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1743308\">",
"    <span class=\"h1\">",
"     CONTINUING CARE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Following acute treatment with 20 sessions, clinical experience suggests that a tapered schedule of visits, for example, every other week for two months and then once a month for four months, may delay or prevent relapse. These sessions are used to consolidate gains that patients have made to reduce overvaluing body weight and shape, and to monitor binge-eating, purging, healthy eating patterns, as well as mood and social interactions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1743322\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The core features of bulimia nervosa are excessive concern about body weight and shape, binge-eating, and inappropriate compensatory behaviors (",
"      <a class=\"graphic graphic_table graphicRef70006 \" href=\"UTD.htm?2/46/2796\">",
"       table 1",
"      </a>",
"      ). The initial clinical evaluation of patients with a possible diagnosis of bulimia nervosa includes a psychiatric and general medical history, mental status and physical examination, and focused laboratory tests. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=see_link\">",
"       \"Bulimia nervosa in adults: Clinical features, diagnosis, and assessment\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Treatment for bulimia nervosa generally consists of nutritional rehabilitation plus psychotherapy. Nutritional rehabilitation aims to restore a structured and consistent meal pattern. Cognitive-behavioral therapy (CBT) addresses dysfunctional thoughts and problematic behaviors that maintain the disorder. Pharmacotherapy is also efficacious. (See",
"      <a class=\"local\" href=\"#H29271339\">",
"       'Overview of treatment for bulimia nervosa'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=see_link&amp;anchor=H2#H2\">",
"       \"Eating disorders: Treatment\", section on 'Treatment'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/62/7145?source=see_link\">",
"       \"Bulimia nervosa in adults: Pharmacotherapy\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CBT is indicated for outpatients with bulimia nervosa who have the necessary motivation, cognitive capacity, emotional stability, and energy to participate in treatment and complete assigned tasks. Contraindications include medical instability, suicidal ideation or behavior, severe major depression, substance use disorder, psychosis, major life events or crises, and competing commitments. (See",
"      <a class=\"local\" href=\"#H1743280\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT is the treatment of choice for bulimia nervosa, based upon randomized trials that have demonstrated good outcomes, low relapse rates, and superiority to other psychotherapies and to pharmacotherapy. (See",
"      <a class=\"local\" href=\"#H460862\">",
"       'Evidence of efficacy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The cognitive-behavioral model of therapy focuses upon the clinical features that maintain bingeing and purging; the core psychopathology involves problems with self-evaluation and self-esteem, such that patients judge themselves primarily in terms of body weight and shape and the ability to control them. (See",
"      <a class=\"local\" href=\"#H1743287\">",
"       'Theoretical foundation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The standard format for administering CBT to outpatients with bulimia nervosa is individual treatment. CBT has also been adapted for group therapy and other formats. (See",
"      <a class=\"local\" href=\"#H647365\">",
"       'Format'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      CBT for bulimia nervosa generally includes the following elements. (See",
"      <a class=\"local\" href=\"#H647794\">",
"       'Therapeutic techniques and content'",
"      </a>",
"      above.):",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Treatment overview",
"     </li>",
"     <li>",
"      Commitment to change",
"     </li>",
"     <li>",
"      Self-monitoring (",
"      <a class=\"graphic graphic_table graphicRef67548 \" href=\"UTD.htm?32/19/33085\">",
"       table 2",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Healthy eating pattern",
"     </li>",
"     <li>",
"      Food avoidance",
"     </li>",
"     <li>",
"      Weekly weighing",
"     </li>",
"     <li>",
"      Education",
"     </li>",
"     <li>",
"      Cues and consequences",
"     </li>",
"     <li>",
"      Chains of behaviors",
"     </li>",
"     <li>",
"      Alternative behaviors",
"     </li>",
"     <li>",
"      Stress management skills",
"     </li>",
"     <li>",
"      Problem solving skills",
"     </li>",
"     <li>",
"      Cognitive restructuring",
"     </li>",
"     <li>",
"      Body image",
"     </li>",
"     <li>",
"      Assertiveness",
"     </li>",
"     <li>",
"      Family meeting",
"     </li>",
"     <li>",
"      Relapse prevention",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Additional CBT sessions beyond acute treatment may delay or prevent relapse. (See",
"      <a class=\"local\" href=\"#H1743308\">",
"       'Continuing care'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/1\">",
"      Russell G. Bulimia nervosa: an ominous variant of anorexia nervosa. Psychol Med 1979; 9:429.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/2\">",
"      Hay PP, Bacaltchuk J, Stefano S, Kashyap P. Psychological treatments for bulimia nervosa and binging. Cochrane Database Syst Rev 2009; :CD000562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/3\">",
"      Shapiro JR, Berkman ND, Brownley KA, et al. Bulimia nervosa treatment: a systematic review of randomized controlled trials. Int J Eat Disord 2007; 40:321.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/4\">",
"      Wilson GT, Grilo CM, Vitousek KM. Psychological treatment of eating disorders. Am Psychol 2007; 62:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/5\">",
"      Wilson GT, Shafran R. Eating disorders guidelines from NICE. Lancet 2005; 365:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/6\">",
"      Mitchell JE, Agras S, Wonderlich S. Treatment of bulimia nervosa: where are we and where are we going? Int J Eat Disord 2007; 40:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/7\">",
"      Treasure J, Claudino AM, Zucker N. Eating disorders. Lancet 2010; 375:583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/8\">",
"      Hall MN, Friedman RJ 2nd, Leach L. Treatment of bulimia nervosa. Am Fam Physician 2008; 77:1588, 1592.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision, American Psychiatric Association, Washington, DC, 2000.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/10\">",
"      Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.",
"     </a>",
"    </li>",
"    <li>",
"     American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. file://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).",
"    </li>",
"    <li>",
"     Cooper Z, Fairburn C. Cognitive behavior therapy for bulimia nervosa. In: The Treatment of Eating Disorders, Grilo C, Mitchell J.  (Eds), The Guilford Press, New York 2010. p.243.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/13\">",
"      Crow S, Mussell MP, Peterson C, et al. Prior treatment received by patients with bulimia nervosa. Int J Eat Disord 1999; 25:39.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/14\">",
"      American Psychiatric Association. Treatment of patients with eating disorders,third edition. American Psychiatric Association. Am J Psychiatry 2006; 163:4.",
"     </a>",
"    </li>",
"    <li>",
"     Eating Disorders: Core Interventions in the Treatment of and Management of Anorexia Nervosa, Bulimia Nervosa and Related Eating Disorders. National Institute for Clinical Excellence, Clinical Guideline 9. file://guidance.nice.org.uk (Accessed on December 22, 2010).",
"    </li>",
"    <li>",
"     National Institute for Clinical Excellence. Eating Disorders: Core interventions in the treatment and management of anorexia nervosa, bulimia nervosa and related eating disorders. National Clinical Practice Guideline Number CG9, 2004. file://www.nice.org.uk/ (Accessed on January 23, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/17\">",
"      Cassin SE, von Ranson KM. Personality and eating disorders: a decade in review. Clin Psychol Rev 2005; 25:895.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/18\">",
"      Chen EY, Matthews L, Allen C, et al. Dialectical behavior therapy for clients with binge-eating disorder or bulimia nervosa and borderline personality disorder. Int J Eat Disord 2008; 41:505.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/19\">",
"      Sysko R, Walsh BT. A critical evaluation of the efficacy of self-help interventions for the treatment of bulimia nervosa and binge-eating disorder. Int J Eat Disord 2008; 41:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/20\">",
"      Grilo CM. Recent research of relationships among eating disorders and personality disorders. Curr Psychiatry Rep 2002; 4:18.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/21\">",
"      Keel PK, Mitchell JE. Outcome in bulimia nervosa. Am J Psychiatry 1997; 154:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/22\">",
"      Rowe SL, Jordan J, McIntosh VV, et al. Impact of borderline personality disorder on bulimia nervosa. Aust N Z J Psychiatry 2008; 42:1021.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/23\">",
"      Sansone RA, Levitt JL. Borderline personality and eating disorders. Eat Disord 2005; 13:71.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/24\">",
"      Linehan MM, Comtois KA, Murray AM, et al. Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006; 63:757.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/25\">",
"      Bulik CM, Marcus MD, Zerwas S, et al. The changing \"weightscape\" of bulimia nervosa. Am J Psychiatry 2012; 169:1031.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/26\">",
"      Murphy R, Straebler S, Cooper Z, Fairburn CG. Cognitive behavioral therapy for eating disorders. Psychiatr Clin North Am 2010; 33:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/27\">",
"      McIntosh VV, Carter FA, Bulik CM, et al. Five-year outcome of cognitive behavioral therapy and exposure with response prevention for bulimia nervosa. Psychol Med 2011; 41:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/28\">",
"      Fairburn CG, Cooper Z, Shafran R. Cognitive behaviour therapy for eating disorders: a \"transdiagnostic\" theory and treatment. Behav Res Ther 2003; 41:509.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/29\">",
"      Wonderlich SA, Engel SG, Peterson CB, et al. Examining the conceptual model of integrative cognitive-affective therapy for BN: Two assessment studies. Int J Eat Disord 2008; 41:748.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/30\">",
"      Hsu LK, Rand W, Sullivan S, et al. Cognitive therapy, nutritional therapy and their combination in the treatment of bulimia nervosa. Psychol Med 2001; 31:871.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/31\">",
"      Thompson-Brenner H, Glass S, Weston D. A multidimensional meta-analysis of psychotherapy for bulimia nervosa. Clin Psychol 2003; 10:269.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/32\">",
"      Fern&aacute;ndez-Aranda F, N&uacute;&ntilde;ez A, Mart&iacute;nez C, et al. Internet-based cognitive-behavioral therapy for bulimia nervosa: a controlled study. Cyberpsychol Behav 2009; 12:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/33\">",
"      Crow SJ, Mitchell JE, Crosby RD, et al. The cost effectiveness of cognitive behavioral therapy for bulimia nervosa delivered via telemedicine versus face-to-face. Behav Res Ther 2009; 47:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/34\">",
"      Mitchell JE, Crosby RD, Wonderlich SA, et al. A randomized trial comparing the efficacy of cognitive-behavioral therapy for bulimia nervosa delivered via telemedicine versus face-to-face. Behav Res Ther 2008; 46:581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/35\">",
"      S&aacute;nchez-Ortiz VC, Munro C, Stahl D, et al. A randomized controlled trial of internet-based cognitive-behavioural therapy for bulimia nervosa or related disorders in a student population. Psychol Med 2011; 41:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/36\">",
"      Pretorius N, Arcelus J, Beecham J, et al. Cognitive-behavioural therapy for adolescents with bulimic symptomatology: the acceptability and effectiveness of internet-based delivery. Behav Res Ther 2009; 47:729.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/37\">",
"      S&aacute;nchez-Ortiz VC, Munro C, Startup H, et al. The role of email guidance in internet-based cognitive-behavioural self-care treatment for bulimia nervosa. Eur Eat Disord Rev 2011; 19:342.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/38\">",
"      Wagner G, Penelo E, Wanner C, et al. Internet-delivered cognitive-behavioural therapy v. conventional guided self-help for bulimia nervosa: long-term evaluation of a randomised controlled trial. Br J Psychiatry 2013; 202:135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/39\">",
"      Shapiro JR, Bauer S, Andrews E, et al. Mobile therapy: Use of text-messaging in the treatment of bulimia nervosa. Int J Eat Disord 2010; 43:513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/40\">",
"      Schmidt U, Andiappan M, Grover M, et al. Randomised controlled trial of CD-ROM-based cognitive-behavioural self-care for bulimia nervosa. Br J Psychiatry 2008; 193:493.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/41\">",
"      Striegel-Moore RH, Wilson GT, DeBar L, et al. Cognitive behavioral guided self-help for the treatment of recurrent binge eating. J Consult Clin Psychol 2010; 78:312.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/42\">",
"      Lynch FL, Striegel-Moore RH, Dickerson JF, et al. Cost-effectiveness of guided self-help treatment for recurrent binge eating. J Consult Clin Psychol 2010; 78:322.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/43\">",
"      Mitchell JE, Pyle RL, Pomeroy C, et al. Cognitive-behavioral group psychotherapy of bulimia nervosa: importance of logistical variables. Int J Eat Disord 1993; 14:277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7560/abstract/44\">",
"      Laessle RG, Beumont PJ, Butow P, et al. A comparison of nutritional management with stress management in the treatment of bulimia nervosa. Br J Psychiatry 1991; 159:250.",
"     </a>",
"    </li>",
"    <li>",
"     Fairburn, CG. Cognitive behavior therapy and eating disorders, Guilford Press, New York 2008.",
"    </li>",
"    <li>",
"     Fairburn C. Cognitive Behavior Therapy and Eating Disorders, The Guilford Press, New York 2008.",
"    </li>",
"    <li>",
"     Marino J, Mitchell J. Bulimia Nervosa. In: How to Practice Evidence-based Psychiatry, Basic Principles and Case Studies, Barr Taylor C.  (Ed), American Psychiatric Publishing, Inc., Washington, DC 2010. p.253.",
"    </li>",
"    <li>",
"     Braun D. Cognitive behavioral therapy for bulimia nervosa. In: Evidence-based Treatments for Eating Disorders; Children, Adolescents and Adults, Dancyger I, Fornari V.  (Eds), Nova Science Publishers, Inc., New York 2009. p.207.",
"    </li>",
"    <li>",
"     Campbell M, Schmidt U. Cognitive-behavioral therapy for adolescent bulimia nervosa and binge-eating disorder. In: Eating Disorders in Children and Adolescents: A clinical handbook, Le Grange D, Lock J.  (Eds), The Guilford Press, New York 2011. p.305.",
"    </li>",
"    <li>",
"     Touyz S, Polivy J, Hay P. Advances in Psychotherapy: Evidence-based Practice, Hogrefe &amp; Huber Publishers, Cambridge 2008. p.43.",
"    </li>",
"    <li>",
"     Peterson C, Wonderlich S, Mitchell J, Crow S. Integrative cognitive therapy for bulimia nervosa. In: Handbook of Eating Disorders and Obesity, Thompson J.  (Ed), Wiley, Hoboken, NJ 2004. p.245.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14746 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-199.231.185.123-894C5EFDCE-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7560=[""].join("\n");
var outline_f7_24_7560=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H1743322\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1743273\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29270630\">",
"      DEFINITION OF BULIMIA NERVOSA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H173355904\">",
"      Assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H29271339\">",
"      OVERVIEW OF TREATMENT FOR BULIMIA NERVOSA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1743280\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7441169\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H460862\">",
"      EVIDENCE OF EFFICACY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1743287\">",
"      THEORETICAL FOUNDATION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1743301\">",
"      TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647365\">",
"      Format",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647794\">",
"      Therapeutic techniques and content",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647595\">",
"      Nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H647374\">",
"      Other resources",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1743308\">",
"      CONTINUING CARE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1743322\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14746\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14746|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?2/46/2796\" title=\"table 1\">",
"      DSM-IV-TR diagnostic criteria for bulimia nervosa",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/19/33085\" title=\"table 2\">",
"      Food records standard",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?39/41/40593?source=related_link\" title=\"calculator 1\">",
"      Calculator: Body mass index (BMI; Quetelet's index)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/28/15816?source=related_link\">",
"      Behavioral strategies in the treatment of obesity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/1/33816?source=related_link\">",
"      Bulimia nervosa and binge eating disorder in adults: Medical complications and their management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/50/33577?source=related_link\">",
"      Bulimia nervosa in adults: Clinical features, diagnosis, and assessment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/62/7145?source=related_link\">",
"      Bulimia nervosa in adults: Pharmacotherapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/2/23593?source=related_link\">",
"      Eating disorders: Epidemiology, pathogenesis, clinical features, and course of illness",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/63/44023?source=related_link\">",
"      Eating disorders: Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/3/29751?source=related_link\">",
"      Overview of psychotherapies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/45/13016?source=related_link\">",
"      Overview of therapy for obesity in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_24_7561="Secondary immune deficiency due to miscellaneous causes";
var content_f7_24_7561=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Secondary immune deficiency due to miscellaneous causes",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7561/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7561/contributors\">",
"     Francisco A Bonilla, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7561/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7561/contributors\">",
"     E Richard Stiehm, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7561/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7561/contributors\">",
"     Anna M Feldweg, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/24/7561/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Sep 27, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune system function is altered by many conditions which primarily impair function of other organ systems (",
"    <a class=\"graphic graphic_table graphicRef71244 \" href=\"UTD.htm?37/20/38220\">",
"     table 1",
"    </a>",
"    ). As with primary immune deficiency, secondary immune dysfunction leads to an increased incidence of infection and malignancy, and the occurrence of autoimmune disease.",
"   </p>",
"   <p>",
"    The mechanisms and sequelae of the immune dysfunction, occurring as the result of biochemical abnormalities, environmental exposures, miscellaneous disorders, and infections other than HIV will be reviewed here. Secondary immune deficiencies resulting from immunosuppressive agents and malignancy are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=see_link\">",
"     \"Secondary immune deficiency induced by drugs and biologics\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Infection with the human immunodeficiency virus (HIV) and the acquired immunodeficiency syndrome (AIDS) constitute an entire discipline by themselves, and are discussed separately in the appropriate topic reviews.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     DISORDERS OF BIOCHEMICAL HOMEOSTASIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease processes that lead to chronic imbalances in hormones, nutrients, and toxic metabolic waste products in body fluids may have profound effects on the function of one or more components of the immune system. There are a great many diagnostic entities that may be grouped under this broad heading. It may be that many have as yet unknown effects on immune function. A few disorders where clinically significant immune dysfunction is regularly encountered are presented in this section.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Diabetes mellitus",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutrophil dysfunction underlies much of the predisposition to fungal infections found in patients with diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/1\">",
"     1",
"    </a>",
"    ]. The decreased neutrophil function is directly related to the level of hyperglycemia. In addition, poor peripheral circulation leads to skin ulceration, and diminished delivery of neutrophils to sites of microbial entry. Some characteristic infectious complications of diabetes include disseminated candidiasis, rhinopulmonary zygomycosis (mucormycosis), and malignant otitis due to P. aeruginosa. One epidemiologic study indicated that most or all of the increased risk of infection-related mortality in patients with diabetes is due to associated cardiovascular compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Dialysis and uremia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients receiving hemodialysis display reduced T cell function in vitro and in vivo (cutaneous anergy), diminished antibody production, and compromised neutrophil and dendritic function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/1\">",
"     1",
"    </a>",
"    ]. Compromised neutrophil function may be due in part to the use of bioincompatible dialysis membranes, resulting in impaired adherence and attenuated responses to phagocytic stimuli. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=see_link\">",
"     \"Clinical consequences of hemodialysis membrane biocompatibility\"",
"    </a>",
"    .) Low expression",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    function of IgG Fc receptors have also been noted. Some of these immune defects may be partly explained by the presence of high endogenous glucocorticoid levels. Patients with end stage renal disease, regardless of dialysis treatment, have very high blood levels of soluble interleukin-2 receptor and this may be responsible for reducing the bioavailability of and diminishing in vitro T cell responses to IL-2 [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients undergoing chronic peritoneal dialysis do not display systemic immune defects. However, peritoneal neutrophil function is depressed as a result of the removal of opsonic factors (immunoglobulin and complement) with the dialysate, as well as directly suppressive effects of the dialysate itself [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/1\">",
"     1",
"    </a>",
"    ]. These features, together with the presence of an indwelling foreign body, explain the susceptibility to bacterial peritonitis observed in these patients. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=see_link\">",
"     \"Pathophysiology and prevention of peritonitis in peritoneal dialysis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Cirrhosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reduced hepatic metabolism in cirrhosis leads to high levels of endogenous glucocorticoids, which may partly explain the immune dysfunction associated with liver disease. In addition, shunting of portal blood reduces the ability of hepatic Kupffer cells to clear opsonized particles, and hypocomplementemia reduces serum opsonic activity. The most common infectious complications of severe cirrhosis are sepsis, and bacterial peritonitis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/1\">",
"     1",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34197?source=see_link\">",
"     \"Pathogenesis of spontaneous bacterial peritonitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=see_link\">",
"     \"Acquired disorders of the complement system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Malnutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most studies on nutritionally-determined immune suppression have focused on protein-energy malnutrition. This is associated with a spectrum of immune defects including cutaneous anergy, diminished T cell mitogen responses, and decreased phagocytic cell function [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/4\">",
"     4",
"    </a>",
"    ]. Additional abnormalities include the following:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The number of circulating T cells declines, while the percentage of natural killer cells rises.",
"     </li>",
"     <li>",
"      Serum immunoglobulin is normal or increased; however, specific antibody responses are impaired.",
"     </li>",
"     <li>",
"      Primary and secondary lymphoid organs are relatively depleted of cells, and lymphoid follicles are sparse.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    An acute lowering of food intake may also severely affect immune function. One study, for example, found depression of circulating lymphocytes and interleukin-2 production following mitogen stimulation after a fast of only seven days [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Malnutrition predisposes to a greater incidence of clinically apparent infection, and increased morbidity and mortality due to infection with the pathogens prevalent in a given geographic area. It is estimated that worldwide, for example, malnutrition leads to 10- and 30-fold increased mortality from pneumonia and gastroenteritis, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/4\">",
"     4",
"    </a>",
"    ]. In Latin America, malnutrition is a contributing factor in approximately 60 percent of the deaths due to infection. In a study conducted in rural Bangladesh, the severity of malnutrition was linked to the rate of symptomatic upper respiratory infection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/6\">",
"     6",
"    </a>",
"    ]. Reduced blood levels of the hormone leptin may be an important pathway in the immune, endocrine and neurological dysregulation associated with starvation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A similar spectrum of defects and increased susceptibility to infection has also been linked to restricted nutritional deficiencies of zinc, iron, folate, pyridoxine, and vitamin A [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/8\">",
"     8",
"    </a>",
"    ]. Immune function returns to normal when proper nutritional balance is restored.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16802278\">",
"    <span class=\"h1\">",
"     DISORDERS OF PROTEIN LOSS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Certain disorders, such as nephrotic syndrome, protein losing enteropathies, severe dermatitis, peritoneal dialysis, and rare pulmonary diseases, can result in hypogammaglobulinemia due to loss of protein via the kidneys, intestinal tract, lymphatic system, or skin.",
"   </p>",
"   <p>",
"    Hypogammaglobulinemia from protein loss may present as low IgG and IgA, sometimes with near normal IgM. Often antibody levels are present in low titer and as a result, the patient may not have increased susceptibility to infection. Accelerated loss of IgG globulin can be documented by giving a large bolus of immune globulin (IVIG, 1 to 2",
"    <span class=\"nowrap\">",
"     grams/kg)",
"    </span>",
"    and then assessing daily IgG levels [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/9\">",
"     9",
"    </a>",
"    ]. A half life, after equilibration, of less than 15 days suggests protein loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2625243\">",
"    <span class=\"h2\">",
"     Nephrotic syndrome",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with nephrotic syndrome can develop hypogammaglobulinemia due to protein loss, as well as depressed cellular immunity due to loss of vitamin D and other serum factors [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Treatment with immunosuppressive drugs, such as glucocorticoids, further increases the risk of infection.",
"   </p>",
"   <p>",
"    Hypogammaglobulinemia may be severe with total IgG less than 200",
"    <span class=\"nowrap\">",
"     mg/dL.",
"    </span>",
"    Infectious complications of nephrotic syndrome include recurrent respiratory tract infections, urinary tract infections, peritonitis, and sepsis, particularly with encapsulated bacteria such as Streptococcus pneumonia. Varicella infections are also problematic in patients requiring immunosuppression. Prevention includes vaccination and careful attention to early symptoms, as discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=see_link&amp;anchor=H18#H18\">",
"     \"Overview of heavy proteinuria and the nephrotic syndrome\", section on 'Infection'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=see_link&amp;anchor=H3#H3\">",
"     \"Complications of idiopathic nephrotic syndrome in children\", section on 'Bacterial infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H184536898\">",
"    <span class=\"h2\">",
"     Peritoneal dialysis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many patients undergoing regular peritoneal dialysis for chronic renal disease develop hypogammaglobulinemia; this may contribute to their defective peritoneal defenses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H462979059\">",
"    <span class=\"h2\">",
"     Protein losing enteropathies",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of gastrointestinal disorders can result in protein loss and hypogammaglobulinemia. More common diseases include celiac disease, inflammatory bowel disease, and intestinal lymphangiectasia. Protein loss should be demonstrable by measurement of the alpha-1 antitrypsin clearance in the stool. Alpha-l antitrypsin has a moderately higher molecular weight than albumin (50,000) and, because it is resistant to proteolysis, is not degraded in the intestinal lumen. Thus, it passes intact into the stool when there is mucosal inflammation. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=see_link&amp;anchor=H17#H17\">",
"     \"Protein-losing gastroenteropathy\", section on 'Diagnosis'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2625885\">",
"    <span class=\"h3\">",
"     Intestinal lymphangiectasia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Intestinal lymphangiectasia is abnormal dilatation of intestinal mucosal lymphatic channels leading to loss of lymph with immunoglobulins and lymphocytes into the gut. The disorder may be congenital, or may arise secondarily to processes which obstruct lymph drainage of the gut or raise central venous pressure. Congenital forms may also be associated with pulmonary chylothorax and lymphedema. It may occur as a result of surgery for congenital heart disease, particularly after the Fontan procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/13\">",
"     13",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41401?source=see_link&amp;anchor=H18895232#H18895232\">",
"     \"Hypoplastic left heart syndrome\", section on 'Management'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Hypogammaglobulinemia and lymphopenia are variable, and some patients have an increased rate of infections, including opportunistic infections. Naive CD4 and CD8 T cells are lost preferentially to memory T cells and NK cells, which are retained. Mitogen proliferative responses are preserved [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/14\">",
"     14",
"    </a>",
"    ]. Similar alterations are observed in patients with chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients with recurrent infections and low serum IgG may benefit from gamma globulin infusions; however, relatively large doses may be required due to ongoing intestinal loss. Replacement therapy in this setting remains controversial.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2625420\">",
"    <span class=\"h2\">",
"     Other disorders",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other disorders that can result in hypogammaglobulinemia due to protein loss include severe dermatitis and plastic bronchitis with chylothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     TRAUMA",
"    </span>",
"    &nbsp;&mdash;&nbsp;Trauma is associated with subsequent defects in host defense that are generally proportional to the extent of tissue injury [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/17\">",
"     17",
"    </a>",
"    ]. The mechanism initiating the cascade of immune effects is thought to be the massive release of inflammatory cytokines (interleukin-1, tumor necrosis factor) due to widespread activation of monocytes and macrophages by the products of cellular necrosis. The spectrum of immune defects associated with trauma is summarized in the table (",
"    <a class=\"graphic graphic_table graphicRef72931 \" href=\"UTD.htm?26/48/27403\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Burns",
"    </span>",
"    &nbsp;&mdash;&nbsp;Burn trauma tends to result in a relatively greater immune suppression than mechanical trauma, when the extent of injury is similar [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/18\">",
"     18",
"    </a>",
"    ]. The reason for this is not known. In addition to depression of specific immune activation and effector mechanisms, burns also disrupt a relatively large area of nonspecific defense (the skin). This also greatly increases the risk of infection by providing microbes ready access to the interior of the body.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     ENVIRONMENTAL EXPOSURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Environmental exposures that can result in immune dysfunction include ionizing and ultraviolet radiation, and toxic chemicals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Ionizing radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ionizing radiation (X-rays, gamma rays) damages DNA by causing single and double-stranded breaks, as well as chemical changes in nucleotide base structure. This leads to impaired cell division, as well as to somatic mutations which may be expressed.",
"   </p>",
"   <p>",
"    Impaired cell division is the main mechanism of impairment of immune system function, and operates in a manner entirely analogous to what has been described for chemotherapeutic immune suppressive agents. In addition, radiation may induce apoptosis (programmed cell death) in susceptible lymphocyte populations. Somatic mutations may impair the function of cellular proteins that regulate cell division (eg, the p53 tumor suppressor gene), and lead to malignant cell growth.",
"   </p>",
"   <p>",
"    Radiation induces a rapid (hours) dose-dependent decline in peripheral blood lymphocyte counts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/19\">",
"     19",
"    </a>",
"    ]. B cells are more sensitive to radiation than T cells, as reflected in the depletion of germinal centers and other B cell rich areas of irradiated lymph nodes and spleens. Lymphocyte homing and recirculation are also affected, such that lymphocytes do not properly traffic between different lymphoid organs and regions of the body. In general, T cell numbers recover more rapidly following irradiation in comparison to B cells.",
"   </p>",
"   <p>",
"    Thymic cortical cells are undergoing rapid cell division, and are more radiosensitive than medullary thymocytes. Other thymic cell populations (epithelial cells) are relatively radioresistant. Several decades ago, when an \"enlarged\" thymus was considered a risk factor for infant mortality, the thymus was irradiated to reduce its size. This frequently resulted in long-lasting depression in blood T cell counts, as well as reduction in the in vitro response to mitogens [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/19\">",
"     19",
"    </a>",
"    ]. In vivo cutaneous delayed type hypersensitivity (DTH) responses were relatively preserved. However, these children showed several delayed effects including a higher rate of thymoma, as well as allergic and autoimmune diseases such as asthma, vasculitides, sarcoidosis, inflammatory bowel disease, and thyroiditis. The specific tolerance mechanisms which are affected by radiation leading to autoimmune disease have not been defined.",
"   </p>",
"   <p>",
"    Primary antibody responses are most often diminished by whole body irradiation, both due to suppression of proliferation",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    induction of apoptosis in B and T cells [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/19\">",
"     19",
"    </a>",
"    ]. As after thymic irradiation, DTH responses and in vitro cellular allocytotoxicity are relatively intact following whole body irradiation. In addition, most functions of mature, long-lived phagocytic cells, such as macrophages, appear to be relatively radiation-resistant.",
"   </p>",
"   <p>",
"    Even regional radiation therapy applied for the treatment of malignancy can have systemic immunologic effects. Radiation treatment of lung cancer may lead to diminished T cell numbers and reduced mitogen proliferative response in vitro [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The increased susceptibility to infection that results from high doses of whole body irradiation arises not only from general bone marrow and lymphocyte suppression, but also from damage to local defensive barriers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/19\">",
"     19",
"    </a>",
"    ]. The gastrointestinal tract, and to a slightly lesser extent the skin, are both organs which always sustain a high rate of cell division to replace cell loss. Irradiation interferes with cell replacement and leads to breakdown of these defensive barriers. Fatal infections may be caused not only by common pathogens, but also by normal commensal flora.",
"   </p>",
"   <p>",
"    Measurable immunologic effects of intense radiation exposure may be long-lived. Japanese studies of survivors of atomic bomb explosions have shown the persistence over 60 years of reduced proportions of helper T cells, diminished in vitro mitogen responses and poor IL-2 production, and reduced serum levels of inflammatory cytokines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Ultraviolet radiation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Ultraviolet B (UVB) radiation via sun exposure is the major determinant of risk for skin cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/22\">",
"     22",
"    </a>",
"    ] . This occurs through both direct mutagenesis and disruption of the cell cycle in skin epithelial cells, and from suppression of skin immune function. Chronic UV exposure leads to diminished function of all skin resident immune cells including lymphocytes, mast cells, and mononuclear derived cells including macrophages and dendritic cells. Immune suppressive alterations include an increased production of the antiinflammatory cytokine interleukin-10 and an increase in CD25+ regulatory T cells (Treg) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/22,23\">",
"     22,23",
"    </a>",
"    ]. These skin Treg cells have been shown to exert direct effects on skin tumorigenesis in UV-exposed mice [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/22\">",
"     22",
"    </a>",
"    ]. Treg cells can be induced in the skin of neonates exposed to UV and may persist for many years, possibly even into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/24\">",
"     24",
"    </a>",
"    ]. The implications for long-term health are unknown.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Toxic chemicals",
"    </span>",
"    &nbsp;&mdash;&nbsp;Numerous environmental chemicals have been incriminated in causing harm to the immune system, giving rise to the discipline of immunotoxicology [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/25\">",
"     25",
"    </a>",
"    ]. Many of these reports are anecdotal, and clinical studies frequently suffer from difficulties in the definition of insults to the immune system, small numbers, inadequacy or lack of appropriate controls, insufficient correlation between clinical problems and laboratory observations, quantitation of exposure to the substance in question, and lack of reproducibility of findings.",
"   </p>",
"   <p>",
"    Nevertheless, accumulated experience supports the importance of environmental chemical exposure for immune system dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/26\">",
"     26",
"    </a>",
"    ]. The table lists some of the \"xenobiotics\" which have been found or suggested to cause immune defects in animals and humans, and associated toxicities (",
"    <a class=\"graphic graphic_table graphicRef60126 \" href=\"UTD.htm?23/61/24541\">",
"     table 3",
"    </a>",
"    ). In no case has a specific molecular pathophysiology been described. Many of these compounds are variably bone marrow suppressive, and have also been linked to abnormalities of T cell function in vivo (thymic atrophy, circulating lymphocyte subsets, DTH) and in vitro (mitogen, antigen, and mixed lymphocyte responses, cytotoxicity). Some compounds have also been found to cause polyclonal B cell activation and have been associated with autoimmune phenomena. In some cases, exposure has been found to cause an increased incidence of infection, predominantly of the respiratory tract. Several compounds are also implicated in an increased cancer risk, either through direct mutagenic potential, decreased immune tumor surveillance, or both.",
"   </p>",
"   <p>",
"    Developmental immunotoxicology has emerged as a subdiscipline [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/27\">",
"     27",
"    </a>",
"    ]. Since the immune system changes significantly from the newborn period through adulthood, the immunologic insults (immune suppression, predisposition to allergy or autoimmunity) resulting from some environmental toxic exposures have different effects depending on age (including gestational age). In general, immunologic (and other) toxic effects are more pronounced in younger developing individuals compared to adults.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     ALLOGENEIC BLOOD TRANSFUSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Blood transfusion from major-histocompatibility-unrelated donors increases the rate of postoperative infection by 30 percent or more [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/28\">",
"     28",
"    </a>",
"    ]. As an example, in a retrospective study of almost 10,000 consecutive hip fracture patients undergoing surgical repair, allogeneic blood transfusion was associated with a significant increase in the risk of serious postoperative bacterial infection (5.2 versus 3.7 percent with no transfusion) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/29\">",
"     29",
"    </a>",
"    ]. There was a significant dose-response relationship between the adjusted hazard ratios for these two complications and the number of units of allogeneic blood transfused. The mechanism of susceptibility is unknown, but the effect is not seen with leukocyte-depleted blood in animal studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=see_link\">",
"     \"Leukoreduction to prevent complications of blood transfusion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    One estimate of excess mortality due to infection resulting from blood transfusion-induced immune suppression is 125",
"    <span class=\"nowrap\">",
"     deaths/million",
"    </span>",
"    units. In animal models, blood transfusion also leads to accelerated tumor growth and increased mortality. This may be important in the occurrence and recurrence of malignancy in humans. Blood transfusion increases mortality by 9 percent in patients with colorectal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/30\">",
"     30",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h1\">",
"     NORMAL LIFE STAGES AND EVENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune function may be impaired by normal life stages and events, such as aging, pregnancy, and extreme stress.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Aging",
"    </span>",
"    &nbsp;&mdash;&nbsp;Immune dysfunction associated with aging is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15178?source=see_link\">",
"     \"Immune function in older adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h2\">",
"     Pregnancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pregnant women have a higher incidence of numerous infectious diseases dependent upon cellular immunity for their control [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/31\">",
"     31",
"    </a>",
"    ]. These include hepatitis A and B, influenza, herpesviruses, chlamydia, listeria, Campylobacter, tuberculosis, and several fungal, protozoan, and helminthic infections.",
"   </p>",
"   <p>",
"    Depressed cellular immunity during pregnancy is assumed to have a \"survival benefit\" by reducing the likelihood of maternal \"rejection\" of the fetus which contains potent alloantigenic stimuli derived from the father. Multiple etiologic factors have been implicated:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Progesterone may be a major immunosuppressive factor in pregnancy. It has been shown to inhibit lymphocyte proliferation in vitro.",
"     </li>",
"     <li>",
"      A pregnancy-specific serum factor called uromodulin has been shown to inhibit B cell activity, although antibody responses are generally preserved during pregnancy.",
"     </li>",
"     <li>",
"      Depressed T cell responses to mitogens have been observed only in the presence of autologous serum, suggesting the importance of circulating suppressive factors [",
"      <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h2\">",
"     Stress",
"    </span>",
"    &nbsp;&mdash;&nbsp;Major life stresses such as bereavement, as well as less catastrophic stresses such as examinations in medical school, have been associated with increased rates of respiratory tract infection, reactivation of herpesvirus infections, and increased incidence of cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/33,34\">",
"     33,34",
"    </a>",
"    ]. Similar findings occur in humans and animals during and after space flight [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/35\">",
"     35",
"    </a>",
"    ]. While the space environment may play a role, this is thought to be most likely the result of a relatively extreme occupational psychological stress, with possible implications for more down-to-earth highly stressful occupations. Diminished cellular immune function has also been described in those suffering from post-traumatic stress disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/36\">",
"     36",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Laboratory studies have consistently shown reduced natural killer cell activity and depressed lymphocyte mitogen responses in stressed individuals. The discipline of psychoneuroimmunology is devoted to the study of these phenomena, although well-defined mechanisms of neural regulation of immunity are yet to be described. Increased production of corticotropin-releasing factor and sympathetic autonomic activity has been suggested to play a role.",
"   </p>",
"   <p>",
"    It is unlikely that emotional stress alone, however severe, will commonly cause an increased incidence or severity of infection sufficient to prompt investigation of immune function. The degree to which chronic stress contributes to the public health burden of infectious disease and malignancy remains a subject of debate.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h1\">",
"     INFECTIONS (OTHER THAN HIV)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many human pathogens have evolved sophisticated means for surviving attack by the immune systems of their hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]. In most cases, these mechanisms selectively affect host response to the invader and are not generally immunosuppressive, with the important exception of the profound immune suppression resulting from HIV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Instances in which microbial infection leads to less profound generalized immune suppression will be discussed here. Laboratory studies of immune function are not routinely conducted in patients with these infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Viral infections",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h3\">",
"     Measles",
"    </span>",
"    &nbsp;&mdash;&nbsp;Aside from HIV, measles (morbillivirus) is the only viral agent implicated in significant global immune suppression, leading to severe, and sometimes fatal, superinfection [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/39,40\">",
"     39,40",
"    </a>",
"    ]. Secondary immunosuppression due to measles virus infection is particularly important in the developing world, and malnutrition is an important independent risk factor for severe immune compromise, superinfection, and death from measles infection. In one retrospective study of measles fatalities in South Africa, 85 percent of deaths were mainly attributed to viral, bacterial, or fungal lung super- or co-infections [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/39\">",
"     39",
"    </a>",
"    ]. The most frequent infectious complications of measles are pneumonia, gastroenteritis, otitis media, gingivostomatitis, and laryngotracheobronchitis. Pathogens included common viral agents such as herpes simplex, cytomegalovirus, parainfluenza, adenovirus, coxsackie, and respiratory syncytial virus. Bacteria included community-acquired organisms such as Staphylococcus aureus and Streptococcus pneumoniae, as well as nosocomial pathogens such as Klebsiella, Pseudomonas, and Acinetobacter. Mycobacterium tuberculosis and Candida albicans were also found.",
"   </p>",
"   <p>",
"    Immune alterations induced by measles include T cell lymphopenia with depletion of T-dependent areas of lymph nodes and spleen, cutaneous anergy, diminished in vitro T cell proliferation with mitogens or alloantigens, and diminished antibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/40\">",
"     40",
"    </a>",
"    ]. These effects are caused by direct infection of T cells by measles virus and by infection of dendritic cells, impairing their important antigen",
"    <span class=\"nowrap\">",
"     presenting/accessory",
"    </span>",
"    function in T cell activation. A diminished number of circulating T cells indicates the potential for significant immune compromise and is associated with doubling of the fatality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h3\">",
"     Herpesviruses",
"    </span>",
"    &nbsp;&mdash;&nbsp;Herpesvirus infections can cause transient depression of cell-mediated immunity manifested by decreased in vitro proliferation with mitogens, and reduced interferon-gamma production in response to mitogens during the acute phase of the illness [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/41\">",
"     41",
"    </a>",
"    ]. These phenomena are most profound and long-lived with cytomegalovirus, but secondary superinfection is unusual. Herpesvirus persistence has also been implicated in the mechanisms of immunosenescence (see above) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/42\">",
"     42",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h2\">",
"     Bacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection by bacteria is not generally associated with significant secondary immune suppression. One exception may be bacteria that produce \"superantigen\" toxins (eg, staphylococci, streptococci). Superantigens can bind simultaneously to MHC class II antigens and to the non-antigen-binding region of T cell receptor variable regions, thereby stimulating large numbers (up to 20 percent) of T cells. These T cells then produce large amounts of inflammatory cytokines, which lead to a syndrome resembling septic shock with multisystem organ failure (eg, staphylococcal toxic shock syndrome). Following interaction with superantigens, circulating T cells first increase, then decrease. Animal studies have shown that some T cells enter a state of anergy and cannot be further activated [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/43\">",
"     43",
"    </a>",
"    ]. These bacteria also produce superantigen like molecules with distinct biological activities, including interference with opsonophagocytosis and other neutrophil functions. Although these bacterial products are very important as virulence factors, their role in inducing any secondary immune suppression is unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h2\">",
"     Mycobacterial infections",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mycobacteria establish chronic infections and replicate within phagocytic cells (monocytes and macrophages). Several secreted and surface mycobacterial products inhibit the ability of the infected cell to kill the invader and also prevent normal cooperation with other cells in immune responses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/44\">",
"     44",
"    </a>",
"    ]. This may lead to some increase in the risk of secondary infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Parasite infestation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The immune suppression resulting from protozoan infestation tends to be more pronounced than that found with other classes of microbes, with the exception of HIV. As an example, cell-mediated immunity is generally suppressed in malaria [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/45\">",
"     45",
"    </a>",
"    ]. This leads to susceptibility to infections by other microbes, delayed graft rejection, and to a higher rate of various malignancies.",
"   </p>",
"   <p>",
"    Some of the possible mechanisms underlying the immune suppression occurring during parasitic infection include [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/45\">",
"     45",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Alteration in macrophage function",
"     </li>",
"     <li>",
"      The induction of suppressor T cells",
"     </li>",
"     <li>",
"      Production of immunosuppressive factors by the parasites themselves, which may promote the first two mechanisms or may affect other aspects of immune function",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    A decreased capacity for antigen presentation and microbicidal activity has been demonstrated in macrophages in malaria, trypanosomiasis, and leishmaniasis. Leishmaniasis is also associated with diminished macrophage expression of MHC class II and interleukin-1 production, while the function of normal T cells may be suppressed when cultured together in malaria and trypanosomiasis [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/45,46\">",
"     45,46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Suppressor T cells have been implicated in the immune dysfunction in many parasitic diseases, but a detailed description of their phenotype and function is lacking [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/47,48\">",
"     47,48",
"    </a>",
"    ]. Similarly, many studies have demonstrated the presence of factors in parasite culture fluids that may nonspecifically suppress lymphocyte proliferation [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/49\">",
"     49",
"    </a>",
"    ] or may activate B cells polyclonally, leading to autoantibody production [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/45\">",
"     45",
"    </a>",
"    ]. The chemical characteristics and function of any of these factors has not yet been determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h3\">",
"     Malaria",
"    </span>",
"    &nbsp;&mdash;&nbsp;Malaria infection is one aspect of the marked association of Epstein-Barr virus (EBV) infection with Burkitt lymphoma that is observed in Africa, but not in Europe or America [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. Although the seroprevalence of EBV in western countries is significant, malaria is uncommon. Plasmodia inhibit the ability of cytotoxic T cells to maintain EBV transformed B cells under control, leading to lymphomas. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=see_link&amp;anchor=H18#H18\">",
"     \"Clinical manifestations and treatment of Epstein-Barr virus infection\", section on 'Burkitt lymphoma'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h3\">",
"     Other parasites",
"    </span>",
"    &nbsp;&mdash;&nbsp;Delayed graft rejection and impaired humoral immunity have also been found in infestations with helminths, such as Trichinella and schistosomes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/52-54\">",
"     52-54",
"    </a>",
"    ]. Infection with Trypanosoma brucei is associated with diminished antibody responses, cutaneous anergy, and diminished in vitro T cell mitogen responses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7561/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13895?source=see_link\">",
"     \"Epidemiology, pathogenesis, and prevention of African trypanosomiasis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Secondary immune dysfunction can result from a wide array of disease processes and presents as an increased susceptibility to infection, malignancy, and autoimmune disease (",
"      <a class=\"graphic graphic_table graphicRef71244 \" href=\"UTD.htm?37/20/38220\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Chronic imbalances in blood chemistry, nutrients, and metabolic waste products can cause immune dysfunction. Examples include diabetes, cirrhosis, and malnutrition. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Disorders of biochemical homeostasis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Hypogammaglobulinemia can result from protein loss from the kidney, gastrointestinal tract, lymphatic circulation, peritoneal dialysis, and skin. (See",
"      <a class=\"local\" href=\"#H16802278\">",
"       'Disorders of protein loss'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Trauma, including burns, can result in secondary immunodeficiency both through the disruption of physical barriers (eg, skin, gut), and through massive release of inflammatory cytokines due to widespread activation of monocytes and macrophages by the products of cellular necrosis (",
"      <a class=\"graphic graphic_table graphicRef72931 \" href=\"UTD.htm?26/48/27403\">",
"       table 2",
"      </a>",
"      ). The degree of immune dysfunction is generally proportional to the extent of tissue injury. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Trauma'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Exposure to ionizing radiation damages DNA, leading to impaired cell division and somatic mutations. Circulating lymphocytes numbers are reduced and bone marrow hemopoiesis is suppressed. Ultraviolet radiation causes immune dysfunction that is largely limited to the skin, increasing the risk for cutaneous infections and malignancies. Certain chemicals have been implicated in immune dysfunction in animals and humans (",
"      <a class=\"graphic graphic_table graphicRef60126 \" href=\"UTD.htm?23/61/24541\">",
"       table 3",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Environmental exposures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Common life events and stages can also result in decrements in immune function. These include aging, pregnancy, and extreme psychological stress. (See",
"      <a class=\"local\" href=\"#H19\">",
"       'Normal life stages and events'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Certain infectious organisms have evolved to evade detection and killing by the host, resulting in impairment of specific immune mechanisms. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Infections (other than HIV)'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/1\">",
"      de Marie S. Diseases and drug-related interventions affecting host defence. Eur J Clin Microbiol Infect Dis 1993; 12 Suppl 1:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/2\">",
"      Bertoni AG, Saydah S, Brancati FL. Diabetes and the risk of infection-related mortality in the U.S. Diabetes Care 2001; 24:1044.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/3\">",
"      Donati D, Degiannis D, Homer L, et al. Immune deficiency in uremia: interleukin-2 production and responsiveness and interleukin-2 receptor expression and release. Nephron 1991; 58:268.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/4\">",
"      Santos JI. Nutrition, infection, and immunocompetence. Infect Dis Clin North Am 1994; 8:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/5\">",
"      S&auml;vendahl L, Underwood LE. Decreased interleukin-2 production from cultured peripheral blood mononuclear cells in human acute starvation. J Clin Endocrinol Metab 1997; 82:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/6\">",
"      Zaman K, Baqui AH, Yunus M, et al. Malnutrition, cell-mediated immune deficiency and acute upper respiratory infections in rural Bangladeshi children. Acta Paediatr 1997; 86:923.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/7\">",
"      Faggioni R, Feingold KR, Grunfeld C. Leptin regulation of the immune response and the immunodeficiency of malnutrition. FASEB J 2001; 15:2565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/8\">",
"      Corman LC. The relationship between nutrition, infection, and immunity. Med Clin North Am 1985; 69:519.",
"     </a>",
"    </li>",
"    <li>",
"     Stiehm ER, Ochs HD, Winkelstein JA. Immunodeficiency disorders: General considerations. In: Immunologic disorders in infants and children, 5th ed, Stiehm ER, Ochs HD, Winkelstein JA.  (Eds), Elsevier/Saunders, Philadelphia 2005. p.315.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/10\">",
"      Harris RC, Ismail N. Extrarenal complications of the nephrotic syndrome. Am J Kidney Dis 1994; 23:477.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/11\">",
"      Crew RJ, Radhakrishnan J, Appel G. Complications of the nephrotic syndrome and their treatment. Clin Nephrol 2004; 62:245.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/12\">",
"      Akman S, G&uuml;ven AG, Ince S, Ye��in O. IgG and IgG subclasses deficiency in children undergoing continuous ambulatory peritoneal dialysis and its provocative factors. Pediatr Int 2002; 44:273.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/13\">",
"      Ostrow AM, Freeze H, Rychik J. Protein-losing enteropathy after fontan operation: investigations into possible pathophysiologic mechanisms. Ann Thorac Surg 2006; 82:695.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/14\">",
"      Vignes S, Carcelain G. Increased surface receptor Fas (CD95) levels on CD4+ lymphocytes in patients with primary intestinal lymphangiectasia. Scand J Gastroenterol 2009; 44:252.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/15\">",
"      Orange JS, Geha RS, Bonilla FA. Acute chylothorax in children: selective retention of memory T cells and natural killer cells. J Pediatr 2003; 143:243.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/16\">",
"      Brogan TV, Finn LS, Pyskaty DJ Jr, et al. Plastic bronchitis in children: a case series and review of the medical literature. Pediatr Pulmonol 2002; 34:482.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/17\">",
"      Faist E, Schinkel C, Zimmer S. Update on the mechanisms of immune suppression of injury and immune modulation. World J Surg 1996; 20:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/18\">",
"      Barlow Y. T lymphocytes and immunosuppression in the burned patient: a review. Burns 1994; 20:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/19\">",
"      Anderson RE, Warner NL. Ionizing radiation and the immune response. Adv Immunol 1976; 24:215.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/20\">",
"      Uh S, Lee SM, Kim HT, et al. The effect of radiation therapy on immune function in patients with squamous cell lung carcinoma. Chest 1994; 105:132.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/21\">",
"      Kusunoki Y, Hayashi T. Long-lasting alterations of the immune system by ionizing radiation exposure: implications for disease development among atomic bomb survivors. Int J Radiat Biol 2008; 84:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/22\">",
"      Beissert S, Loser K. Molecular and cellular mechanisms of photocarcinogenesis. Photochem Photobiol 2008; 84:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/23\">",
"      Norval M, McLoone P, Lesiak A, Narbutt J. The effect of chronic ultraviolet radiation on the human immune system. Photochem Photobiol 2008; 84:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/24\">",
"      Muller HK, Malley RC, McGee HM, et al. Effect of UV radiation on the neonatal skin immune system- implications for melanoma. Photochem Photobiol 2008; 84:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/25\">",
"      Karol MH, Stoliker D. Immunotoxicology: past, present, and future. Inhal Toxicol 1999; 11:523.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/26\">",
"      Luster MI, Blank JA, Dean JH. Molecular and cellular basis of chemically induced immunotoxicity. Annu Rev Pharmacol Toxicol 1987; 27:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/27\">",
"      Dietert RR. Developmental immunotoxicology: focus on health risks. Chem Res Toxicol 2009; 22:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/28\">",
"      Dzik S, Blajchman MA, Blumberg N, et al. Current research on the immunomodulatory effect of allogeneic blood transfusion. Vox Sang 1996; 70:187.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/29\">",
"      Carson JL, Altman DG, Duff A, et al. Risk of bacterial infection associated with allogeneic blood transfusion among patients undergoing hip fracture repair. Transfusion 1999; 39:694.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/30\">",
"      Vamvakas E, Moore SB. Perioperative blood transfusion and colorectal cancer recurrence: a qualitative statistical overview and meta-analysis. Transfusion 1993; 33:754.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/31\">",
"      Weinberg ED. Pregnancy-associated immune suppression: risks and mechanisms. Microb Pathog 1987; 3:393.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/32\">",
"      Matthiesen L, Berg G, Ernerudh J, H&aring;kansson L. Lymphocyte subsets and mitogen stimulation of blood lymphocytes in normal pregnancy. Am J Reprod Immunol 1996; 35:70.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/33\">",
"      Irwin M. Stress-induced immune suppression: role of brain corticotropin releasing hormone and autonomic nervous system mechanisms. Adv Neuroimmunol 1994; 4:29.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/34\">",
"      Glaser R, Rice J, Sheridan J, et al. Stress-related immune suppression: health implications. Brain Behav Immun 1987; 1:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/35\">",
"      Taylor GR, Konstantinova I, Sonnenfeld G, Jennings R. Changes in the immune system during and after spaceflight. Adv Space Biol Med 1997; 6:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/36\">",
"      Namazi MR. The cellular immunodeficiency associated with post-traumatic stress disorder may be the result of sympathetic overactivity and be correctable by beta-2-blockers. Neuro Endocrinol Lett 2003; 24:468.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/37\">",
"      Marrack P, Kappler J. Subversion of the immune system by pathogens. Cell 1994; 76:323.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/38\">",
"      Haase R, Kirschning CJ, Sing A, et al. A dominant role of Toll-like receptor 4 in the signaling of apoptosis in bacteria-faced macrophages. J Immunol 2003; 171:4294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/39\">",
"      Beckford AP, Kaschula RO, Stephen C. Factors associated with fatal cases of measles. A retrospective autopsy study. S Afr Med J 1985; 68:858.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/40\">",
"      Griffin DE. Measles virus-induced suppression of immune responses. Immunol Rev 2010; 236:176.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/41\">",
"      Rinaldo CR Jr. Immune suppression by herpesviruses. Annu Rev Med 1990; 41:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/42\">",
"      Koch S, Larbi A, Ozcelik D, et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann N Y Acad Sci 2007; 1114:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/43\">",
"      Langley R, Patel D, Jackson N, et al. Staphylococcal superantigen super-domains in immune evasion. Crit Rev Immunol 2010; 30:149.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/44\">",
"      Reiner NE. Altered cell signaling and mononuclear phagocyte deactivation during intracellular infection. Immunol Today 1994; 15:374.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/45\">",
"      Dessaint JP, Capron A. Immunodeficiencies in parasitic diseases. Immunodefic Rev 1989; 1:311.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/46\">",
"      Engelhorn S, Bruckner A, Remold HG. A soluble factor produced by inoculation of human monocytes with Leishmania donovani promastigotes suppresses IFN-gamma-dependent monocyte activation. J Immunol 1990; 145:2662.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/47\">",
"      Tarleton RL. Trypanosoma cruzi-induced suppression of IL-2 production. II. Evidence for a role for suppressor cells. J Immunol 1988; 140:2769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/48\">",
"      Abe T, Colley DG. Modulation of Schistosoma mansoni egg-induced granuloma formation. III. Evidence for an anti-idiotypic, I-J-positive, I-J-restricted, soluble T suppressor factor. J Immunol 1984; 132:2084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/49\">",
"      Sztein MB, Kierszenbaum F. A soluble factor from Trypanosoma brucei rhodesiense that prevents progression of activated human T lymphocytes through the cell cycle. Immunology 1991; 73:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/50\">",
"      Magrath I, Jain V, Bhatia K. Epstein-Barr virus and Burkitt's lymphoma. Semin Cancer Biol 1992; 3:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/51\">",
"      de Th&eacute; G. The etiology of Burkitt's lymphoma and the history of the shaken dogmas. Blood Cells 1993; 19:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/52\">",
"      Camus D, Nosseir A, Mazingue C, Capron A. Immunoregulation by Schistosoma mansoni. Immunopharmacology 1981; 3:193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/53\">",
"      Ottesen EA, Hiatt RA, Cheever AW, et al. The acquisition and loss of antigen-specific cellular immune responsiveness in acute and chronic schistosomiasis in man. Clin Exp Immunol 1978; 33:37.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/54\">",
"      Feldmeier H, Gastl GA, Poggensee U, et al. Relationship between intensity of infection and immunomodulation in human schistosomiasis. I. Lymphocyte subpopulations and specific antibody responses. Clin Exp Immunol 1985; 60:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7561/abstract/55\">",
"      Greenwood BM, Whittle HC, Molyneux DH. Immunosuppression in Gambian trypanosomiasis. Trans R Soc Trop Med Hyg 1973; 67:846.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3946 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-203.80.222.8-5CA963D2D9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7561=[""].join("\n");
var outline_f7_24_7561=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H32\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      DISORDERS OF BIOCHEMICAL HOMEOSTASIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Diabetes mellitus",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Dialysis and uremia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Cirrhosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Malnutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16802278\">",
"      DISORDERS OF PROTEIN LOSS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2625243\">",
"      Nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H184536898\">",
"      Peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H462979059\">",
"      Protein losing enteropathies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H2625885\">",
"      - Intestinal lymphangiectasia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H2625420\">",
"      Other disorders",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      TRAUMA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Burns",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      ENVIRONMENTAL EXPOSURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Ionizing radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Ultraviolet radiation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Toxic chemicals",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      ALLOGENEIC BLOOD TRANSFUSION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      NORMAL LIFE STAGES AND EVENTS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Aging",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      Pregnancy",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      Stress",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      INFECTIONS (OTHER THAN HIV)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Viral infections",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      - Measles",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      - Herpesviruses",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      Bacterial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      Mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Parasite infestation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      - Malaria",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      - Other parasites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ALLRG/3946\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ALLRG/3946|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?37/20/38220\" title=\"table 1\">",
"      Conditions assoc second imm def",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?26/48/27403\" title=\"table 2\">",
"      Immune defects and trauma",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/61/24541\" title=\"table 3\">",
"      Chemicals immune dysfunction",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/54/29542?source=related_link\">",
"      Acquired disorders of the complement system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/17/26902?source=related_link\">",
"      Clinical consequences of hemodialysis membrane biocompatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/55/14202?source=related_link\">",
"      Clinical manifestations and treatment of Epstein-Barr virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/23/25974?source=related_link\">",
"      Complications of idiopathic nephrotic syndrome in children",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/36/13895?source=related_link\">",
"      Epidemiology, pathogenesis, and prevention of African trypanosomiasis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/27/41401?source=related_link\">",
"      Hypoplastic left heart syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/52/15178?source=related_link\">",
"      Immune function in older adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/5/24665?source=related_link\">",
"      Leukoreduction to prevent complications of blood transfusion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/18/32041?source=related_link\">",
"      Overview of heavy proteinuria and the nephrotic syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/25/34197?source=related_link\">",
"      Pathogenesis of spontaneous bacterial peritonitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/40/26248?source=related_link\">",
"      Pathophysiology and prevention of peritonitis in peritoneal dialysis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/50/3881?source=related_link\">",
"      Protein-losing gastroenteropathy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/0/29706?source=related_link\">",
"      Secondary immune deficiency induced by drugs and biologics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_24_7562="First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects";
var content_f7_24_7562=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   First-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7562/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7562/contributors\">",
"     Michael D Jibson, MD, PhD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7562/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7562/contributors\">",
"     Stephen Marder, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?7/24/7562/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?7/24/7562/contributors\">",
"     Richard Hermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?7/24/7562/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jun 3, 2011.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H272233773\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Antipsychotic medications were introduced more than 50 years ago. They have efficacy in the treatment of acute psychosis (regardless of cause), chronic psychotic disorders, and other psychiatric conditions. Drugs in this class have comparable efficacy in the treatment of psychosis.",
"   </p>",
"   <p>",
"    First-generation antipsychotic medications (FGAs), also known as neuroleptics or conventional antipsychotics, cause high rates of extrapyramidal side effects (EPS), including rigidity, bradykinesia, tremor, and akathisia (restlessness). They also frequently lead to tardive dyskinesia&mdash;hyperkinetic, involuntary movements most readily observed in the face and extremities.",
"   </p>",
"   <p>",
"    The pharmacology,",
"    <strong>",
"    </strong>",
"    administration, and comparative side effects of first-generation antipsychotics available in the US are discussed here. Second-generation antipsychotics and antipsychotics in the treatment of schizophrenia and bipolar disorder are discussed separately, as are antipsychotic poisoning, tardive dyskinesia, and neuroleptic malignant syndrome (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=see_link\">",
"     \"Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=see_link\">",
"     \"First generation (Typical) antipsychotic medication poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43320?source=see_link\">",
"     \"Second generation (atypical) antipsychotic medication poisoning\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=see_link\">",
"     \"Tardive dyskinesia: Etiology and epidemiology\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233780\">",
"    <span class=\"h1\">",
"     PHARMACOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-generation antipsychotics (FGAs) are characterized by strong antagonism of dopamine D2 receptors in both cortical and striatal areas [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/1\">",
"     1",
"    </a>",
"    ]. Their dopamine D2 binding is highly correlated with clinical potency [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/2\">",
"     2",
"    </a>",
"    ]. The nonspecific localization of their dopamine binding is consistent with their risk of movement disorders and prolactinemia. While FGAs share potent dopamine D2 blockade, each agent has distinct effects on other neuronal receptors (5-HT2a, alpha-1, histaminic and muscarinic) which generally correspond with their variable side-effects profiles. Side effects of the FGAs are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18716722\">",
"    <span class=\"h1\">",
"     PHARMACOKINETICS",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-generation antipsychotics (FGAs) are lipophilic, highly protein and tissue-bound compounds with large volumes of distribution (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). Most have prolonged half-lives (20 to 40 hours) that permit once or twice daily dose administration after the dose has been stabilized. All FGAs are subject to extensive metabolism via cytochrome P450 (CYP) -2D6, -3A4, -1A2",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    other enzymes, and several have active metabolites. The FGAs can interact with other drugs that have potent effects on CYP metabolism. The CYP-2D6 gene is polymorphic and altered serum concentrations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    as well as more prominent side effects such as oversedation, have been described among CYP-2D6 slow metabolizers [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Their oral absorption tends to be somewhat erratic and several of the FGAs undergo extensive first-pass metabolism by the liver, yielding low or variable oral bioavailability. Pharmacokinetics and selected drug interactions of the FGAs are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Therapeutic blood levels have not been established for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , the most widely studied of these drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. Positron emission tomography (PET) studies have found a 65 percent occupancy of dopamine D2 receptors to be correlated with antipsychotic activity, and about 80 percent occupancy with onset of EPS [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/7\">",
"     7",
"    </a>",
"    ] has given rise to the possibility that PET scanning may prove useful in establishing and monitoring drug levels. However, more research is needed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233787\">",
"    <span class=\"h1\">",
"     INDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initially shown to provide efficacious treatment for schizophrenia, antipsychotic medications are effective in reducing acute and chronic psychosis regardless of cause, and have shown efficacy for other psychiatric disorders. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=see_link\">",
"     \"Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=see_link\">",
"     \"Treatment of behavioral symptoms related to dementia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=see_link\">",
"     \"Treatment of postpartum psychosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=see_link\">",
"     \"Prevention and treatment of delirium and confusional states\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233794\">",
"    <span class=\"h1\">",
"     SIDE EFFECTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Common side effects associated with first-generation antipsychotic antipsychotics (FGAs) include extrapyramidal symptoms (EPS), tardive dyskinesia, hyperprolactinemia, neuroleptic malignant syndrome, QT prolongation, sudden death, and an increased risk of mortality when used to treat psychiatric symptoms associated with dementia in elderly patients (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). These side effects and their management are described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=see_link\">",
"     \"Pharmacotherapy for schizophrenia: Side effect management\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=see_link\">",
"     \"Tardive dyskinesia: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=see_link\">",
"     \"Causes of hyperprolactinemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=see_link\">",
"     \"Neuroleptic malignant syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Tardive dyskinesia has been reported with all FGAs at a cumulative rate of 5 percent per year, with higher risk in the older population [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. The severity and rate of EPS, hyperprolactinemia, and QT prolongation vary across individual FGAs. QT prolongation and sudden cardiac death are especially noteworthy with the low-potency FGAs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    , and mesoridazine), with IV administration of high potency drugs in the medically ill, and in the presence of other drugs that prolong QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/11-16\">",
"     11-16",
"    </a>",
"    ]. In these cases ECG, potassium, and magnesium should be assessed at baseline, and ECG should be monitored after dose changes, periodically during maintenance therapy, during acute intravenous (IV) drug administration, and for two to three hours after IV dosing. Caution should be exercised with a baseline QT greater than 440 msec and the drug should be discontinued if the QT increases by more than 25 percent during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/12\">",
"     12",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H272233815\">",
"     'Individual medications'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233801\">",
"    <span class=\"h1\">",
"     COST",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-generation antipsychotics (FGAs) have marked cost advantages over second-generation drugs. Generic formulations of FGAs are typically priced 10 to 20 times below the newer agents (",
"    <a class=\"graphic graphic_table graphicRef51828 \" href=\"UTD.htm?23/6/23662\">",
"     table 3",
"    </a>",
"    ). Due to the disease burden of conditions treated with antipsychotics and the greater affordability of FGAs (particularly for developing nations with limited resources for health care) the World Health Organization classifies three of these drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    ) on its list of essential medicines [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/17\">",
"     17",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The relative cost-effectiveness of first- versus second-generation drugs has not been adequately studied [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/18\">",
"     18",
"    </a>",
"    ]. In one randomized, 18-month trial of 1500 patients with schizophrenia,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    , a first-generation agent, was found to have greater cost-effectiveness, measured in quality-adjusted life years, when compared to four second-generation antipsychotics (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/56/20361?source=see_link\">",
"     quetiapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/39/4728?source=see_link\">",
"     ziprasidone",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/19\">",
"     19",
"    </a>",
"    ]. Weaknesses of this study included its limited duration and exclusion of patients with tardive dyskinesia from analyses involving perphenazine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233808\">",
"    <span class=\"h1\">",
"     FORMULATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most first-generation antipsychotic medications are available in oral formulations. Several are also available in injectable, intramuscular formulations, which are useful in the treatment of psychotic agitation (",
"    <a class=\"graphic graphic_table graphicRef60846 \" href=\"UTD.htm?32/7/32893\">",
"     table 4",
"    </a>",
"    ). Intravenous formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    are sometimes used to treat acute psychosis, agitation, or delirium in medical settings; intravenous medications are generally not used on psychiatric units. Available formulations of the FGAs are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Long-acting decanoate formulations of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    can be administered via intramuscular injection one to two times per month, which can be useful for patients who are nonadherent with daily oral dosing (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233815\">",
"    <span class=\"h1\">",
"     INDIVIDUAL MEDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;First-generation antipsychotics (FGAs) differ in potency, pharmacokinetics, routes of administration, and side effects. Medication-specific characteristics are described below.",
"   </p>",
"   <p>",
"    These medications have traditionally been classified by their chemical structure (eg, phenothiazines, butyrophenones, thioxanthenes). However, differences among these chemical classes have not been shown to have clinical consequences, eg, in terms of drug efficacy, side effects, or types of patients responding. Therefore, we use the more clinically relevant classification of high- and low-potency agents.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233822\">",
"    <span class=\"h2\">",
"     High-potency antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;High-potency FGAs, dosed in one to tens of milligrams, are minimally sedating and only slightly anticholinergic (less than low-potency agents in both respects) but carry a low to moderate risk of weight gain and a higher risk of extrapyramidal symptoms (EPS) than low-potency antipsychotics. Specifically, a recent review found that 21 to 31 percent of patients experienced drug-induced EPS in three to eight week studies of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , compared with 0 to 18 percent of patients receiving second-generation drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/21\">",
"     21",
"    </a>",
"    ]. Average weight gain in long-term studies is 8 to 21 pounds, comparable to that seen with the atypical drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    , but less weight gain than that seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/21-23\">",
"     21-23",
"    </a>",
"    ]. All drugs within this group have comparable efficacy and side effect profiles. As a representative of this class, haloperidol has been most extensively studied and remains widely used.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233829\">",
"    <span class=\"h3\">",
"     Haloperidol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is a butyrophenone, available in tablets, liquid concentrate, short-acting injectable formulations for intramuscular and intravenous use, and a long-acting intramuscular form for depot injection (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is readily absorbed orally, but extensive first-pass hepatic metabolism reduces its bioavailability to 60 percent. The drug is cleared by cytochrome P450 isoenzymes CYP3A4 and CYP2D6, and glucuronidation, with a half life of about 20 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/24\">",
"     24",
"    </a>",
"    ]. The clinical significance of haloperidol metabolites remains unclear, though some regard the pyridinium metabolite to be potentially neurotoxic [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/25\">",
"     25",
"    </a>",
"    ]. Haloperidol can interact with potent inhibitors or inducers of CYP3A4 and 2D6, giving elevated serum levels with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/50/15146?source=see_link\">",
"     paroxetine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and decreased levels with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . In most instances, these interactions can be adequately addressed with dose adjustments. Clinically significant interactions can occur with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/13/216?source=see_link\">",
"     metoclopramide",
"    </a>",
"    , and drugs that also prolong the QTc interval or lower the seizure threshold. Selected drug interactions and kinetics are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The recommended dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    has decreased steadily over the past 20 years (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). Most recent guidelines recommend a maximum daily dose of 20 to 30 milligrams [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/26-28\">",
"     26-28",
"    </a>",
"    ]. Analysis of two large randomized trials comparing different dosing levels of oral haloperidol, concluded that the optimal daily dose was between 10 and 20 milligrams per day [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/29\">",
"     29",
"    </a>",
"    ]. It is increasingly common for patients to receive daily doses less than 10 mg.",
"   </p>",
"   <p>",
"    Intramuscular injection of antipsychotics is used, particularly on inpatient psychiatric units, to treat agitation associated with psychosis (",
"    <a class=\"graphic graphic_table graphicRef60846 \" href=\"UTD.htm?32/7/32893\">",
"     table 4",
"    </a>",
"    ). The usual intramuscular dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    for short-term treatment of acute agitation is 2 to 10 mg, as often as every 30 minutes. Intramuscular administration results in a peak serum concentration after 20 minutes.",
"   </p>",
"   <p>",
"    Intravenous (IV)",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    is commonly used in intensive care units to treat agitation associated with delirium in the US and other countries. This route of administration has not been approved by the United States (US) Food and Drug Administration (FDA). As in the case of oral dosing, IV doses of haloperidol in excess of 100",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    for schizophrenia have been reported, but there is little evidence that doses higher than 20 to 30",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are beneficial, and the risk of cardiac conduction abnormalities increases above 35",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/11\">",
"     11",
"    </a>",
"    ]. Although oral and intramuscular dosing of haloperidol have been associated with minimal change in QT interval, intravenous (IV) haloperidol has an elevated risk of prolonged QTc interval and torsades de pointes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/11,12,16\">",
"     11,12,16",
"    </a>",
"    ]. Continuous cardiac monitoring is recommended during acute IV drug administration and for two to three hours thereafter [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/16,30\">",
"     16,30",
"    </a>",
"    ] and IV dosing should be avoided in patients with pre-existing QT prolongation, other cardiac abnormalities, electrolyte imbalance, or who are taking other drugs known to increase QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/12,30\">",
"     12,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=see_link&amp;anchor=H11#H11\">",
"     \"Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects\", section on 'Neuroleptics'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     Haloperidol",
"    </a>",
"    is available as a decanoate preparation for depot administration, which is cleared with a half life of about 21 days (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ). The usual dose of haloperidol decanoate is 50 to 200 mg intramuscularly every two to four weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/31\">",
"     31",
"    </a>",
"    ]. The depot formulation is used in maintenance treatment, particularly when adherence to daily oral administration is poor. Although atypical agents are also available for depot injection, the lower cost of the conventional depot drugs makes their use common. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=see_link&amp;anchor=H16350534#H16350534\">",
"     \"Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment\", section on 'Maintenance treatment'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although generally considered to be metabolically more benign than newer drugs,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    &rsquo;s major advantage is primarily over",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/22,23\">",
"     22,23",
"    </a>",
"    ], with only a slight difference in risk compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/23\">",
"     23",
"    </a>",
"    ]. Even so, haloperidol has long been associated with a moderate risk of weight gain [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/32\">",
"     32",
"    </a>",
"    ] and diabetes [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/33\">",
"     33",
"    </a>",
"    ]. As such, in this regard, it should not be considered a safer alternative to atypical medications (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233836\">",
"    <span class=\"h3\">",
"     Droperidol",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     Droperidol",
"    </a>",
"    is chemically and pharmacologically similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    . However, it is only available as a sterile solution for parenteral administration. Approved for use in the US for treatment of nausea, it is commonly used in many countries to address acute psychotic agitation or delirium in medical settings (",
"    <a class=\"graphic graphic_table graphicRef60846 \" href=\"UTD.htm?32/7/32893\">",
"     table 4",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H272233829\">",
"     'Haloperidol'",
"    </a>",
"    above.) As with haloperidol, intravenous administration carries a dose-dependent risk of QT prolongation and torsades de pointes and patients who are medically ill, elderly, or receiving other agents that prolong QT interval should be monitored before and for two to three hours after drug administration [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/12,15\">",
"     12,15",
"    </a>",
"    ]. Additional side effects include hypotension, alpha blockade, and acute dystonia.",
"   </p>",
"   <p>",
"    Some emergency room physicians and anesthesiologists prefer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"     droperidol",
"    </a>",
"    to other antipsychotics for treatment of agitation because of its rapid onset of action and relatively short clearance half life of 127 minutes, which shows little change in the presence of other drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/36,37\">",
"     36,37",
"    </a>",
"    ]. Doses of 0.625 to 2.5 mg are generally used for post-operative nausea and vomiting. When used for agitation, droperidol is typically administered intravenously in single doses of 2.5 to 5 mg.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233843\">",
"    <span class=\"h3\">",
"     Fluphenazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     Fluphenazine",
"    </a>",
"    is chemically classified as a phenothiazine piperazine compound. It is clinically comparable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    in most regards, with similar efficacy, potency, routes of administration, dosing, and side effects (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H272233829\">",
"     'Haloperidol'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The serum clearance half life of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    has been reported as 15 to 33 hours [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/38,39\">",
"     38,39",
"    </a>",
"    ]. Its metabolism is primarily hepatic via the cytochrome P450 isoenzyme CYP2D6. Selected drug interactions are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Oral dosing of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    typically ranges from 2 to 15 mg per day.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     Fluphenazine",
"    </a>",
"    is available in two depot formulations, fluphenazine decanoate and fluphenazine enanthate; only the former is approved for use in the US (",
"    <a class=\"graphic graphic_table graphicRef59201 \" href=\"UTD.htm?9/36/9806\">",
"     table 5",
"    </a>",
"    ). Fluphenazine decanoate has a serum clearance time of 7 to 10 days, and is typically used at doses of 12.5 to 50 mg every one to two weeks. The enanthate preparation has a clearance half life of three to four days and is typically dosed at 12.5 to 25 mg every one to two weeks. The shorter serum clearance time of fluphenazine decanoate and enanthate may make them somewhat less advantageous than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    decanoate.",
"   </p>",
"   <p>",
"    A short acting",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"     fluphenazine",
"    </a>",
"    hydrochloride IM injection is also available in the US for acute agitation (",
"    <a class=\"graphic graphic_table graphicRef60846 \" href=\"UTD.htm?32/7/32893\">",
"     table 4",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233850\">",
"    <span class=\"h3\">",
"     Loxapine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The dibenzoxazepine medication",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/2/27687?source=see_link\">",
"     loxapine",
"    </a>",
"    has somewhat lower potency than other medications of this class, and is sometimes considered separately as a mid-potency drug.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/2/27687?source=see_link\">",
"     Loxapine",
"    </a>",
"    is more readily absorbed from the GI tract than from muscle and reaches peak serum concentration one hour after an oral dose, but five hours after intramuscular injection. The presence of at least two active metabolites give it more complex pharmacokinetics than other antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/40\">",
"     40",
"    </a>",
"    ], and the overall clearance of the clinically relevant compounds occurs with a half life of 4 to 12 hours. The drug is primarily metabolized via glucuronidation. Selected drug interactions and kinetics are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/2/27687?source=see_link\">",
"     Loxapine",
"    </a>",
"    is available in oral capsules. A sterile solution is available for intramuscular injection in some countries but not in the US. Because of its lower potency, loxapine requires doses of 20 to 80",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    divided into at least two daily doses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/41,42\">",
"     41,42",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/2/27687?source=see_link\">",
"     Loxapine",
"    </a>",
"    's efficacy and side effects are similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/43,44\">",
"     43,44",
"    </a>",
"    ], with the possible exception of weight gain. In one retrospective study, weight gain with loxapine was found to be less than with other medications of this class (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/45\">",
"     45",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H272233829\">",
"     'Haloperidol'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233864\">",
"    <span class=\"h3\">",
"     Perphenazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     Perphenazine",
"    </a>",
"    is a piperazinyl phenothiazine with slightly lower potency than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , sometimes classified along with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/2/27687?source=see_link\">",
"     loxapine",
"    </a>",
"    as a mid-potency drug.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     Perphenazine",
"    </a>",
"    is readily absorbed from the GI tract with a one to three-hour time to peak concentration, followed by a nine-hour clearance half life. An active metabolite, 7-hydroxyperphenazine, requires up to 19 hours for clearance. The drug is oxidized by the cytochrome P450 isozyme CYP2D6, but may also be metabolized through dealkylation, hydroxylation, glucuronidation and sulfoxidation.",
"    <strong>",
"    </strong>",
"    This broad range of metabolic pathways makes the drug relatively free of drug-induced increases in serum levels. Levels may be decreased by the CYP2D6 inducer",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    , however, and interactions with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/11/23736?source=see_link\">",
"     lithium",
"    </a>",
"    have been reported.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     Perphenazine",
"    </a>",
"    is usually administered twice daily at doses totaling 16 to 32",
"    <span class=\"nowrap\">",
"     mg/day;",
"    </span>",
"    doses higher than 64",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    are not recommended. Perphenazine is available only in an oral formulation. It is also sold in the form of a combination tablet containing both perphenazine and the tricyclic antidepressant",
"    <a class=\"drug drug_general\" href=\"UTD.htm?26/30/27112?source=see_link\">",
"     amitriptyline",
"    </a>",
"    for treatment of depression with psychotic features.",
"   </p>",
"   <p>",
"    A recent review of schizophrenia treatments found",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    to be associated with a lower rate of EPS compared to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , and comparable to the second-generation antipsychotic",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"     risperidone",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Side effects of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). Selected drug interactions and kinetics are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233871\">",
"    <span class=\"h3\">",
"     Pimozide",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     Pimozide",
"    </a>",
"    is a diphenylbutylpiperidine compound originally marketed for Tourette's disorder and later used for psychosis. Its early use in a positive study of delusional parasitosis gave it an unwarranted reputation as uniquely effective for that disorder [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/47\">",
"     47",
"    </a>",
"    ]. Studies of several antipsychotics for the disorder do not find evidence that any demonstrate superior efficacy in comparison to the others [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/48\">",
"     48",
"    </a>",
"    ]. Similarly, initial reports of preferential effectiveness for tic disorders [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/48\">",
"     48",
"    </a>",
"    ] were not substantiated in subsequent studies [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/49\">",
"     49",
"    </a>",
"    ]. Because of its adverse cardiac effects, it is not a first-line agent for any condition",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     Pimozide",
"    </a>",
"    is available only in an oral formulation. The drug undergoes extensive first-pass hepatic metabolism, giving it a somewhat more variable bioavailability than other drugs. It is metabolized primarily via CYP3A4, with lesser contributions from CYP2D6 and CYP1A2. It has a relatively long elimination half life of about 55 hours. Selected drug interactions and kinetics are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    The usual dose range is 8 to 16 mg daily; doses higher than 20 mg daily are not recommended.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"     Pimozide",
"    </a>",
"    prolongs the QT interval [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/50\">",
"     50",
"    </a>",
"    ], which has been associated with cardiac death in the presence of metabolic inhibitors of CYP3A4, specifically",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/57/10138?source=see_link\">",
"     clarithromycin",
"    </a>",
"    , and in theory other macrolide antibiotics, antifungals such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     ketoconazole",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/51\">",
"     51",
"    </a>",
"    ]. It should be avoided in patients with prolonged QT interval, history of cardiac arrhythmia, or who are taking other drugs that may increase QT interval [69]. Cardiac monitoring is recommended at initiation of treatment, after dose adjustments, and periodically thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233878\">",
"    <span class=\"h3\">",
"     Trifluoperazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The phenothiazine piperazine drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"     trifluoperazine",
"    </a>",
"    is efficacious in the treatment of schizophrenia, agitation, and nausea [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/52\">",
"     52",
"    </a>",
"    ]. It is somewhat less potent than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    , but similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"     perphenazine",
"    </a>",
"    in dosing. Its side effects are comparable to haloperidol and other drugs of this class (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/53\">",
"     53",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H272233829\">",
"     'Haloperidol'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"     Trifluoperazine",
"    </a>",
"    is available only in oral tablets. Typical doses for treatment of psychosis are 15 to 30",
"    <span class=\"nowrap\">",
"     mg/day,",
"    </span>",
"    usually in two divided doses, with a maximum recommended dose of 40 mg daily. Doses of 1 to 6 mg daily are recommended for nausea. The drug is metabolized by the liver with a clearance half life of 22 hours. Selected drug interactions and kinetics are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233885\">",
"    <span class=\"h3\">",
"     Thiothixene",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"     Thiothixene",
"    </a>",
"    is available only in oral tablets. The drug is absorbed rapidly through the GI tract, reaching peak serum levels one to three hours after ingestion [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. It undergoes hepatic metabolism, primarily via the cytochrome P450 isozyme CYP1A2, and is cleared with a half life of 33 hours. Selected drug interactions are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Its efficacy, potency, dosing, and side effects are indistinguishable from those of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ). (See",
"    <a class=\"local\" href=\"#H272233829\">",
"     'Haloperidol'",
"    </a>",
"    above.) &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233892\">",
"    <span class=\"h2\">",
"     Low-potency antipsychotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Low potency FGAs, dosed in hundreds of milligrams, tend to be highly sedating, have strong anticholinergic properties, cause significant weight gain, induce hypotension, and carry a moderate risk of EPS. Weight gain associated with these drugs is greater than that caused by the high potency first-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/56\">",
"     56",
"    </a>",
"    ] and is comparable to what is seen with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/31\">",
"     31",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/57\">",
"     57",
"    </a>",
"    ]. Hyperlipidemia risk is likewise similar to that of clozapine or olanzapine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/58\">",
"     58",
"    </a>",
"    ]. EPS risk is about half as great as with high potency drugs, and overlaps that seen with higher doses of some second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/21,59\">",
"     21,59",
"    </a>",
"    ]. One large review found no difference in EPS risk in those groups, although none of the studies involved direct comparisons [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/60\">",
"     60",
"    </a>",
"    ]. Two of these drugs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    and mesoridazine) are now recognized as having clinically significant cardiac conduction abnormalities, and are associated with arrhythmia and sudden cardiac death.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233906\">",
"    <span class=\"h3\">",
"     Chlorpromazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;The earliest and most commonly used member of this drug class is the phenothiazine drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    .",
"   </p>",
"   <p>",
"    Due to its side effects,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    has largely been supplanted by other antipsychotics in adult psychiatry and by newer antiemetics, which have better efficacy and fewer side effects (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/61\">",
"     61",
"    </a>",
"    ]. It continues to be used in pediatric anesthesia, and in child psychiatry, largely because of clinicians' extensive experience with the drug in children.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    is somewhat unpredictable in the rate of its absorption from the GI tract, and times to peak concentration of two to four hours have been observed. It is metabolized via the cytochrome P450 isozymes CYP2D6 and 1A2 with a clearance half life of about 30 hours. Serum levels of chlorpromazine may be elevated by inhibitors of CYP2D6 and 1A2, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/45/35536?source=see_link\">",
"     ciprofloxacin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/18/9514?source=see_link\">",
"     verapamil",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    , and are decreased by CYP2D6 inducers such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/10/25770?source=see_link\">",
"     carbamazepine",
"    </a>",
"    . In most instances, these interactions can be addressed by adjustment of medication dose to maintain clinical efficacy or avoid additional side effects. Selected drug interactions and kinetics are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    is available in tablets and sterile solution for intramuscular or intravenous injection. The usual dose range for schizophrenia or bipolar mania in adults is 400 to 600 mg daily, either as single or divided doses. Single injectable doses for acute agitation are usually 50 to 200 mg.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     Chlorpromazine",
"    </a>",
"    causes significant weight gain, more than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"     haloperidol",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/56\">",
"     56",
"    </a>",
"    ], and comparable to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?34/21/35161?source=see_link\">",
"     clozapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/31\">",
"     31",
"    </a>",
"    ] and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?36/36/37449?source=see_link\">",
"     olanzapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/57\">",
"     57",
"    </a>",
"    ]. Hyperlipidemia similarly occurs at levels similar to those seen with clozapine or olanzapine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/58\">",
"     58",
"    </a>",
"    ]. Hypotension is common with chlorpromazine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/62\">",
"     62",
"    </a>",
"    ], occurring in clinical trials more often than with olanzapine [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/57\">",
"     57",
"    </a>",
"    ] or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/2/27687?source=see_link\">",
"     loxapine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/63\">",
"     63",
"    </a>",
"    ], and is particularly common when the drug is given parenterally [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/64\">",
"     64",
"    </a>",
"    ]. Cholestatic jaundice has been reported in 1 to 2 percent of patients on the drug [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/65\">",
"     65",
"    </a>",
"    ], usually occurring in the first month of treatment (",
"    <a class=\"graphic graphic_table graphicRef82533 \" href=\"UTD.htm?32/57/33694\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233913\">",
"    <span class=\"h3\">",
"     Thioridazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     Thioridazine",
"    </a>",
"    is a piperidine phenothiazine compound similar in its dosing to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/66\">",
"     66",
"    </a>",
"    ]. Thioridazine is an effective treatment for schizophrenia [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/14\">",
"     14",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H272233906\">",
"     'Chlorpromazine'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    The risks of QT prolongation and lethal torsade de pointes are greater with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    than with high potency first- or second-generation antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/67,68\">",
"     67,68",
"    </a>",
"    ]. As a result, the FDA has issued a \"black box\" warning in the US, recommending use of thioridazine be reserved for patients who have failed adequate courses of other antipsychotics. Expert guidelines concur that thioridazine not be used as a first-line treatment for psychosis, and encourage ongoing cardiac monitoring during its use [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/14,15\">",
"     14,15",
"    </a>",
"    ]. Specifically, ECG and serum potassium should be checked prior to the first dose. ECG should be checked at least annually thereafter, including during dose adjustments and in response to any changes in the patient&rsquo;s cardiac condition. The drug should be discontinued if the QT interval exceeds 450 msec. Inhibitors of CYP2D6 such as",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/49/15130?source=see_link\">",
"     fluoxetine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?25/29/26073?source=see_link\">",
"     bupropion",
"    </a>",
"    should be avoided, as should drugs that prolong QT interval. Sales of the drug have been terminated in some countries. Selected drug interactions and kinetics are listed in the table (",
"    <a class=\"graphic graphic_table graphicRef60624 \" href=\"UTD.htm?30/58/31663\">",
"     table 2",
"    </a>",
"    ). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=see_link\">",
"     \"Acquired long QT syndrome\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    A side effect unique to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    among the antipsychotics is the risk of retinitis pigmentosa at higher doses [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/69,70\">",
"     69,70",
"    </a>",
"    ]. This finding has limited use of the medication to a maximum of 800",
"    <span class=\"nowrap\">",
"     mg/day.",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=see_link\">",
"     \"Retinitis pigmentosa: Clinical presentation and diagnosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233920\">",
"    <span class=\"h3\">",
"     Mesoridazine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mesoridazine is a piperidine phenothiazine similar to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"     chlorpromazine",
"    </a>",
"    in dosing and side effects. Mesoridazine, like",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"     thioridazine",
"    </a>",
"    , has a propensity to prolong QT interval beyond levels seen with other antipsychotics [",
"    <a class=\"abstract\" href=\"UTD.htm?7/24/7562/abstract/7\">",
"     7",
"    </a>",
"    ]. Mesoridazine is not available in US or Canada.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H272233927\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      First-generation antipsychotic drugs, also known as typical or conventional antipsychotics or neuroleptics, are efficacious in the treatment of acute psychosis, chronic psychotic conditions, and other psychiatric disorders. Drugs in this class have comparable efficacy in the treatment of psychosis. (See",
"      <a class=\"local\" href=\"#H272233787\">",
"       'Indications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Extrapyramidal side effects (EPS), including rigidity, bradykinesia, tremor, and akathisia (restlessness), are commonly seen in first-generation antipsychotics. These drugs frequently lead to tardive dyskinesia&mdash;hyperkinetic, involuntary movements most readily observed in the face and extremities. (See",
"      <a class=\"local\" href=\"#H272233794\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Compared with other first-generation agents, greater rates of QT prolongation and cardiac arrhythmia are seen with intravenous",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      and oral forms of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"       thioridazine",
"      </a>",
"      , mesoridazine, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"       pimozide",
"      </a>",
"      ; cardiac monitoring is recommended with these agents. (See",
"      <a class=\"local\" href=\"#H272233829\">",
"       'Haloperidol'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H272233913\">",
"       'Thioridazine'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H272233920\">",
"       'Mesoridazine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      First-generation antipsychotics have marked cost advantages over second-generation drugs (",
"      <a class=\"graphic graphic_table graphicRef51828 \" href=\"UTD.htm?23/6/23662\">",
"       table 3",
"      </a>",
"      ). Generic formulations of the first-generation agents are typically priced 10 to 20 times lower than the newer antipsychotics. The cost of generic",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/33/11802?source=see_link\">",
"       risperidone",
"      </a>",
"      is closer to that of first-generation agents. (See",
"      <a class=\"local\" href=\"#H272233801\">",
"       'Cost'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      High-potency first-generation antipsychotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/50/32553?source=see_link\">",
"       haloperidol",
"      </a>",
"      are dosed in the one to tens milligram range, are minimally sedating and anticholinergic, but have a higher risk of EPS than low-potency antipsychotics. Other high-potency agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/19/9527?source=see_link\">",
"       droperidol",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/10/38055?source=see_link\">",
"       fluphenazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?27/2/27687?source=see_link\">",
"       loxapine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/49/19223?source=see_link\">",
"       perphenazine",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6472?source=see_link\">",
"       pimozide",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/2/19495?source=see_link\">",
"       trifluoperazine",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?40/35/41526?source=see_link\">",
"       thiothixene",
"      </a>",
"      . (See",
"      <a class=\"local\" href=\"#H272233822\">",
"       'High-potency antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low-potency antipsychotics such as",
"      <a class=\"drug drug_general\" href=\"UTD.htm?29/38/30312?source=see_link\">",
"       chlorpromazine",
"      </a>",
"      are dosed in the hundreds of milligrams, and are more sedating and anticholinergic than high potency first-generation drugs, but have a lower risk of EPS. Other low-potency agents include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?31/35/32311?source=see_link\">",
"       thioridazine",
"      </a>",
"      and mesoridazine. (See",
"      <a class=\"local\" href=\"#H272233892\">",
"       'Low-potency antipsychotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Low potency antipsychotics carry a higher risk of weight gain and metabolic disturbances. The risk is less prominent with the high potency drugs. (See",
"      <a class=\"local\" href=\"#H272233794\">",
"       'Side effects'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/1\">",
"      Stone JM, Davis JM, Leucht S, Pilowsky LS. Cortical dopamine D2/D3 receptors are a common site of action for antipsychotic drugs--an original patient data meta-analysis of the SPECT and PET in vivo receptor imaging literature. Schizophr Bull 2009; 35:789.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/2\">",
"      Seeman P. Atypical antipsychotics: mechanism of action. Can J Psychiatry 2002; 47:27.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/3\">",
"      Dahl ML. Cytochrome p450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing? Clin Pharmacokinet 2002; 41:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/4\">",
"      Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet 2009; 48:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/5\">",
"      Odou P, Vaiva G, Luyckx M, et al. Neuroleptic monitoring: relation between antipsychotic efficiency and radioreceptor assay of serum haloperidol. Eur J Clin Pharmacol 1996; 50:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/6\">",
"      Ulrich S, Neuhof S, Braun V, Meyer FP. Therapeutic window of serum haloperidol concentration in acute schizophrenia and schizoaffective disorder. Pharmacopsychiatry 1998; 31:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/7\">",
"      Salih IS, Thanacoody RH, McKay GA, Thomas SH. Comparison of the effects of thioridazine and mesoridazine on the QT interval in healthy adults after single oral doses. Clin Pharmacol Ther 2007; 82:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/8\">",
"      Morgenstern H, Glazer WM. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch Gen Psychiatry 1993; 50:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/9\">",
"      Glazer WM, Morgenstern H, Doucette JT. Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J Clin Psychiatry 1993; 54:133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/10\">",
"      Tarsy D, Baldessarini RJ. Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov Disord 2006; 21:589.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/11\">",
"      Sharma ND, Rosman HS, Padhi ID, Tisdale JE. Torsades de Pointes associated with intravenous haloperidol in critically ill patients. Am J Cardiol 1998; 81:238.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/12\">",
"      Lawrence KR, Nasraway SA. Conduction disturbances associated with administration of butyrophenone antipsychotics in the critically ill: a review of the literature. Pharmacotherapy 1997; 17:531.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/13\">",
"      Ray WA, Chung CP, Murray KT, et al. Atypical antipsychotic drugs and the risk of sudden cardiac death. N Engl J Med 2009; 360:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/14\">",
"      Fenton M, Rathbone J, Reilly J, Sultana A. Thioridazine for schizophrenia. Cochrane Database Syst Rev 2007; :CD001944.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/15\">",
"      Marder SR, Essock SM, Miller AL, et al. Physical health monitoring of patients with schizophrenia. Am J Psychiatry 2004; 161:1334.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/16\">",
"      Riker RR, Fraser GL, Cox PM. Continuous infusion of haloperidol controls agitation in critically ill patients. Crit Care Med 1994; 22:433.",
"     </a>",
"    </li>",
"    <li>",
"     Most first-generation antipsychotic medications are available in oral RH: form?. (Accessed on May 06, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/18\">",
"      Polsky D, Doshi JA, Bauer MS, Glick HA. Clinical trial-based cost-effectiveness analyses of antipsychotic use. Am J Psychiatry 2006; 163:2047.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/19\">",
"      Rosenheck RA, Leslie DL, Sindelar J, et al. Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am J Psychiatry 2006; 163:2080.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/20\">",
"      Lieberman JA, Stroup TS, McEvoy JP, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/21\">",
"      Gao K, Kemp DE, Ganocy SJ, et al. Antipsychotic-induced extrapyramidal side effects in bipolar disorder and schizophrenia: a systematic review. J Clin Psychopharmacol 2008; 28:203.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/22\">",
"      Vidarsdottir S, de Leeuw van Weenen JE, Fr&ouml;lich M, et al. Effects of olanzapine and haloperidol on the metabolic status of healthy men. J Clin Endocrinol Metab 2010; 95:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/23\">",
"      Saddichha, S, Manjunatha, N, Ameen, S, et al. Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study. Schizophrenia Res 2008; 101:266.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/24\">",
"      Kudo S, Ishizaki T. Pharmacokinetics of haloperidol: an update. Clin Pharmacokinet 1999; 37:435.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/25\">",
"      Eyles DW, McLennan HR, Jones A, et al. Quantitative analysis of two pyridinium metabolites of haloperidol in patients with schizophrenia. Clin Pharmacol Ther 1994; 56:512.",
"     </a>",
"    </li>",
"    <li>",
"     Fuller, MA, Sajatovic, M.  Psychotropic Drug Information Handbook, 6th ed. Lexi-Comp, Fuller, Ohio, 2005.",
"    </li>",
"    <li>",
"     Labbate FA, Rosenbaum JF, Fava M, Arana GW. Handbook of Psychiatric Drug Therapy, 6th ed., Lippincott, Williams, and Wilkins, Philadelphia 2010.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/28\">",
"      Baldessarini RJ, Cohen BM, Teicher MH. Significance of neuroleptic dose and plasma level in the pharmacological treatment of psychoses. Arch Gen Psychiatry 1988; 45:79.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/29\">",
"      Rifkin A, Doddi S, Karajgi B, et al. Dosage of haloperidol for schizophrenia. Arch Gen Psychiatry 1991; 48:166.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration.  Information for Healthcare Professionals: Haloperidol (marketed as Haldol, Haldol Decanoate and Haldol Lactate). FDA Alert. [9/2007]. Available at: file://www.fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/DrugSafetyInformationforHeathcareProfessionals/ucm085203.htm.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/31\">",
"      Kane JM, Davis JM, Schooler N, et al. A multidose study of haloperidol decanoate in the maintenance treatment of schizophrenia. Am J Psychiatry 2002; 159:554.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/32\">",
"      Cookson JC. Side effects during long-term treatment with depot antipsychotic medication. Clin Neuropharmacol 1991; 14 Suppl 2:S24.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/33\">",
"      Brambilla F, Guastalla A, Guerrini A, et al. Glucose-insulin metabolism in chronic schizophrenia. Dis Nerv Syst 1976; 37:98.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/34\">",
"      Knott JC, Taylor DM, Castle DJ. Randomized clinical trial comparing intravenous midazolam and droperidol for sedation of the acutely agitated patient in the emergency department. Ann Emerg Med 2006; 47:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/35\">",
"      Frye MA, Coudreaut MF, Hakeman SM, et al. Continuous droperidol infusion for management of agitated delirium in an intensive care unit. Psychosomatics 1995; 36:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/36\">",
"      Resnick M, Burton BT. Droperidol vs. haloperidol in the initial management of acutely agitated patients. J Clin Psychiatry 1984; 45:298.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/37\">",
"      Lehmann KA, Van Peer A, Ikonomakis M, et al. Pharmacokinetics of droperidol in surgical patients under different conditions of anaesthesia. Br J Anaesth 1988; 61:297.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/38\">",
"      Curry SH, Whelpton R, de Schepper PJ, et al. Kinetics of fluphenazine after fluphenazine dihydrochloride, enanthate and decanoate administration to man. Br J Clin Pharmacol 1979; 7:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/39\">",
"      Midha KK, McKay G, Edom R, et al. Kinetics of oral fluphenazine disposition in humans by GC-MS. Eur J Clin Pharmacol 1983; 25:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/40\">",
"      Midha KK, Hubbard JW, McKay G, et al. The role of metabolites in a bioequivalence study 1: loxapine, 7-hydroxyloxapine and 8-hydroxyloxapine. Int J Clin Pharmacol Ther Toxicol 1993; 31:177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/41\">",
"      Zisook S, Click MA Jr. Evaluations of loxapine succinate in the ambulatory treatment of acute schizophrenic episodes. Int Pharmacopsychiatry 1980; 15:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/42\">",
"      Fruensgaard K, Wollenberg J, Hansen KM, et al. Loxapine versus perphenazine in psychotic patients. A double-blind, randomized, multicentre trial. Curr Med Res Opin 1978; 5:601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/43\">",
"      Paprocki J, Barcala Peixoto MP, Andrade NM. A controlled double-blind comparison between loxapine and haloperidol in acute newly hospitalized schizophrenic patients. Psychopharmacol Bull 1976; 12:32.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/44\">",
"      Chakrabarti A, Whicher E, Morrison M, Douglas-Hall P. 'As required' medication regimens for seriously mentally ill people in hospital. Cochrane Database Syst Rev 2007; :CD003441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/45\">",
"      Doss FW. The effect of antipsychotic drugs on body weight: a retrospective review. J Clin Psychiatry 1979; 40:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/46\">",
"      Coley KC, Carter CS, DaPos SV, et al. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol. J Clin Psychiatry 1999; 60:850.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/47\">",
"      Riding BE, Munro A. Letter: Pimozide in monosymptomatic psychosis. Lancet 1975; 1:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/48\">",
"      Lepping P, Russell I, Freudenmann RW. Antipsychotic treatment of primary delusional parasitosis: systematic review. Br J Psychiatry 2007; 191:198.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/49\">",
"      Pringsheim T, Marras C. Pimozide for tics in Tourette's syndrome. Cochrane Database Syst Rev 2009; :CD006996.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/50\">",
"      Shapiro E, Shapiro AK, Fulop G, et al. Controlled study of haloperidol, pimozide and placebo for the treatment of Gilles de la Tourette's syndrome. Arch Gen Psychiatry 1989; 46:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/51\">",
"      Desta Z, Kerbusch T, Flockhart DA. Effect of clarithromycin on the pharmacokinetics and pharmacodynamics of pimozide in healthy poor and extensive metabolizers of cytochrome P450 2D6 (CYP2D6). Clin Pharmacol Ther 1999; 65:10.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/52\">",
"      Mendels J, Krajewski TF, Huffer V, et al. Effective short-term treatment of generalized anxiety disorder with trifluoperazine. J Clin Psychiatry 1986; 47:170.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/53\">",
"      Cunha IW, Carvalho KC, Martins WK, et al. Identification of genes associated with local aggressiveness and metastatic behavior in soft tissue tumors. Transl Oncol 2010; 3:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/54\">",
"      Hobbs DC, Welch WM, Short MJ, et al. Pharmacokinetics of thiothixene in man. Clin Pharmacol Ther 1974; 16:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/55\">",
"      Hobbs DC. Metabolism of thiothixene. J Pharm Sci 1968; 57:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/56\">",
"      Serafetinides EA, Collins S, Clark ML. Haloperidol, clopenthixol, and chlorpromazine in chronic schizophrenia. Chemically unrelated antipsychotics as therapeutic alternatives. J Nerv Ment Dis 1972; 154:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/57\">",
"      Dossenbach M, Treuer T, Kryzhanovskaya L, et al. Olanzapine versus chlorpromazine in the treatment of schizophrenia: a pooled analysis of four 6-week, randomized, open-label studies in the Middle East and North Africa. J Clin Psychopharmacol 2007; 27:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/58\">",
"      Meyer JM, Koro CE. The effects of antipsychotic therapy on serum lipids: a comprehensive review. Schizophr Res 2004; 70:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/59\">",
"      Leucht C, Kitzmantel M, Chua L, et al. Haloperidol versus chlorpromazine for schizophrenia. Cochrane Database Syst Rev 2008; :CD004278.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/60\">",
"      Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361:1581.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/61\">",
"      Sykes AJ, Kiltie AE, Stewart AL. Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy. Support Care Cancer 1997; 5:500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/62\">",
"      DiGiacomo J. Cardiovascular effects of psychotropic drugs. Cardiovasc Rev Rep 1989; 10:31.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/63\">",
"      Tuason VB, Escobar JI, Garvey M, Schiele B. Loxapine versus chlorpromazine in paranoid schizophrenia: a double-blind study. J Clin Psychiatry 1984; 45:158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/64\">",
"      Fruensgaard K. Parenteral treatment of acute psychotic patients with agitation: a review. Curr Med Res Opin 1978; 5:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/65\">",
"      Regal RE, Billi JE, Glazer HM. Phenothiazine-induced cholestatic jaundice. Clin Pharm 1987; 6:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/66\">",
"      STABENAU JR, GRINOLS DR. A DOUBLE-BLIND COMPARISON OF THIORIDAZINE AND CHLORPROMAZINE. Psychiatr Q 1964; 38:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/67\">",
"      Harrigan EP, Miceli JJ, Anziano R, et al. A randomized evaluation of the effects of six antipsychotic agents on QTc, in the absence and presence of metabolic inhibition. J Clin Psychopharmacol 2004; 24:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/68\">",
"      Reilly JG, Ayis SA, Ferrier IN, et al. QTc-interval abnormalities and psychotropic drug therapy in psychiatric patients. Lancet 2000; 355:1048.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/69\">",
"      Hagopian V, Stratton DB, Busiek RD. Five cases of pigmentary retinopathy associated with thioridazine administration. Am J Psychiatry 1966; 123:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?7/24/7562/abstract/70\">",
"      Tekell JL, Silva JA, Maas JA, et al. Thioridazine-induced retinopathy. Am J Psychiatry 1996; 153:1234.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 14773 Version 6.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-122.72.76.133-5682FA82D5-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7562=[""].join("\n");
var outline_f7_24_7562=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H272233927\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233773\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233780\">",
"      PHARMACOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18716722\">",
"      PHARMACOKINETICS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233787\">",
"      INDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233794\">",
"      SIDE EFFECTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233801\">",
"      COST",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233808\">",
"      FORMULATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233815\">",
"      INDIVIDUAL MEDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H272233822\">",
"      High-potency antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233829\">",
"      - Haloperidol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233836\">",
"      - Droperidol",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233843\">",
"      - Fluphenazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233850\">",
"      - Loxapine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233864\">",
"      - Perphenazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233871\">",
"      - Pimozide",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233878\">",
"      - Trifluoperazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233885\">",
"      - Thiothixene",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H272233892\">",
"      Low-potency antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233906\">",
"      - Chlorpromazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233913\">",
"      - Thioridazine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H272233920\">",
"      - Mesoridazine",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H272233927\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PSYCH/14773\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PSYCH/14773|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/57/33694\" title=\"table 1\">",
"      Adverse effects for antipsychotic meds",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?30/58/31663\" title=\"table 2\">",
"      Dosage and pharmacology of antipsychotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/6/23662\" title=\"table 3\">",
"      Oral antipsychotics cost comparison",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?32/7/32893\" title=\"table 4\">",
"      Antipsychotics for management of acute agitation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?9/36/9806\" title=\"table 5\">",
"      Dose and admin of LAI antipsychotic for schizophrenia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/55/23418?source=related_link\">",
"      Acquired long QT syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/8/38026?source=related_link\">",
"      Bipolar disorder in adults: Pharmacotherapy for acute mania, mixed episodes, and hypomania",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/41/22167?source=related_link\">",
"      Causes of hyperprolactinemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/31/4600?source=related_link\">",
"      First generation (Typical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/4/20553?source=related_link\">",
"      Neuroleptic malignant syndrome",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/35/29241?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Acute and maintenance phase treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/45/44760?source=related_link\">",
"      Pharmacotherapy for schizophrenia: Side effect management",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28185?source=related_link\">",
"      Prevention and treatment of delirium and confusional states",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/27/19896?source=related_link\">",
"      Retinitis pigmentosa: Clinical presentation and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?42/19/43320?source=related_link\">",
"      Second generation (atypical) antipsychotic medication poisoning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/10/15530?source=related_link\">",
"      Second-generation antipsychotic medications: Pharmacology, administration, and comparative side effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/31/25082?source=related_link\">",
"      Sedative-analgesic medications in critically ill patients: Properties, dosage regimens, and adverse effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/40/27269?source=related_link\">",
"      Tardive dyskinesia: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/26/36264?source=related_link\">",
"      Tardive dyskinesia: Etiology and epidemiology",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27402?source=related_link\">",
"      Treatment of behavioral symptoms related to dementia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/62/29670?source=related_link\">",
"      Treatment of postpartum psychosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f7_24_7563="Priorities for management of cerebral palsy";
var content_f7_24_7563=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F60793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F60793&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Priorities for management of individuals with cerebral palsy",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Communication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Social and emotional development",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Education",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Maximal independence in activities of daily living",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        As near-normal appearance as possible",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Nutrition",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Mobility",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Miller G. Cerebral palsies. In: Static Encephalopathies of Infancy and Childhood, Miller G, Ramer JC (Eds), Raven, New York 1992. Copyright &copy; 1992 Lippincott Williams &amp; Wilkins.",
"    </div>",
"    <div class=\"contractual\">",
"     <br/>",
"     <a href=\"file://www.lww.com\">",
"      file://www.lww.com",
"     </a>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7563=[""].join("\n");
var outline_f7_24_7563=null;
var title_f7_24_7564="ACC AHA preop stress test";
var content_f7_24_7564=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F77115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F77115&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    ACC/AHA guideline summary: Exercise or pharmacologic stress testing prior to noncardiac surgery",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIa - The evidence or opinion is in favor of benefit from exercise or pharmacological stress testing prior to noncardiac in the following setting",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For evaluation of patients scheduled to undergo vascular surgery with three or more clinical risk factors and poor functional capacity (&lt;4 METS) if it will change management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class IIb - The weight of evidence or opinion is less well established for the benefit of exercise or pharmacological stress testing prior to noncardiac surgery in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For evaluation of patients scheduled to undergo intermediate-risk surgery with at least one clinical risk factor and poor functional capacity (&lt;4 METS) if it will change management",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For evaluation of patients scheduled to undergo vascular surgery with at least one clinical risk factor and good functional capacity (&ge;4 METS)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Class III - There is evidence and/or general agreement that exercise or pharmacological stress testing prior to noncardiac surgery is not useful in the following settings",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For evaluation of patients scheduled to undergo intermediate-risk surgery with no clinical risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &bull; For evaluation of patients scheduled to undergo low-risk noncardiac surgery",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Fleisher LA, Beckman JA, Brown KA, et al. ACC/AHA 2007 guidelines on perioperative cardiovascular evaluation and care for noncardiac surgery: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 2002 Guidelines on Perioperative Cardiovascular Evaluation for Noncardiac Surgery) developed in collaboration with the American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Rhythm Society, Society of Cardiovascular Anesthesiologists, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, and Society for Vascular Surgery. J Am Coll Cardiol 2007; 50:e159.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7564=[""].join("\n");
var outline_f7_24_7564=null;
var title_f7_24_7565="Sorbitol pathway in diabetes";
var content_f7_24_7565=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ENDO%2F81926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ENDO%2F81926&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Role of sorbitol in diabetic microvascular disease",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 409px; height: 194px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the pathways of sorbitol synthesis and metabolism. Hyperglycemia is associated with increased cell glucose in certain tissues, such as the peripheral nerves and the retina, leading to the accumulation of sorbitol. The increase in cell osmolality, decreased cell myoinositol, and perhaps other factors may contribute to tissue injury.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Frank RN. On the pathogenesis of diabetic retinopathy. A 1990 update. Ophthalmology 1991; 98:586.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7565=[""].join("\n");
var outline_f7_24_7565=null;
var title_f7_24_7566="Splenic platelet pooling";
var content_f7_24_7566=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F52400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F52400&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Effect of spleen size on platelet pooling",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 388px; height: 380px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This figure shows the two-hour recovery in the general circulation of radioactively-labeled platelets transfused to asplenic (red), normal (green), and splenomegalic (orange) patients. The vast majority of the splenomegalic patients had congestive splenomegaly secondary to cirrhosis with portal hypertension.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from: Aster RH. Pooling of platelets in the spleen: role in the pathogenesis of 'hypersplenic' thrombocytopenia. J Clin Invest 1966; 45:645.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7566=[""].join("\n");
var outline_f7_24_7566=null;
var title_f7_24_7567="Fibrosing mediastinitis PAgram";
var content_f7_24_7567=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PULM%2F50957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PULM%2F50957&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Pulmonary arteriogram in fibrosing mediastinitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 260px; height: 303px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Pulmonary arteriogram reveals an abrupt cutoff (red arrow) of a right pulmonary artery branch in a patient with fibrosing mediastinitis.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Joseph Wheat, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f7_24_7567=[""].join("\n");
var outline_f7_24_7567=null;
